Document and Entity Information
Document and Entity Information | 6 Months Ended |
Jun. 30, 2020 | |
Document and Entity Information | |
Entity Registrant Name | ASTRAZENECA PLC |
Entity Central Index Key | 0000901832 |
Document Type | 6-K/A |
Document Period End Date | Jun. 30, 2020 |
Amendment Flag | false |
Current Fiscal Year End Date | --12-31 |
Document Fiscal Period Focus | Q2 |
Document Fiscal Year Focus | 2020 |
Consolidated Statement of Compr
Consolidated Statement of Comprehensive Income - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Consolidated Statement of Comprehensive Income | ||||
Product Sales | $ 6,048 | $ 5,718 | $ 12,359 | $ 11,183 |
Collaboration Revenue | 227 | 105 | 270 | 131 |
Total Revenue | 6,275 | 5,823 | 12,629 | 11,314 |
Cost of sales | (984) | (1,063) | (2,404) | (2,192) |
Gross Profit | 5,291 | 4,760 | 10,225 | 9,122 |
Distribution costs | (104) | (81) | (191) | (159) |
Research and development expense | (1,389) | (1,356) | (2,777) | (2,622) |
Selling, general and administrative costs | (2,635) | (2,943) | (5,354) | (5,457) |
Other operating income and expense | 121 | 113 | 601 | 706 |
Operating Profit | 1,284 | 493 | 2,504 | 1,590 |
Finance income | 22 | 41 | 73 | 96 |
Finance expense | (329) | (361) | (661) | (728) |
Share of after-tax losses in associates and joint ventures | (16) | (32) | (20) | (59) |
Profit Before Tax | 961 | 141 | 1,896 | 899 |
Taxation | (223) | (34) | (408) | (229) |
Profit for the period | 738 | 107 | 1,488 | 670 |
Other comprehensive income: | ||||
Remeasurement of the defined benefit pension liability | (645) | (257) | (205) | (247) |
Net gains/(losses) on equity investments measured at fair-value through other comprehensive income | 898 | (174) | 1,069 | (54) |
Fair value movements related to own credit risk on bonds designated as fair value through profit or loss | (15) | (1) | 6 | (2) |
Tax on items that will not be reclassified to profit or loss | (13) | 60 | (79) | 17 |
Total other comprehensive income that will not be reclassified to profit or loss, net of tax | 225 | (372) | 791 | (286) |
Foreign exchange arising on consolidation | 114 | (139) | (494) | (86) |
Foreign exchange arising on designating borrowings in net investment hedges | 363 | (6) | (17) | (186) |
Fair value movements on cash flow hedges | 56 | 11 | (131) | (43) |
Fair value movements on cash flow hedges transferred to profit or loss | (46) | (33) | (1) | 14 |
Fair value movements on derivatives designated in net investment hedges | 12 | (60) | 9 | |
Costs of hedging | 9 | 9 | 4 | 3 |
Tax on items that may be reclassified subsequently to profit or loss | (44) | (3) | 29 | 20 |
Total other comprehensive income/(loss) that will be reclassified to profit or loss, net of tax | 452 | (173) | (550) | (287) |
Other comprehensive loss for the period, net of tax | 677 | (545) | 241 | (573) |
Total comprehensive income/(loss) for the period | 1,415 | (438) | 1,729 | 97 |
Owners of the Parent | 756 | 130 | 1,536 | 723 |
Non-controlling interests | (18) | (23) | (48) | (53) |
Total comprehensive income attributable to: | ||||
Owners of the Parent | 1,432 | (415) | 1,777 | 150 |
Non-controlling interests | (17) | (23) | (48) | (53) |
Total comprehensive income/(loss) for the period | $ 1,415 | $ (438) | $ 1,729 | $ 97 |
Basic earnings loss per (in dollars per share) | $ 0.58 | $ 0.09 | $ 1.17 | $ 0.56 |
Diluted earnings loss per Share (in dollars per share) | $ 0.58 | $ 0.10 | $ 1.17 | $ 0.56 |
Weighted average number of Ordinary Shares in issue for basic earnings | 1,312 | 1,311 | 1,312 | 1,289 |
Diluted weighted average number of Ordinary Shares in issue (millions) | 1,313 | 1,312 | 1,313 | 1,290 |
Consolidated Statement of Com_2
Consolidated Statement of Comprehensive Income (Parenthetical) - $ / shares | Jun. 30, 2020 | Jun. 30, 2019 |
Consolidated Statement of Comprehensive Income | ||
Par value per ordinary share | $ 0.25 | $ 0.25 |
Consolidated Statement of Finan
Consolidated Statement of Financial Position - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 | Jun. 30, 2019 |
Non-current assets | |||
Property, plant and equipment | $ 7,475 | $ 7,688 | $ 7,442 |
Right-of-use assets | 634 | 647 | 702 |
Goodwill | 11,645 | 11,668 | 11,668 |
Intangible assets | 19,728 | 20,833 | 22,257 |
Derivative financial instruments | 122 | 61 | 124 |
Investments in associates and joint ventures | 41 | 58 | 73 |
Other investments | 1,577 | 1,401 | 1,362 |
Other receivables | 644 | 740 | 454 |
Deferred tax assets | 3,133 | 2,718 | 2,588 |
Total non-current assets | 44,999 | 45,814 | 46,670 |
Current assets | |||
Inventories | 3,562 | 3,193 | 3,197 |
Trade and other receivables | 5,024 | 5,761 | 5,319 |
Other investments | 442 | 849 | 819 |
Derivative financial instruments | 16 | 36 | 210 |
Income tax receivable | 213 | 285 | 246 |
Cash and cash equivalents | 5,673 | 5,369 | 5,428 |
Assets held for sale | 70 | ||
Total current assets | 14,930 | 15,563 | 15,219 |
Total assets | 59,929 | 61,377 | 61,889 |
Current liabilities | |||
Interest-bearing loans and borrowings | (3,958) | (1,822) | (1,629) |
Lease liabilities | (174) | (188) | (206) |
Trade and other payables | (12,028) | (13,987) | (12,637) |
Derivative financial instruments | (35) | (36) | (11) |
Provisions | (612) | (723) | (410) |
Income tax payable | (1,376) | (1,361) | (1,141) |
Current liabilities | (18,183) | (18,117) | (16,034) |
Non-current liabilities | |||
Interest-bearing loans and borrowings | (15,150) | (15,730) | (17,355) |
Lease liabilities | (465) | (487) | (514) |
Derivative financial instruments | (121) | (18) | (2) |
Deferred tax liabilities | (2,526) | (2,490) | (2,932) |
Retirement benefit obligations | (2,847) | (2,807) | (2,632) |
Provisions | (835) | (841) | (376) |
Other payables | (6,144) | (6,291) | (6,973) |
Total non-current liabilities | (28,088) | (28,664) | (30,784) |
Total liabilities | (46,271) | (46,781) | (46,818) |
Net assets | 13,658 | 14,596 | 15,071 |
Equity | |||
Share capital | 328 | 328 | 328 |
Share premium account | 7,950 | 7,941 | 7,911 |
Other reserves | 2,046 | 2,046 | 2,044 |
Retained earnings | 1,913 | 2,812 | 3,265 |
Total equity attributable to owners of parent | 12,237 | 13,127 | 13,548 |
Non-controlling interests | 1,421 | 1,469 | 1,523 |
Total equity | $ 13,658 | $ 14,596 | $ 15,071 |
Consolidated Statement of Chang
Consolidated Statement of Changes in Equity - USD ($) $ in Millions | Share Capital | Share Premium account | Other reserves | Retained earnings. | Total attributable to owners of the parent | Non-controlling interests. | Total |
Equity at beginning of period at Dec. 31, 2018 | $ 317 | $ 4,427 | $ 2,041 | $ 5,683 | $ 12,468 | $ 1,576 | $ 14,044 |
Profit for the period | 723 | 723 | (53) | 670 | |||
Other comprehensive income loss | (573) | (573) | (573) | ||||
Transfer to other reserves | 3 | (3) | |||||
Dividends | (2,403) | (2,403) | (2,403) | ||||
Issue of Ordinary Shares | 11 | 3,484 | 3,495 | 3,495 | |||
Share-based payments charge for the period | 102 | 102 | 102 | ||||
Settlement of share plan awards | (318) | (318) | (318) | ||||
Net movement | 11 | 3,484 | 3 | (2,418) | 1,080 | (53) | 1,027 |
Equity at end of period at Jun. 30, 2019 | 328 | 7,911 | 2,044 | 3,265 | 13,548 | 1,523 | 15,071 |
Adoption of new accounting standard | 54 | 54 | 54 | ||||
Equity at beginning of period at Dec. 31, 2019 | 328 | 7,941 | 2,046 | 2,812 | 13,127 | 1,469 | 14,596 |
Profit for the period | 1,536 | 1,536 | (48) | 1,488 | |||
Other comprehensive income loss | 241 | 241 | 241 | ||||
Dividends | (2,489) | (2,489) | (2,489) | ||||
Issue of Ordinary Shares | 9 | 9 | 9 | ||||
Share-based payments charge for the period | 118 | 118 | 118 | ||||
Settlement of share plan awards | (305) | (305) | (305) | ||||
Net movement | 9 | (899) | (890) | (48) | (938) | ||
Equity at end of period at Jun. 30, 2020 | $ 328 | $ 7,950 | $ 2,046 | $ 1,913 | $ 12,237 | $ 1,421 | $ 13,658 |
Consolidated Statement of Cha_2
Consolidated Statement of Changes in Equity (Parenthetical) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Par value per ordinary share | $ 0.25 | $ 0.25 | $ 0.25 | $ 0.25 |
Issue of equity | $ 9 | $ 3,495 | ||
Costs of hedging | $ (9) | $ (9) | (4) | (3) |
Share Capital | ||||
Issue of equity | 11 | |||
Share Premium account | ||||
Issue of equity | 9 | 3,484 | ||
Total attributable to owners of the parent | ||||
Issue of equity | $ 9 | $ 3,495 |
Consolidated Statement of Cash
Consolidated Statement of Cash Flows - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Cash flows from operating activities | ||
Profit Before Tax | $ 1,896 | $ 899 |
Finance income and expense | 588 | 632 |
Share of after-tax losses of associates and joint ventures | 20 | 59 |
Depreciation, amortisation and impairment | 1,551 | 1,403 |
Increase in working capital and short-term provisions | (780) | (634) |
Gains on disposal of intangible assets | (411) | (590) |
Fair value movements on contingent consideration arising from business combinations | (44) | |
Non-cash and other movements | (511) | (177) |
Cash generated from operations | 2,309 | 1,592 |
Interest paid | (338) | (378) |
Tax paid | (792) | (723) |
Net cash inflow from operating activities | 1,179 | 491 |
Cash flows from investing activities | ||
Payment of contingent consideration from business combinations | (353) | (368) |
Purchase of property, plant and equipment | (370) | (438) |
Disposal of property, plant and equipment | 67 | 27 |
Purchase of intangible assets | (983) | (1,296) |
Disposal of intangible assets | 474 | 1,071 |
Movement in profit participation liability | 150 | |
Purchase of non-current asset investments | (119) | (7) |
Disposal of non-current asset investments | 949 | 18 |
Movement in short-term investments, fixed deposits and other investing instruments | 463 | 21 |
Payments to associates and joint ventures | (8) | (39) |
Interest received | 37 | 72 |
Net cash inflow/(outflow) from investing activities | 157 | (789) |
Net cash inflow/(outflow) before financing activities | 1,336 | (298) |
Cash flows from financing activities | ||
Proceeds from issue of share capital | 9 | 3,495 |
Issue of loans | 500 | |
Repayment of loans | (500) | |
Dividends paid | (2,398) | (2,432) |
Hedge contracts relating to dividend payments | (93) | 26 |
Repayment of obligations under leases | (107) | (84) |
Movement in short-term borrowings | 1,353 | (64) |
Net cash (outflow)/inflow from financing activities | (1,236) | 941 |
Net increase in cash and cash equivalents in the period | 100 | 643 |
Cash and cash equivalents at the beginning of the period | 5,223 | 4,671 |
Exchange rate effects | (18) | 16 |
Cash and cash equivalents at the end of the period | 5,305 | 5,330 |
Cash and cash equivalents | 5,673 | 5,428 |
Overdrafts | $ (368) | $ (98) |
Basis of Preparation and Accoun
Basis of Preparation and Accounting Policies | 6 Months Ended |
Jun. 30, 2020 | |
Basis of Presentation and Accounting Policies | |
Basis of Presentation and Accounting Policies | 1 Basis of preparation and accounting policies These unaudited Interim Financial Statements for the six months ended 30 June 2020 have been prepared in accordance with IAS 34 ‘Interim Financial Reporting’ as issued by the International Accounting Standards Board (IASB) and as adopted by the EU. The UK is in the process of establishing its post-Brexit IFRS-adoption authority, which is expected to be operational later in 2020, but for the current time, will follow the EU approval process . The unaudited Interim Financial Statements for the six months ended 30 June 2020 were approved by the Board of Directors for release on 30 July 2020. The annual financial statements of the Group are prepared in accordance with IFRSs as issued by the IASB and adopted by the EU. Except as noted below, the Interim Financial Statements have been prepared applying the accounting policies that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2019 . IFRS 3 An amendment to IFRS 3 ‘Business Combinations’ relating to the definition of a business was endorsed by the EU in April 2020 with an effective date of 1 January 2020. The change in definition of a business within IFRS 3 introduces an optional concentration test to perform a simplified assessment of whether an acquired set of activities and assets is or is not a business on a transaction by transaction basis. This change is expected to provide more reliable and comparable information about certain transactions as it provides more consistency in accounting in the pharmaceutical industry for substantially similar transactions for which, under the previous definition, may have been accounted in different ways, despite limited differences in substance. The Group has adopted this amendment from the effective date. IFRS 9, IAS 39 and IFRS 7 Amendments to IFRS 9 ‘Financial Instruments’, IAS 39 ‘Financial Instruments: Recognition and Measurement’ and IFRS 7 ‘Financial Instruments: Disclosures’ relating to interbank offered rate (IBOR) reform were endorsed by the EU in January 2020. The Group adopted the amendments in the year ended 31 December 2019. The replacement of benchmark interest rates such as the London Inter-bank Offered Rate (LIBOR) and other IBORs is a priority for global regulators. The amendments provide relief from applying specific hedge-accounting requirements to hedge relationships directly affected by IBOR reform and have the effect that IBOR reform should generally not cause hedge accounting to terminate. There is no financial impact from the early adoption of these amendments. The Group has one IFRS 9 designated hedge relationship that is potentially impacted by IBOR reform, namely a € 300m cross-currency interest-rate swap in a fair-value hedge relationship with € 300m of a € 750m 0.875% 2021 non-callable bond. This swap references three-month USD LIBOR and uncertainty arising from the Group’s exposure to IBOR reform will cease when the swap matures in 2021. The implications on the wider business of IBOR reform are currently being assessed. COVID-19 AstraZeneca has assessed the impact of the uncertainty presented by the COVID-19 pandemic on the Interim Financial Statements comprising the financial results to 30 June 2020 and the financial position as at 30 June 2020, specifically considering the impact on key judgements and significant estimates as detailed on page 173 of the Annual Report and 20-F Information 2019 along with a several other areas of increased risk. A detailed assessment has been performed, focussing on the following areas: - recoverable value of goodwill, intangible assets and property, plant and equipment - impact on key assumptions used to estimate contingent consideration liabilities - key assumptions used in estimating the Group’s defined-benefit pension obligations - basis for estimating clinical-trial accruals - key assumptions used in estimating rebates, chargebacks and returns for US Product Sales - valuations of unlisted equity investments - expected credit losses associated with changes in credit risk relating to trade and other receivables - net realisable value of inventories - fair value of certain financial instruments - recoverability of deferred-tax assets - effectiveness of hedge relationships Given the significant volatility experienced in the financial markets, the assumptions used to estimate the Group’s material defined-benefit pension obligations are updated quarterly and resulted in an overall $40m increase in the Group’s defined-benefit pension deficit in the six months ended 30 June 2020. The increase in the deficit primarily reflected increased liability valuations as a result of lower discount rates (due to falling long term AA corporate bond yields linked to the launch of a quantitative easing bond-buying programme in the UK and other regions in June 2020), with an increase in asset values providing a partial offset. In the UK, £79m of deficit-recovery contributions were also paid during the period. The sensitivity of the Group’s main defined-benefit liability valuations to changes in assumptions is set out on page 207 of the Annual Report and 20-F Information 2019 . No further material accounting impacts relating to the areas assessed above were recognised during the six-month period ending 30 June 2020. The Group will continue to monitor these areas of increased judgement, estimation and risk for material changes. Going concern The Group has considerable financial resources available. As at 30 June 2020 the Group had $10.2bn in financial resources (cash and cash-equivalent balances of $5.7bn, $0.4bn of liquid fixed income securities and undrawn committed bank facilities of $4.1bn, of which $3.4bn is available until April 2022, $0.5bn is available until November 2020 (extendable to November 2021) and $0.2bn is available until December 2020, with only $4.1bn of borrowings due within one year). The Group’s revenues are largely derived from sales of medicines that are covered by patents which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to affect adversely revenues in many of the mature markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. In the current environment, the Directors have also considered the impact of possible future COVID-19 related scenarios and believe the Group retains sufficient liquidity to continue to operate. Based on the above paragraph, the going-concern basis has been adopted in these Interim Financial Statements. Legal proceedings The information contained in Note 5 updates the disclosures concerning legal proceedings and contingent liabilities in the Group’s Annual Report and 20-F Information 2019 . Financial information The comparative figures for the financial year ended 31 December 2019 are not the Group’s statutory accounts for that financial year. Those accounts have been reported on by the Group’s auditors and have been delivered to the registrar of companies; their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006. |
Intangible assets
Intangible assets | 6 Months Ended |
Jun. 30, 2020 | |
Intangible assets | |
Intangible assets | 2 Intangible assets In accordance with IAS 36 ‘Impairment of Assets’, reviews for triggers at an individual asset or cash-generating-unit level were conducted. This resulted in a total impairment charge of $119m being recorded against intangible assets during the six months ended 30 June 2020. During the first quarter of 2020, a charge of $102m was recorded in relation to Bydureon (revised carrying amount of $612m). The impairment was driven by an overall reduction in forecast Total Revenue over the remaining asset life, reflecting expectations of returns from promotional activities, including a level of anticipated impact resulting from the restrictions in place due to the COVID-19 pandemic. If Total Revenue projections for Bydureon were to decline by a further 10% over the forecast period, it would result in a reduction in the recoverable amount of c.$100m. During the second quarter, charges recorded included $65m and $31m in relation to Duaklir and Eklira/Tudorza respectively, (revised carrying amount of $274m and $130m, respectively), and a $95m impairment reversal in relation to FluMist (revised carrying amount of $258m). The impairment charges for Duaklir and Eklira/Tudorza were a consequence of revised market volume and share assumptions following adverse performances during H1 2020, compared to previous forecasts during the H1 2020. If Total Revenue projections for these assets were to decline by a further 20% over the forecast period, it would result in additional reductions to the recoverable amounts of c.$60m for Duaklir and c.$30m for Eklira/Tudorza. The $95m impairment reversal in relation to FluMist reflected a change in expected sales volumes following pre-orders received during the period. |
Net Debt
Net Debt | 6 Months Ended |
Jun. 30, 2020 | |
Net Debt | |
Net Debt | 3 Net Debt The table below provides an analysis of Net Debt and a reconciliation of Net Cash Flow to the movement in Net Debt. The Group monitors Net Debt as part of its capital-management policy as described in Note 27 of the Annual Report and 20-F Information 2019 . Net Debt is a non-GAAP financial measure. At 1 Jan Cash Non-cash Exchange At 30 Jun flow & other movements $m $m $m $m $m Non-current instalments of loans (15,730) - 550 30 (15,150) Non-current instalments of leases (487) - 11 11 (465) Total long-term debt (16,217) - 561 41 (15,615) Current instalments of loans (1,597) - (556) (6) (2,159) Current instalments of leases (188) 117 (107) 4 (174) Commercial paper - (1,262) - - (1,262) Bank collateral (71) (34) - - (105) Other short-term borrowings excluding overdrafts (8) (57) - 1 (64) Overdraft (146) (230) - 8 (368) Total current debt (2,010) (1,466) (663) 7 (4,132) Gross borrowings (18,227) (1,466) (102) 48 (19,747) Net derivative financial instruments 43 93 (154) - (18) Net borrowings (18,184) (1,373) (256) 48 (19,765) Cash and cash equivalents 5,369 330 - (26) 5,673 Other investments - current 849 (463) 62 (6) 442 Other investments - non-current 62 - (62) - - Cash and investments 6,280 (133) - (32) 6,115 Net Debt (11,904) (1,506) (256) 16 (13,650) Non-cash movements in the period include fair-value adjustments under IFRS 9. Other investments – non-current are included within the balance of $1,577m (31 December 2019: $1,401m) in the Condensed consolidated statement of financial position. The equivalent GAAP measure to net debt is ‘liabilities arising from financing activities’ which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives shown above and includes the Acerta Pharma put-option liability of $2,219m (31 December 2019: $2,146m) shown in non-current other payables. Net Debt increased by $1,746m in the six months to 30 June 2020, principally due to Net Cash Inflow from Operating Activities of $1,179m being more than offset by the payment of the second interim dividend of 2019 of $2,398m (representing two thirds of the 2019 full year). Details of the committed undrawn bank facilities are disclosed within the going-concern section of Note 1. During the six months to 30 June 2020, there were no changes to the Company’s credit ratings issued by Standard and Poor’s (long term: BBB+, short term A-2) and Moody’s (long term:A3, short term P-2) . |
Financial Instruments
Financial Instruments | 6 Months Ended |
Jun. 30, 2020 | |
Financial Instruments | |
Financial Instruments | 4 Financial instruments As detailed in the Group’s most recent annual financial statements, the principal financial instruments consist of derivative financial instruments, other investments, trade and other receivables, cash and cash equivalents, trade and other payables, leases and interest-bearing loans and borrowings. During the period, equity investments previously categorised as Level 3 in the fair-value hierarchy (carrying value of $103m at 31 December 2019) are now categorised as Level 1 (carrying value of $188m at 30 June 2020) on availability of quoted prices in an active market. There have been no other changes of significance to the categorisation or fair-value hierarchy classification of financial instruments from those detailed in the Notes to the Group Financial Statements in the Annual Report and 20-F Information 2019 . The Group holds certain equity investments that are categorised as Level 3 in the fair-value hierarchy and for which fair-value gains of $65m have been recognised in the six months ended 30 June 2020. All other fair-value gains and/or losses that are presented in Net gains/(losses) on Equity Investments measured at fair value through other comprehensive income in the condensed consolidated statement of comprehensive income for the six months ended 30 June 2020 are Level 1 fair value measurements . Financial instruments measured at fair value include $2,019m of other investments, $4,743m held in money-market funds, $339m of loans designated at fair value through profit or loss, $339m of loans designated in a fair value hedge relationship and ($18m) of derivatives as at 30 June 2020. The total fair value of interest-bearing loans and borrowings at 30 June 2020, which have a carrying value of $19,747m in the Condensed consolidated statement of financial position, was $22,992m. Contingent-consideration liabilities arising on business combinations have been classified under Level 3 in the fair-value hierarchy and movements in fair value are shown below: Diabetes alliance Other Total Total $m $m $m $m At 1 January 3,300 839 4,139 5,106 Settlements (257) (96) (353) (368) Revaluations (22) (22) (44) - Discount unwind 115 26 141 179 At 30 June 3,136 747 3,883 4,917 Contingent consideration arising from business combinations is fair-valued using decision-tree analysis, with key inputs including the probability of success, consideration of potential delays and the expected levels of future revenues. The contingent consideration balance relating to BMS’s share of the global diabetes alliance of $3,136m (31 December 2019: $3,300m) would increase/decline by $314m with an increase/decline in sales of 10%, as compared with the current estimates. Included within the BMS contingent consideration liability are estimates of royalties payable in relation to Bydureon . The revised Total Revenue projections for Bydureon also resulted in a $22m reduction in the contingent consideration balance as at 30 June 2020. A further 10% reduction in Bydureon Total Revenue would result in an additional $22m reduction. |
Legal Proceedings and Contingen
Legal Proceedings and Contingent Liabilities | 6 Months Ended |
Jun. 30, 2020 | |
Legal Proceedings and Contingent Liabilities | |
Legal Proceedings and Contingent Liabilities | 5 AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and investigations relating to product liability, commercial disputes, infringement of intellectual property rights, the validity of certain patents, anti-trust law and sales and marketing practices. The matters discussed below constitute the more significant developments since publication of the disclosures concerning legal proceedings in the Company's Annual Report and Form 20-F Information 2019 (the Disclosures). Unless noted otherwise below or in the Disclosures, no provisions have been established in respect of the claims discussed below. As discussed in the Disclosures, for the majority of claims in which AstraZeneca is involved, it is not possible to make a reasonable estimate of the expected financial effect, if any, that will result from ultimate resolution of the proceedings. In these cases, AstraZeneca discloses information with respect only to the nature and facts of the cases, but no provision is made. In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed and which are not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate of the loss, AstraZeneca records the loss absorbed or makes a provision for its best estimate of the expected loss. The position could change over time and the estimates that the Company made, and upon which the Company has relied in calculating these provisions are inherently imprecise. There can, therefore, be no assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of the provisions that have been booked in the accounts. The major factors causing this uncertainty are described more fully in the Disclosures and herein. AstraZeneca has full confidence in, and will vigorously defend and enforce, its intellectual property. Matters disclosed in respect of the second quarter of 2020 and to 30 July 2020 Patent litigation Tagrisso US patent proceedings As previously disclosed, in February 2020, in response to Paragraph IV notices from multiple abbreviated new drug application (ANDA) filers, AstraZeneca filed patent infringement lawsuits in the US District Court for the District of Delaware. In its complaint, AstraZeneca alleged that a generic version of Tagrisso , if approved and marketed, would infringe a US Orange Book-listed Tagrisso patent. The trial is scheduled for May 2022. Faslodex Patent proceedings outside the US In Italy, Actavis Group Ptc ehf and Actavis Italy S.p.A. filed actions alleging that the Italian part of European Patent No. EP 1,250,138 (the ‘138 patent) and European Patent Nos. EP 2,266,573 (the ‘573 patent) are invalid. In July 2018, the Court of Turin determined that the ‘138 patent is invalid. In July 2019, the Court of Milan determined that the ‘573 patent is invalid. AstraZeneca appealed both decisions. In June 2020, the Court of Appeal of Turin upheld the invalidity decision as to the ‘138 patent. Patent infringement and patent-invalidity proceedings are ongoing against various parties. In Russia, in July 2020, following a challenge to the validity of the Faslodex formulation patent by ZAO BIOCAD (Biocad), the Russian Patent Office maintained the patent as valid and dismissed the opposition filed by Biocad. Symbicort US patent proceedings As previously disclosed, AstraZeneca has ANDA litigation against Mylan Pharmaceuticals Inc. (Mylan) and 3M Company (3M) in the US District Court for the Northern District of West Virginia. In the action, AstraZeneca alleges that the defendants’ generic versions of Symbicort , if approved and marketed, would infringe various AstraZeneca patents. Mylan and 3M allege that their proposed generic product does not infringe the asserted patents and/or that the asserted patents are invalid and/or unenforceable. In July 2020, AstraZeneca added Kindeva Drug Delivery L.P. as a defendant in the case. The trial of the matter is scheduled for October 2020. Product liability litigation Nexium and Losec / Prilosec As previously disclosed, in the US, AstraZeneca is defending various lawsuits brought in federal and state courts involving multiple plaintiffs claiming that they have been diagnosed with various injuries following treatment with proton pump inhibitors (PPIs), including Nexium and Prilosec . The vast majority of those lawsuits relate to allegations of kidney injuries. In particular, in May 2017, counsel for a group of such plaintiffs claiming that they have been diagnosed with kidney injuries filed a motion with the Judicial Panel on Multidistrict Litigation (JPML) seeking the transfer of any currently pending federal court cases as well as any similar, subsequently filed cases to a coordinated and consolidated pre-trial multidistrict litigation (MDL) proceeding. In August 2017, the JPML granted the motion and consolidated the pending federal court cases in an MDL proceeding in federal court in New Jersey for pre-trial purposes. A trial in the MDL has been scheduled for November 2021. In addition to the MDL cases, there are cases filed in several state courts around the US. In addition, AstraZeneca has been defending lawsuits involving allegations of gastric cancer following treatment with PPIs. All but one of these claims is filed in the MDL. One claim is filed in the US District Court for the Middle District of Louisiana, where the court has scheduled a trial for March 2022. Commercial litigation Amplimmune As previously disclosed, in June 2017, AstraZeneca was served with a lawsuit filed by the stockholders' agents for Amplimmune, Inc. (Amplimmune) in Delaware State Court that alleged, among other things, breaches of contractual obligations relating to a 2013 merger agreement between AstraZeneca and Amplimmune. Trial of the matter was held in February 2020 and post-trial oral argument is scheduled for August 2020 . Array In December 2017, AstraZeneca was served with a complaint filed in New York State court by Array BioPharma, Inc. (Array) alleging breaches of contractual obligations relating to a 2003 collaboration agreement between AstraZeneca and Array . In June 2020, an appeal court denied AstraZeneca’s motion for an early dismissal of the case, allowing the case to continue towards trial. No trial date has been set. Anti-Terrorism Act Civil Lawsuit As previously disclosed, in October 2017, AstraZeneca and certain other pharmaceutical and/or medical device companies were named as defendants in a complaint, filed in the US District Court for the District of Columbia (the District Court) by US nationals (or their estates, survivors, or heirs) who were killed or wounded in Iraq between 2005 and 2011, that alleged that the defendants violated the US Anti-Terrorism Act and various state laws by selling pharmaceuticals and medical supplies to the Iraqi Ministry of Health. In July 2020, the District Court granted AstraZeneca’s and its co-defendants’ jointly filed motion and dismissed the lawsuit in its entirety. Ocimum lawsuit In December 2017, AstraZeneca was served with a complaint filed by Ocimum Biosciences, Ltd. (Ocimum) in the Superior Court for the State of Delaware that alleges, among other things, breaches of contractual obligations and misappropriation of trade secrets, relating to a now terminated 2001 licensing agreement between AstraZeneca and Gene Logic, Inc. (Gene Logic), the rights to which Ocimum purports to have acquired from Gene Logic. In December 2019, the court granted AstraZeneca’s motion for summary judgment and dismissed the case. Ocimum has appealed. Government investigations/proceedings Synagis Litigation in New York As previously disclosed, in the US, in June 2011, MedImmune received a demand from the US Attorney’s Office for the Southern District of New York requesting certain documents related to the sales and marketing activities of Synagis . In July 2011, MedImmune received a similar court order to produce documents from the Office of the Attorney General for the State of New York Medicaid and Fraud Control Unit pursuant to what the government attorneys advised was a joint investigation. MedImmune has cooperated with these inquiries. In March 2017, MedImmune was served with a lawsuit filed in US District Court for the Southern District of New York by the Attorney General for the State of New York alleging that MedImmune inappropriately provided assistance to a single specialty care pharmacy. In September 2018, the US District Court in New York denied MedImmune’s motion to dismiss the lawsuit brought by the Attorney General for the State of New York. This matter has been resolved and is now concluded. In June 2017, MedImmune was served with a lawsuit in US District Court for the Southern District of New York by a relator under the qui tam (whistleblower) provisions of the federal and certain state False Claims Acts. The lawsuit was originally filed under seal in April 2009 and alleges that MedImmune made false claims about Synagis . In November 2017, MedImmune was served with an amended complaint in which relator set forth additional false claims allegations relating to Synagis. In September 2018, the US District Court in New York dismissed the relator’s lawsuit. In January 2019, relator appealed the decision of the US District Court in New York. In March 2020, the United States Court of Appeals for the Second Circuit affirmed the US District Court’s decision dismissing the relator’s lawsuit. This matter is now concluded. Toprol -XL Louisiana Attorney General Litigation As previously disclosed, in April 2019, a Louisiana state court (State Court) granted AstraZeneca’s motion for summary judgment and dismissed a state court complaint brought by the Attorney General for the State of Louisiana (the State), which alleged that, in connection with enforcement of its patents for Toprol -XL, AstraZeneca engaged in unlawful monopolisation and unfair trade practices, causing the State government to pay increased prices for Toprol -XL, and the State appealed that ruling. In July 2020, the Louisiana First Court of Appeals reversed the State Court’s ruling and remanded the case to the State Court. Matters disclosed in respect of the first quarter of 2020 and to 29 April 2020 Patent litigation Tagrisso US patent proceedings As disclosed in February 2020, in response to Paragraph IV notices from multiple ANDA filers, AstraZeneca filed patent-infringement lawsuits in the US District Court for the District of Delaware. In its complaint, AstraZeneca alleged that a generic version of Tagrisso, if approved and marketed, would infringe a US Orange Book-listed Tagrisso patent. No trial date has been set. Symbicort US patent proceedings As previously disclosed, AstraZeneca has ANDA litigation against Mylan Pharmaceuticals Inc. (Mylan) and 3M Company (3M) in the US District Court for the Northern District of West Virginia. In the action, AstraZeneca alleges that the defendants’ generic versions of Symbicort , if approved and marketed, would infringe various AstraZeneca patents. Mylan and 3M allege that their proposed generic medicines do not infringe the asserted patents and/or that the asserted patents are invalid and/or unenforceable. The trial of the Mylan and 3M matter is scheduled for October 2020. Movantik US patent proceedings In March 2020, Aether Therapeutics, Inc. filed a patent infringement lawsuit in the US District Court for the District of Delaware against AstraZeneca, Nektar Therapeutics and Daiichi Sankyo relating to Movantik . Commercial litigation Amplimmune As disclosed in the US in June 2017, AstraZeneca was served with a lawsuit filed by the stockholders' agents for Amplimmune, Inc. (Amplimmune) in Delaware State Court that alleged, among other things, breaches of contractual obligations relating to a 2013 merger agreement between AstraZeneca and Amplimmune. Trial of the matter was held in February 2020 and post-trial oral argument is scheduled for June 2020. Government investigations/proceedings Crestor Qui tam litigation As previously disclosed, in the US, in January and February 2014, AstraZeneca was served with lawsuits filed in the US District Court for the District of Delaware under the qui tam provisions of the federal False Claims Act and related state statutes, alleging that AstraZeneca directed certain employees to promote Crestor off-label and provided unlawful remuneration to physicians in connection with the promotion of Crestor . The Department of Justice and all US states declined to intervene in the lawsuits. In March 2019, AstraZeneca filed a motion to dismiss the complaint. In February 2020, the District Court partially granted AstraZeneca’s motion to dismiss. Synagis Litigation in New York As disclosed in the US in June 2011, MedImmune received a demand from the US Attorney’s Office for the Southern District of New York requesting certain documents related to the sales and marketing activities of Synagis. In July 2011, MedImmune received a similar court order to produce documents from the Office of the Attorney General for the State of New York Medicaid and Fraud Control Unit pursuant to what the government attorneys advised was a joint investigation. MedImmune has co-operated with these inquiries. In March 2017, MedImmune was served with a lawsuit filed in US District Court for the Southern District of New York by the Attorney General for the State of New York, alleging that MedImmune inappropriately provided assistance to a single specialty-care pharmacy. In September 2018, the US District Court in New York denied MedImmune’s motion to dismiss the lawsuit brought by the Attorney General for the State of New York. In June 2017, MedImmune was served with a lawsuit in US District Court for the Southern District of New York by a relator under the qui tam (whistleblower) provisions of the federal and certain state False Claims Acts. The lawsuit was originally filed under seal in April 2009 and alleged that MedImmune made false claims about Synagis . In November 2017, MedImmune was served with an amended complaint in which relator set forth additional false claims’ allegations relating to Synagis . In September 2018, the US District Court in New York dismissed the relator’s lawsuit. In January 2019, relator appealed the decision of the US District Court in New York. In March 2020, the United States Court of Appeals for the Second Circuit affirmed the US District Court’s decision dismissing the relator’s lawsuit. Vermont US Attorney investigation In April 2020, AstraZeneca received a Civil Investigative Demand from the US Attorney’s Office in Vermont and the Department of Justice, Civil Division, seeking documents and information relating to AstraZeneca’s relationships with electronic health-record vendors. AstraZeneca intends to co-operate with this enquiry. Taxation As previously disclosed in the Annual Report and 20-F Information 2019 , AstraZeneca faces a number of audits and reviews in jurisdictions around the world and, in some cases, is in dispute with the tax authorities. The issues under discussion are often complex and can require many years to resolve. Accruals for tax contingencies require management to make key judgements with respect to the ultimate outcome of current and potential future tax audits, and actual results could vary from these estimates. The total net accrual to cover the worldwide tax exposure for transfer pricing and other international tax contingencies of $139m (December 2019: $140m) reflected the progress in those tax audits and reviews during the half and for those audits where AstraZeneca and tax authorities are in dispute, AstraZeneca estimates the potential for reasonably possible additional liabilities above and beyond the amount provided to be up to $226m, including associated interest (December 2019: $76m). However, the Company believes that it is unlikely that these additional liabilities will arise. It is possible that some of these contingencies may reduce in the future to the extent that any tax authority challenge is concluded, or matters lapse following expiry of the relevant statutes of limitation resulting in a reduction in the tax charge in future periods. There was no material change in the period to the other tax contingencies. |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2020 | |
Subsequent Events | |
Subsequent Events | 6 Subsequent Events In July 2020, the Company announced that it had entered into a new global development and commercialisation agreement with Daiichi Sankyo for DS-1062, its proprietary TROP2-directed antibody drug conjugate and potential new medicine for the treatment of multiple tumour types. AstraZeneca will pay Daiichi Sankyo an upfront payment of $1bn in staged payments, additional conditional amounts of up to $1bn for the successful achievement of regulatory approvals and up to $4bn for sales-related milestones. The transaction will be accounted for as an intangible-asset acquisition, recognised initially at the present value of non-contingent consideration, with any potential future milestone payments capitalised into the intangible asset as they are recognised. The companies will jointly develop and commercialise DS-1062 jointly worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. AstraZeneca and Daiichi Sankyo will share equally development and commercialisation expenses as well as profits relating to DS-1062 worldwide, except for Japan where Daiichi Sankyo will be responsible for such costs and will pay AstraZeneca mid single-digit royalties. Daiichi Sankyo will record sales in the US, certain countries in Europe and certain other countries where Daiichi Sankyo has affiliates. Profits shared with AstraZeneca from those countries will be recorded as Collaboration Revenue by AstraZeneca. AstraZeneca will record Product Sales in other countries worldwide, for which profits shared with Daiichi Sankyo will be recorded within Cost of Sales. Daiichi Sankyo will manufacture and supply DS-1062. |
Product Sales year on year anal
Product Sales year on year analysis - H1 2020 | 6 Months Ended |
Jun. 30, 2020 | |
Product Sales year on year analysis - H1 2020 | |
Product Sales year on year analysis - H1 2020 | 7 Product Sales year-on-year analysis – H1 2020 81 World Emerging Markets US Europe Established ROW H1 2020 Actual CER H1 2020 Actual CER H1 2020 Actual H1 2020 Actual CER H1 2020 Actual CER $m % % $m % % $m % $m % % $m % % Oncology Tagrisso 2,016 43 45 595 81 89 725 30 325 53 58 18 18 Imfinzi 954 51 52 63 n/m n/m 574 21 167 n/m n/m 70 71 Lynparza 816 57 60 120 n/m n/m 406 55 198 51 56 35 34 Calquence 195 n/m n/m 2 n/m n/m 193 n/m - - - - - - Koselugo 7 n/m n/m - - - 7 n/m - - - - - - Zoladex* 442 13 18 288 22 29 5 40 68 5 8 (7) (6) Faslodex* 312 (40) (38) 100 4 10 34 (87) 116 6 9 (4) (4) Iressa* 147 (42) (40) 120 (27) (24) 7 (3) 9 (81) (81) (67) (66) Arimidex* 107 (3) - 90 26 30 - - 1 (90) (90) (32) (32) Casodex* 89 (15) (13) 69 8 11 - - 1 (84) (84) (43) (42) Others 26 (50) (47) 14 (23) (14) - - 3 (15) (16) (64) (69) Total Oncology 5,111 26 28 1,461 39 46 1,951 20 888 37 41 10 9 BioPharmaceuticals: CVRM Farxiga 848 17 21 306 49 59 237 (12) 223 25 29 14 15 Brilinta 845 15 17 291 34 40 351 9 173 2 5 7 10 Onglyza 256 (5) (3) 100 15 21 105 (12) 29 (21) (18) (15) (13) Bydureon 216 (24) (23) 2 (74) (72) 185 (21) 24 (29) (26) (37) (34) Byetta 35 (36) (35) 5 13 21 19 (47) 7 (29) (26) (21) (20) Other diabeties 23 3 6 3 n/m n/m 13 (21) 6 44 50 (60) (25) Lokelma 28 n/m n/m 1 n/m n/m 22 n/m 2 n/m n/m 3 n/m n/m Crestor* 582 (10) (8) 369 (9) (6) 45 (17) 64 (15) (13) (5) (5) Seloken / Toprol-XL* 395 - 6 376 8 14 6 (78) 8 (39) (39) - 5 Atacand* 126 19 25 94 23 31 5 (15) 15 (2) (2) 37 43 Others 106 (20) (18) 65 (30) (28) - - 35 15 18 (36) (39) BioPharmaceuticals: total CVRM 3,460 3 6 1,612 11 17 988 (9) 586 3 6 - 2 BioPharmaceuticals: Respiratory & Immunology Symbicort 1,442 23 26 290 10 16 558 46 356 1 4 39 42 Pulmicort 477 (33) (32) 371 (36) (34) 36 (36) 40 (8) (4) (26) (25) Fasenra 426 44 45 7 n/m n/m 272 31 88 96 n/m 41 41 Daliresp / Daxas 106 1 2 2 (13) (7) 90 1 13 7 11 1 (3) (36) Bevespi 22 10 10 - - - 21 5 1 n/m n/m - - - Breztri 11 n/m n/m 9 n/m n/m - - - - - 2 n/m n/m Others 184 (20) (18) 80 (29) (27) 7 n/m 89 (16) (14) (14) 4 BioPharmaceuticals: total Respiratory & Immunology 2,668 5 7 759 (21) (18) 984 30 587 5 8 29 31 Other medicines Nexium 714 (5) (3) 371 - 5 80 (32) 36 14 18 (4) (4) Synagis 176 18 18 5 n/m n/m 21 (40) 150 32 32 - - - Losec / Prilosec 99 (32) (30) 81 (15) (12) 3 (44) 10 (68) (68) (62) (62) Seroquel XR / IR 63 (9) (8) 27 11 15 14 n/m 15 (69) (69) (36) (37) Others 68 (32) (31) 3 (64) (73) 33 (44) 28 5 5 4 (34) (22) Total other medicines 1,120 (8) (6) 487 (2) 1 151 (26) 239 (4) (4) 243 (9) (9) Total Product Sales 12,359 11 13 4,319 9 14 4,074 11 2,300 13 17 1,666 8 9 81 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-or-year growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. *Denotes a legacy medicine. |
Product Sales year-on-year anal
Product Sales year-on-year analysis - Q2 2020 | 6 Months Ended |
Jun. 30, 2020 | |
Product Sales year-on-year analysis - Q2 2020 | |
Product Sales year-on-year analysis - Q2 2020 | 8 Product Sales year-on-year analysis - Q2 2020 (Unreviewed) 82 World Emerging Markets US Europe Established ROW Q2 2020 Actual CER Q2 2020 Actual CER Q2 2020 Actual Q2 2020 Actual CER Q2 2020 Actual CER $m % % $m % % $m % $m % % $m % % Oncology Tagrisso 1,034 32 35 315 65 74 354 18 163 46 51 12 12 Imfinzi 492 46 48 30 n/m n/m 287 19 93 n/m n/m 55 56 Lynparza 419 48 52 64 95 n/m 209 47 96 45 50 20 21 Calquence 107 n/m n/m 1 n/m n/m 107 n/m - - - (1) n/m n/m Koselugo 7 n/m n/m - - - 7 n/m - - - - - - Zoladex* 217 10 17 139 15 24 3 55 33 8 14 (4) (2) Faslodex* 146 (45) (43) 52 2 10 11 (91) 52 (7) (3) (13) (13) Iressa* 70 (41) (38) 58 (26) (23) 4 (5) 3 (85) (85) (65) (62) Arimidex* 58 (4) - 48 35 41 - - 1 (93) (93) (42) (43) Casodex* 47 (17) (15) 37 8 11 - - - n/m n/m (47) (46) Others 12 (59) (55) 6 (35) (18) (1) n/m 1 (32) (35) (67) (74) Total Oncology 2,609 20 24 750 34 43 981 15 442 32 37 3 4 BioPharmaceuticals: CVRM Farxiga 443 17 23 165 49 62 124 (11) 107 20 25 24 26 Brilinta 437 12 16 156 30 39 187 11 80 (9) (5) 6 10 Bydureon 116 (18) (17) 1 (87) (86) 101 (14) 12 (22) (19) (23) (18) Onglyza 115 (1) 3 52 19 27 38 (9) 14 (22) (19) (20) (17) Byetta 15 (42) (41) 2 (37) (30) 7 (53) 4 (16) (13) (26) (26) Other diabeties 10 (9) (5) 1 n/m n/m 6 (31) 3 37 44 - n/m n/m Lokelma 17 n/m n/m 1 n/m n/m 12 n/m 1 n/m n/m 3 n/m n/m Crestor* 281 (10) (6) 177 (3) 2 17 (40) 30 (18) (16) (11) (10) Seloken / Toprol-XL* 218 29 38 210 35 45 2 (53) 4 (48) (48) 2 9 Atacand* 59 6 14 45 21 33 2 (39) 6 (43) (43) 43 52 Others 48 (23) (20) 29 (31) (28) - - 16 25 29 (65) (69) BioPharmaceuticals: total CVRM 1,759 6 10 839 20 28 496 (6) 277 (3) 1 (1) 1 BioPharmaceuticals: Respiratory & Immunology Symbicort 653 12 15 135 3 12 248 20 161 (6) (3) 42 47 Pulmicort 97 (71) (69) 58 (78) (76) 13 (60) 15 (21) (18) (43) (42) Fasenra 227 36 37 1 (30) (5) 152 33 42 57 63 32 33 Daliresp / Daxas 53 (7) (7) 1 (17) (9) 45 (7) 6 (3) 1 1 (37) (70) Bevespi 10 (1) (3) - - - 9 (6) 1 n/m n/m - - - Breztri 7 n/m n/m 5 n/m n/m - - - - - 2 n/m n/m Others 70 (30) (28) 21 (52) (52) 5 n/m 42 (18) (15) (60) (36) BioPharmaceuticals: total Respiratory & Immunology 1,117 (11) (8) 221 (50) (46) 472 15 267 (3) 1 23 26 Other medicines Nexium 377 (4) (1) 184 3 9 40 (24) 15 (7) (4) (5) (5) Synagis 90 (5) (5) - - - 14 41 76 (11) (11) - - - Losec / Prilosec 45 (34) (31) 37 (16) (12) 1 (90) 5 (60) (60) (75) (74) Seroquel XR / IR 27 (16) (14) 15 49 57 1 n/m 7 (71) (71) (23) (25) Others 24 (53) (52) 2 (88) (93) 8 (74) 13 3 1 1 n/m n/m Total other medicines 563 (12) (10) 238 (5) - 64 (29) 116 (23) (23) 145 (3) (3) Total Product Sales 6,048 6 9 2,048 5 12 2,013 7 1,102 5 9 885 4 5 82 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-or-year growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. The Q2 2020 information in respect of the three months ended 30 June 2020 included in the Interim Financial Statements has not been reviewed by PricewaterhouseCoopers LLP. *Denotes a legacy medicine. |
Product Sales quarterly sequent
Product Sales quarterly sequential analysis - Q2 2020 | 6 Months Ended |
Jun. 30, 2020 | |
Product Sales quarterly sequential analysis - Q2 2020 | |
Product Sales quarterly sequential analysis - Q2 2020 | 9 Product Sales quarterly sequential analysis – Q2 2020 (Unreviewed) 83 Q1 2020 Actual CER Q2 2020 Actual CER $m % % $m % % Oncology Tagrisso 982 11 11 1,034 5 7 Imfinzi 462 9 9 492 6 8 Lynparza 397 13 13 419 5 7 Calquence 88 58 58 107 21 23 Koselugo - - - 7 n/m n/m Zoladex* 225 15 15 217 (3) - Faslodex* 166 - - 146 (12) (9) Iressa* 77 (3) (4) 70 (9) (7) Arimidex* 50 (1) (2) 58 17 16 Casodex* 42 (2) (3) 47 14 12 Others 13 (52) (52) 12 (11) (1) Total Oncology 2,502 10 2,609 4 BioPharmaceuticals: CVRM Farxiga 405 (3) (3) 443 9 13 Brilinta 408 (5) (5) 437 7 9 Onglyza 141 8 8 115 (19) (17) Bydureon 100 (28) (28) 116 16 17 Byetta 20 (24) (24) 15 (28) (28) Other diabetes 13 (22) (22) 10 (21) (19) Lokelma 11 42 42 17 56 58 Crestor* 301 2 1 281 (7) (4) Seloken / Toprol-XL* 177 (6) (6) 218 23 27 Atacand* 66 11 12 59 (11) (5) Others 59 (21) (22) 48 (18) (16) BioPharmaceuticals: total CVRM 1,701 (5) (5) 1,759 3 6 BioPharmaceuticals: Respiratory & Immunology Symbicort 790 11 11 653 (17) (15) Pulmicort 380 (8) (9) 97 (74) (73) Fasenra 199 (3) (3) 227 14 15 Daliresp / Daxas 53 (8) (8) 53 (1) (3) Bevespi 12 9 9 10 (19) (21) Breztri 4 n/m n/m 7 58 64 Others 113 (16) (17) 70 (38) (36) BioPharmaceuticals: total Respiratory & Immunology 1,551 1 1 1,117 (28) (26) Other medicines Nexium 338 (4) (4) 377 12 14 Synagis 85 35 35 90 6 7 Losec / Prilosec 54 18 17 45 (15) (15) Seroquel XR / IR 36 (12) (12) 27 (26) (23) Others 44 (71) (70) 24 (46) (42) Total other medicines 557 (15) (15) 563 1 4 Total Product Sales 6,311 1 1 6,048 (4) (2) 83 The table provides an analysis of sequential quarterly Product Sales, with actual and CER growth rates reflecting quarter-on-quarter growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Sequential quarterly Product Sales information included in the Interim Financial Statements has not been reviewed by PricewaterhouseCoopers LLP. *Denotes a legacy medicine. |
Product Sales sequential quarte
Product Sales sequential quarterly analysis - FY 2019 | 6 Months Ended |
Jun. 30, 2020 | |
Product Sales sequential quarterly analysis - FY 2019 | |
Product Sales sequential quarterly analysis - FY 2019 | 10 Product Sales quarterly sequential analysis - FY 2019 (Unreviewed) 84 Q1 2019 Actual CER Q2 2019 Actual CER Q3 2019 Actual CER Q4 2019 Actual CER $m % % $m % % $m % % $m % % Oncology Tagrisso 630 6 6 784 24 25 891 14 13 884 (1) - Imfinzi 295 13 13 338 15 15 412 22 22 424 3 4 Lynparza 237 13 13 283 19 20 327 16 15 351 7 8 Calquence 29 21 23 35 21 19 44 27 27 56 25 25 Faslodex* 254 (6) (6) 267 5 6 205 (23) (23) 166 (20) (19) Zoladex* 194 7 6 197 2 1 226 15 16 196 (14) (12) Iressa* 134 20 18 118 (12) (11) 91 (23) (22) 80 (13) (12) Arimidex* 51 11 10 60 18 17 63 5 5 51 (20) (18) Casodex* 48 4 3 57 19 18 52 (8) (6) 43 (18) (17) Others 20 (13) (14) 28 40 29 20 (27) (22) 26 30 26 Total Oncology 1,892 7 2,167 15 15 2,334 8 8 2,274 (3) (2) BioPharmaceuticals: CVRM Farxiga 349 (12) (12) 377 8 9 398 5 5 419 5 6 Brilinta 348 (7) (8) 389 12 12 416 7 8 428 3 3 Onglyza 153 3 3 116 (24) (24) 127 9 11 131 3 4 Bydureon 142 3 3 141 (1) - 127 (10) (10) 139 9 10 Byetta 30 (6) (5) 25 (17) (16) 28 10 13 27 (2) (4) Other diabetes 11 (8) (17) 11 - 8 14 26 22 16 17 17 Lokelma - n/m n/m 2 n/m n/m 4 n/m n/m 8 87 74 Crestor* 335 (5) (6) 310 (7) (7) 337 9 9 296 (12) (11) Seloken / Toprol-XL* 225 41 38 168 (25) (25) 177 6 8 190 7 8 Atacand* 50 (14) (15) 56 12 14 55 (1) (1) 60 8 9 Others 71 (3) (5) 63 (11) (8) 65 4 2 72 13 16 BioPharmaceuticals: total CVRM 1,714 (2) (3) 1,658 (3) (3) 1,749 5 6 1,785 2 3 BioPharmaceuticals: Respiratory & Immunology Symbicort 585 (8) (8) 585 - 1 613 5 4 712 16 17 Pulmicort 383 (2) (2) 333 (13) (13) 337 1 3 413 22 23 Fasenra 129 3 4 167 29 30 202 21 21 206 2 2 Daliresp / Daxas 48 (11) (12) 56 17 18 53 (6) (7) 58 10 10 Bevespi 10 - (5) 10 - 2 10 4 8 12 8 5 Breztri - - - - - - 1 - - 1 (74) (73) Others 128 (14) (12) 101 (21) (23) 102 1 (1) 135 33 38 BioPharmaceuticals: total Respiratory & Immunology 1,283 (6) (6) 1,252 (2) (2) 1,319 5 6 1,537 17 17 Other medicines Nexium 363 (7) (8) 393 8 8 374 (5) (4) 353 (6) (6) Synagis 53 (79) (79) 96 81 81 146 52 53 63 (57) (57) Losec / Prilosec 76 27 26 68 (11) (10) 73 8 9 46 (38) (38) Seroquel XR / IR 37 (34) (33) 32 (14) (10) 82 n/m n/m 40 (50) (49) Others 47 (65) (64) 52 11 11 56 8 - 151 n/m n/m Total other medicines 576 (35) (36) 641 11 12 731 14 14 653 (11) (10) Total Product Sales 5,465 (5) (6) 5,718 5 5 6,132 7 8 6,250 2 3 84 The table below provides an analysis of sequential quarterly Product Sales, with actual and CER growth rates reflecting quarter-on-quarter growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. The sequential quarterly product sales information included in the Interim Financial Statements has not been reviewed by PricewaterhouseCoopers LLP. *Denotes a legacy medicine. |
Historic Collaberation Revenue
Historic Collaberation Revenue | 6 Months Ended |
Jun. 30, 2020 | |
Historic Collaberation Revenue | |
Historic Collaberation Revenue | 11 Historic Collaboration Revenue 85 H1 2020 H1 2019 FY 2019 FY 2018 $m $m $m $m Initial Collaboration Revenue Crestor (Spain) - - - 61 Lynparza : regulatory milestones 135 60 60 140 Lynparza : sales milestones - - 450 250 Lynparza /selumetinib: option payments - - 100 400 Ongoing Collaboration Revenue Crestor (Spain) - 39 - Enhertu: profit share 36 - - - Roxadustat: profit share 11 - - - Royalty income 34 32 62 49 Other Collaboration Revenue 54 39 108 141 Total 270 131 819 1,041 85 Historic Collaboration Revenue information included in the table above has not been reviewed by PricewaterhouseCoopers LLP. |
Other Operating Income and Expe
Other Operating Income and Expense | 6 Months Ended |
Jun. 30, 2020 | |
Other Operating Income and Expense | |
Other Operating Income and Expense | 12 Other Operating Income and Expense (Unreviewed) 86 The table below provides an analysis of Reported Other Operating Income and Expense. H1 2020 H1 2019 FY 2019 FY 2018 $m $m $m $m Hypertension medicines (ex-US, India and Japan) 350 - - - Inderal, Tenormin, Seloken and Omepral (Japan) 51 - - - Synagis (US) - 515 515 - Losec (ex-China, Japan, US and Mexico) - - 243 - Seroquel and Seroquel XR (US, Canada, Europe and Russia) - - 213 - Arimidex and Casodex (various countries) - - 181 - Nexium (Europe) and Vimovo (ex-US) - - - 728 Seroquel - - - 527 Legal settlement - - - 346 Atacand - - - 210 Anaesthetics - - - 172 Alvesco, Omnaris and Zetonna - - - 139 Other 200 191 389 405 Total 601 706 1,541 2,527 86 The Other Operating Income and Expense information included in the table above has not been reviewed by PricewaterhouseCoopers LLP. |
Group Accounting Policies (Poli
Group Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2020 | |
Group Accounting Policies | |
Basis of accounting and preparation of financial information | These unaudited Interim Financial Statements for the six months ended 30 June 2020 have been prepared in accordance with IAS 34 ‘Interim Financial Reporting’ as issued by the International Accounting Standards Board (IASB) and as adopted by the EU. The UK is in the process of establishing its post-Brexit IFRS-adoption authority, which is expected to be operational later in 2020, but for the current time, will follow the EU approval process . The unaudited Interim Financial Statements for the six months ended 30 June 2020 were approved by the Board of Directors for release on 30 July 2020. The annual financial statements of the Group are prepared in accordance with IFRSs as issued by the IASB and adopted by the EU. Except as noted below, the Interim Financial Statements have been prepared applying the accounting policies that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2019 . |
Adoption of new accounting standards | IFRS 3 An amendment to IFRS 3 ‘Business Combinations’ relating to the definition of a business was endorsed by the EU in April 2020 with an effective date of 1 January 2020. The change in definition of a business within IFRS 3 introduces an optional concentration test to perform a simplified assessment of whether an acquired set of activities and assets is or is not a business on a transaction by transaction basis. This change is expected to provide more reliable and comparable information about certain transactions as it provides more consistency in accounting in the pharmaceutical industry for substantially similar transactions for which, under the previous definition, may have been accounted in different ways, despite limited differences in substance. The Group has adopted this amendment from the effective date. IFRS 9, IAS 39 and IFRS 7 Amendments to IFRS 9 ‘Financial Instruments’, IAS 39 ‘Financial Instruments: Recognition and Measurement’ and IFRS 7 ‘Financial Instruments: Disclosures’ relating to interbank offered rate (IBOR) reform were endorsed by the EU in January 2020. The Group adopted the amendments in the year ended 31 December 2019. The replacement of benchmark interest rates such as the London Inter-bank Offered Rate (LIBOR) and other IBORs is a priority for global regulators. The amendments provide relief from applying specific hedge-accounting requirements to hedge relationships directly affected by IBOR reform and have the effect that IBOR reform should generally not cause hedge accounting to terminate. There is no financial impact from the early adoption of these amendments. The Group has one IFRS 9 designated hedge relationship that is potentially impacted by IBOR reform, namely a € 300m cross-currency interest-rate swap in a fair-value hedge relationship with € 300m of a € 750m 0.875% 2021 non-callable bond. This swap references three-month USD LIBOR and uncertainty arising from the Group’s exposure to IBOR reform will cease when the swap matures in 2021. The implications on the wider business of IBOR reform are currently being assessed. |
COVID-19 | COVID-19 AstraZeneca has assessed the impact of the uncertainty presented by the COVID-19 pandemic on the Interim Financial Statements comprising the financial results to 30 June 2020 and the financial position as at 30 June 2020, specifically considering the impact on key judgements and significant estimates as detailed on page 173 of the Annual Report and 20-F Information 2019 along with a several other areas of increased risk. A detailed assessment has been performed, focussing on the following areas: - recoverable value of goodwill, intangible assets and property, plant and equipment - impact on key assumptions used to estimate contingent consideration liabilities - key assumptions used in estimating the Group’s defined-benefit pension obligations - basis for estimating clinical-trial accruals - key assumptions used in estimating rebates, chargebacks and returns for US Product Sales - valuations of unlisted equity investments - expected credit losses associated with changes in credit risk relating to trade and other receivables - net realisable value of inventories - fair value of certain financial instruments - recoverability of deferred-tax assets - effectiveness of hedge relationships Given the significant volatility experienced in the financial markets, the assumptions used to estimate the Group’s material defined-benefit pension obligations are updated quarterly and resulted in an overall $40m increase in the Group’s defined-benefit pension deficit in the six months ended 30 June 2020. The increase in the deficit primarily reflected increased liability valuations as a result of lower discount rates (due to falling long term AA corporate bond yields linked to the launch of a quantitative easing bond-buying programme in the UK and other regions in June 2020), with an increase in asset values providing a partial offset. In the UK, £79m of deficit-recovery contributions were also paid during the period. The sensitivity of the Group’s main defined-benefit liability valuations to changes in assumptions is set out on page 207 of the Annual Report and 20-F Information 2019 . No further material accounting impacts relating to the areas assessed above were recognised during the six-month period ending 30 June 2020. The Group will continue to monitor these areas of increased judgement, estimation and risk for material changes. |
Going concern | Going concern The Group has considerable financial resources available. As at 30 June 2020 the Group had $10.2bn in financial resources (cash and cash-equivalent balances of $5.7bn, $0.4bn of liquid fixed income securities and undrawn committed bank facilities of $4.1bn, of which $3.4bn is available until April 2022, $0.5bn is available until November 2020 (extendable to November 2021) and $0.2bn is available until December 2020, with only $4.1bn of borrowings due within one year). The Group’s revenues are largely derived from sales of medicines that are covered by patents which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to affect adversely revenues in many of the mature markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. In the current environment, the Directors have also considered the impact of possible future COVID-19 related scenarios and believe the Group retains sufficient liquidity to continue to operate. Based on the above paragraph, the going-concern basis has been adopted in these Interim Financial Statements. |
Legal proceedings | Legal proceedings The information contained in Note 5 updates the disclosures concerning legal proceedings and contingent liabilities in the Group’s Annual Report and 20-F Information 2019 . |
Financial information | Financial information The comparative figures for the financial year ended 31 December 2019 are not the Group’s statutory accounts for that financial year. Those accounts have been reported on by the Group’s auditors and have been delivered to the registrar of companies; their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006. |
Net Debt (Tables)
Net Debt (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Net Debt | |
Schedule of Net Debt | At 1 Jan Cash Non-cash Exchange At 30 Jun flow & other movements $m $m $m $m $m Non-current instalments of loans (15,730) - 550 30 (15,150) Non-current instalments of leases (487) - 11 11 (465) Total long-term debt (16,217) - 561 41 (15,615) Current instalments of loans (1,597) - (556) (6) (2,159) Current instalments of leases (188) 117 (107) 4 (174) Commercial paper - (1,262) - - (1,262) Bank collateral (71) (34) - - (105) Other short-term borrowings excluding overdrafts (8) (57) - 1 (64) Overdraft (146) (230) - 8 (368) Total current debt (2,010) (1,466) (663) 7 (4,132) Gross borrowings (18,227) (1,466) (102) 48 (19,747) Net derivative financial instruments 43 93 (154) - (18) Net borrowings (18,184) (1,373) (256) 48 (19,765) Cash and cash equivalents 5,369 330 - (26) 5,673 Other investments - current 849 (463) 62 (6) 442 Other investments - non-current 62 - (62) - - Cash and investments 6,280 (133) - (32) 6,115 Net Debt (11,904) (1,506) (256) 16 (13,650) |
Financial Instruments (Tables)
Financial Instruments (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Financial Instruments | |
Schedule of Contingent consideration | Diabetes alliance Other Total Total $m $m $m $m At 1 January 3,300 839 4,139 5,106 Settlements (257) (96) (353) (368) Revaluations (22) (22) (44) - Discount unwind 115 26 141 179 At 30 June 3,136 747 3,883 4,917 |
Product Sales year on year an_2
Product Sales year on year analysis - H1 2020 (Table) | 6 Months Ended |
Jun. 30, 2020 | |
Product Sales year on year analysis - H1 2020 | |
Product Sales Analysis, H1 2020 | World Emerging Markets US Europe Established ROW H1 2020 Actual CER H1 2020 Actual CER H1 2020 Actual H1 2020 Actual CER H1 2020 Actual CER $m % % $m % % $m % $m % % $m % % Oncology Tagrisso 2,016 43 45 595 81 89 725 30 325 53 58 18 18 Imfinzi 954 51 52 63 n/m n/m 574 21 167 n/m n/m 70 71 Lynparza 816 57 60 120 n/m n/m 406 55 198 51 56 35 34 Calquence 195 n/m n/m 2 n/m n/m 193 n/m - - - - - - Koselugo 7 n/m n/m - - - 7 n/m - - - - - - Zoladex* 442 13 18 288 22 29 5 40 68 5 8 (7) (6) Faslodex* 312 (40) (38) 100 4 10 34 (87) 116 6 9 (4) (4) Iressa* 147 (42) (40) 120 (27) (24) 7 (3) 9 (81) (81) (67) (66) Arimidex* 107 (3) - 90 26 30 - - 1 (90) (90) (32) (32) Casodex* 89 (15) (13) 69 8 11 - - 1 (84) (84) (43) (42) Others 26 (50) (47) 14 (23) (14) - - 3 (15) (16) (64) (69) Total Oncology 5,111 26 28 1,461 39 46 1,951 20 888 37 41 10 9 BioPharmaceuticals: CVRM Farxiga 848 17 21 306 49 59 237 (12) 223 25 29 14 15 Brilinta 845 15 17 291 34 40 351 9 173 2 5 7 10 Onglyza 256 (5) (3) 100 15 21 105 (12) 29 (21) (18) (15) (13) Bydureon 216 (24) (23) 2 (74) (72) 185 (21) 24 (29) (26) (37) (34) Byetta 35 (36) (35) 5 13 21 19 (47) 7 (29) (26) (21) (20) Other diabeties 23 3 6 3 n/m n/m 13 (21) 6 44 50 (60) (25) Lokelma 28 n/m n/m 1 n/m n/m 22 n/m 2 n/m n/m 3 n/m n/m Crestor* 582 (10) (8) 369 (9) (6) 45 (17) 64 (15) (13) (5) (5) Seloken / Toprol-XL* 395 - 6 376 8 14 6 (78) 8 (39) (39) - 5 Atacand* 126 19 25 94 23 31 5 (15) 15 (2) (2) 37 43 Others 106 (20) (18) 65 (30) (28) - - 35 15 18 (36) (39) BioPharmaceuticals: total CVRM 3,460 3 6 1,612 11 17 988 (9) 586 3 6 - 2 BioPharmaceuticals: Respiratory & Immunology Symbicort 1,442 23 26 290 10 16 558 46 356 1 4 39 42 Pulmicort 477 (33) (32) 371 (36) (34) 36 (36) 40 (8) (4) (26) (25) Fasenra 426 44 45 7 n/m n/m 272 31 88 96 n/m 41 41 Daliresp / Daxas 106 1 2 2 (13) (7) 90 1 13 7 11 1 (3) (36) Bevespi 22 10 10 - - - 21 5 1 n/m n/m - - - Breztri 11 n/m n/m 9 n/m n/m - - - - - 2 n/m n/m Others 184 (20) (18) 80 (29) (27) 7 n/m 89 (16) (14) (14) 4 BioPharmaceuticals: total Respiratory & Immunology 2,668 5 7 759 (21) (18) 984 30 587 5 8 29 31 Other medicines Nexium 714 (5) (3) 371 - 5 80 (32) 36 14 18 (4) (4) Synagis 176 18 18 5 n/m n/m 21 (40) 150 32 32 - - - Losec / Prilosec 99 (32) (30) 81 (15) (12) 3 (44) 10 (68) (68) (62) (62) Seroquel XR / IR 63 (9) (8) 27 11 15 14 n/m 15 (69) (69) (36) (37) Others 68 (32) (31) 3 (64) (73) 33 (44) 28 5 5 4 (34) (22) Total other medicines 1,120 (8) (6) 487 (2) 1 151 (26) 239 (4) (4) 243 (9) (9) Total Product Sales 12,359 11 13 4,319 9 14 4,074 11 2,300 13 17 1,666 8 9 |
Product Sales year-on-year an_2
Product Sales year-on-year analysis - Q2 2020 (Table) | 6 Months Ended |
Jun. 30, 2020 | |
Product Sales year-on-year analysis - Q2 2020 | |
Product Sales year-on-year analysis - Q2 2020 | World Emerging Markets US Europe Established ROW Q2 2020 Actual CER Q2 2020 Actual CER Q2 2020 Actual Q2 2020 Actual CER Q2 2020 Actual CER $m % % $m % % $m % $m % % $m % % Oncology Tagrisso 1,034 32 35 315 65 74 354 18 163 46 51 12 12 Imfinzi 492 46 48 30 n/m n/m 287 19 93 n/m n/m 55 56 Lynparza 419 48 52 64 95 n/m 209 47 96 45 50 20 21 Calquence 107 n/m n/m 1 n/m n/m 107 n/m - - - (1) n/m n/m Koselugo 7 n/m n/m - - - 7 n/m - - - - - - Zoladex* 217 10 17 139 15 24 3 55 33 8 14 (4) (2) Faslodex* 146 (45) (43) 52 2 10 11 (91) 52 (7) (3) (13) (13) Iressa* 70 (41) (38) 58 (26) (23) 4 (5) 3 (85) (85) (65) (62) Arimidex* 58 (4) - 48 35 41 - - 1 (93) (93) (42) (43) Casodex* 47 (17) (15) 37 8 11 - - - n/m n/m (47) (46) Others 12 (59) (55) 6 (35) (18) (1) n/m 1 (32) (35) (67) (74) Total Oncology 2,609 20 24 750 34 43 981 15 442 32 37 3 4 BioPharmaceuticals: CVRM Farxiga 443 17 23 165 49 62 124 (11) 107 20 25 24 26 Brilinta 437 12 16 156 30 39 187 11 80 (9) (5) 6 10 Bydureon 116 (18) (17) 1 (87) (86) 101 (14) 12 (22) (19) (23) (18) Onglyza 115 (1) 3 52 19 27 38 (9) 14 (22) (19) (20) (17) Byetta 15 (42) (41) 2 (37) (30) 7 (53) 4 (16) (13) (26) (26) Other diabeties 10 (9) (5) 1 n/m n/m 6 (31) 3 37 44 - n/m n/m Lokelma 17 n/m n/m 1 n/m n/m 12 n/m 1 n/m n/m 3 n/m n/m Crestor* 281 (10) (6) 177 (3) 2 17 (40) 30 (18) (16) (11) (10) Seloken / Toprol-XL* 218 29 38 210 35 45 2 (53) 4 (48) (48) 2 9 Atacand* 59 6 14 45 21 33 2 (39) 6 (43) (43) 43 52 Others 48 (23) (20) 29 (31) (28) - - 16 25 29 (65) (69) BioPharmaceuticals: total CVRM 1,759 6 10 839 20 28 496 (6) 277 (3) 1 (1) 1 BioPharmaceuticals: Respiratory & Immunology Symbicort 653 12 15 135 3 12 248 20 161 (6) (3) 42 47 Pulmicort 97 (71) (69) 58 (78) (76) 13 (60) 15 (21) (18) (43) (42) Fasenra 227 36 37 1 (30) (5) 152 33 42 57 63 32 33 Daliresp / Daxas 53 (7) (7) 1 (17) (9) 45 (7) 6 (3) 1 1 (37) (70) Bevespi 10 (1) (3) - - - 9 (6) 1 n/m n/m - - - Breztri 7 n/m n/m 5 n/m n/m - - - - - 2 n/m n/m Others 70 (30) (28) 21 (52) (52) 5 n/m 42 (18) (15) (60) (36) BioPharmaceuticals: total Respiratory & Immunology 1,117 (11) (8) 221 (50) (46) 472 15 267 (3) 1 23 26 Other medicines Nexium 377 (4) (1) 184 3 9 40 (24) 15 (7) (4) (5) (5) Synagis 90 (5) (5) - - - 14 41 76 (11) (11) - - - Losec / Prilosec 45 (34) (31) 37 (16) (12) 1 (90) 5 (60) (60) (75) (74) Seroquel XR / IR 27 (16) (14) 15 49 57 1 n/m 7 (71) (71) (23) (25) Others 24 (53) (52) 2 (88) (93) 8 (74) 13 3 1 1 n/m n/m Total other medicines 563 (12) (10) 238 (5) - 64 (29) 116 (23) (23) 145 (3) (3) Total Product Sales 6,048 6 9 2,048 5 12 2,013 7 1,102 5 9 885 4 5 |
Product Sales quarterly seque_2
Product Sales quarterly sequential quarterly - Q2 2020 (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Product Sales quarterly sequential analysis - Q2 2020 | |
Product Sales quarterly sequential quarterly - Q2 2020 | Q1 2020 Actual CER Q2 2020 Actual CER $m % % $m % % Oncology Tagrisso 982 11 11 1,034 5 7 Imfinzi 462 9 9 492 6 8 Lynparza 397 13 13 419 5 7 Calquence 88 58 58 107 21 23 Koselugo - - - 7 n/m n/m Zoladex* 225 15 15 217 (3) - Faslodex* 166 - - 146 (12) (9) Iressa* 77 (3) (4) 70 (9) (7) Arimidex* 50 (1) (2) 58 17 16 Casodex* 42 (2) (3) 47 14 12 Others 13 (52) (52) 12 (11) (1) Total Oncology 2,502 10 2,609 4 BioPharmaceuticals: CVRM Farxiga 405 (3) (3) 443 9 13 Brilinta 408 (5) (5) 437 7 9 Onglyza 141 8 8 115 (19) (17) Bydureon 100 (28) (28) 116 16 17 Byetta 20 (24) (24) 15 (28) (28) Other diabetes 13 (22) (22) 10 (21) (19) Lokelma 11 42 42 17 56 58 Crestor* 301 2 1 281 (7) (4) Seloken / Toprol-XL* 177 (6) (6) 218 23 27 Atacand* 66 11 12 59 (11) (5) Others 59 (21) (22) 48 (18) (16) BioPharmaceuticals: total CVRM 1,701 (5) (5) 1,759 3 6 BioPharmaceuticals: Respiratory & Immunology Symbicort 790 11 11 653 (17) (15) Pulmicort 380 (8) (9) 97 (74) (73) Fasenra 199 (3) (3) 227 14 15 Daliresp / Daxas 53 (8) (8) 53 (1) (3) Bevespi 12 9 9 10 (19) (21) Breztri 4 n/m n/m 7 58 64 Others 113 (16) (17) 70 (38) (36) BioPharmaceuticals: total Respiratory & Immunology 1,551 1 1 1,117 (28) (26) Other medicines Nexium 338 (4) (4) 377 12 14 Synagis 85 35 35 90 6 7 Losec / Prilosec 54 18 17 45 (15) (15) Seroquel XR / IR 36 (12) (12) 27 (26) (23) Others 44 (71) (70) 24 (46) (42) Total other medicines 557 (15) (15) 563 1 4 Total Product Sales 6,311 1 1 6,048 (4) (2) |
Sequential Quarterly Product Sa
Sequential Quarterly Product Sales - FY 2019 (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Product Sales sequential quarterly analysis - FY 2019 | |
Schedule of sequential quarterly product sales - FY 2019 | Q1 2019 Actual CER Q2 2019 Actual CER Q3 2019 Actual CER Q4 2019 Actual CER $m % % $m % % $m % % $m % % Oncology Tagrisso 630 6 6 784 24 25 891 14 13 884 (1) - Imfinzi 295 13 13 338 15 15 412 22 22 424 3 4 Lynparza 237 13 13 283 19 20 327 16 15 351 7 8 Calquence 29 21 23 35 21 19 44 27 27 56 25 25 Faslodex* 254 (6) (6) 267 5 6 205 (23) (23) 166 (20) (19) Zoladex* 194 7 6 197 2 1 226 15 16 196 (14) (12) Iressa* 134 20 18 118 (12) (11) 91 (23) (22) 80 (13) (12) Arimidex* 51 11 10 60 18 17 63 5 5 51 (20) (18) Casodex* 48 4 3 57 19 18 52 (8) (6) 43 (18) (17) Others 20 (13) (14) 28 40 29 20 (27) (22) 26 30 26 Total Oncology 1,892 7 2,167 15 15 2,334 8 8 2,274 (3) (2) BioPharmaceuticals: CVRM Farxiga 349 (12) (12) 377 8 9 398 5 5 419 5 6 Brilinta 348 (7) (8) 389 12 12 416 7 8 428 3 3 Onglyza 153 3 3 116 (24) (24) 127 9 11 131 3 4 Bydureon 142 3 3 141 (1) - 127 (10) (10) 139 9 10 Byetta 30 (6) (5) 25 (17) (16) 28 10 13 27 (2) (4) Other diabetes 11 (8) (17) 11 - 8 14 26 22 16 17 17 Lokelma - n/m n/m 2 n/m n/m 4 n/m n/m 8 87 74 Crestor* 335 (5) (6) 310 (7) (7) 337 9 9 296 (12) (11) Seloken / Toprol-XL* 225 41 38 168 (25) (25) 177 6 8 190 7 8 Atacand* 50 (14) (15) 56 12 14 55 (1) (1) 60 8 9 Others 71 (3) (5) 63 (11) (8) 65 4 2 72 13 16 BioPharmaceuticals: total CVRM 1,714 (2) (3) 1,658 (3) (3) 1,749 5 6 1,785 2 3 BioPharmaceuticals: Respiratory & Immunology Symbicort 585 (8) (8) 585 - 1 613 5 4 712 16 17 Pulmicort 383 (2) (2) 333 (13) (13) 337 1 3 413 22 23 Fasenra 129 3 4 167 29 30 202 21 21 206 2 2 Daliresp / Daxas 48 (11) (12) 56 17 18 53 (6) (7) 58 10 10 Bevespi 10 - (5) 10 - 2 10 4 8 12 8 5 Breztri - - - - - - 1 - - 1 (74) (73) Others 128 (14) (12) 101 (21) (23) 102 1 (1) 135 33 38 BioPharmaceuticals: total Respiratory & Immunology 1,283 (6) (6) 1,252 (2) (2) 1,319 5 6 1,537 17 17 Other medicines Nexium 363 (7) (8) 393 8 8 374 (5) (4) 353 (6) (6) Synagis 53 (79) (79) 96 81 81 146 52 53 63 (57) (57) Losec / Prilosec 76 27 26 68 (11) (10) 73 8 9 46 (38) (38) Seroquel XR / IR 37 (34) (33) 32 (14) (10) 82 n/m n/m 40 (50) (49) Others 47 (65) (64) 52 11 11 56 8 - 151 n/m n/m Total other medicines 576 (35) (36) 641 11 12 731 14 14 653 (11) (10) Total Product Sales 5,465 (5) (6) 5,718 5 5 6,132 7 8 6,250 2 3 |
Historic Collaberation Revenue
Historic Collaberation Revenue (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Historic Collaberation Revenue | |
Schedule of historic collaberation revenue | H1 2020 H1 2019 FY 2019 FY 2018 $m $m $m $m Initial Collaboration Revenue Crestor (Spain) - - - 61 Lynparza : regulatory milestones 135 60 60 140 Lynparza : sales milestones - - 450 250 Lynparza /selumetinib: option payments - - 100 400 Ongoing Collaboration Revenue Crestor (Spain) - 39 - Enhertu: profit share 36 - - - Roxadustat: profit share 11 - - - Royalty income 34 32 62 49 Other Collaboration Revenue 54 39 108 141 Total 270 131 819 1,041 |
Other Operating Income and Ex_2
Other Operating Income and Expense (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Other Operating Income and Expense | |
Schedule of other operating income and expense | H1 2020 H1 2019 FY 2019 FY 2018 $m $m $m $m Hypertension medicines (ex-US, India and Japan) 350 - - - Inderal, Tenormin, Seloken and Omepral (Japan) 51 - - - Synagis (US) - 515 515 - Losec (ex-China, Japan, US and Mexico) - - 243 - Seroquel and Seroquel XR (US, Canada, Europe and Russia) - - 213 - Arimidex and Casodex (various countries) - - 181 - Nexium (Europe) and Vimovo (ex-US) - - - 728 Seroquel - - - 527 Legal settlement - - - 346 Atacand - - - 210 Anaesthetics - - - 172 Alvesco, Omnaris and Zetonna - - - 139 Other 200 191 389 405 Total 601 706 1,541 2,527 |
Basis of Preparation and Acco_2
Basis of Preparation and Accounting Policies (Details) € in Millions, $ in Millions | 6 Months Ended | |||
Jun. 30, 2020EUR (€)item | Jun. 30, 2020USD ($) | Dec. 31, 2019USD ($) | Jun. 30, 2019USD ($) | |
Application of new accounting standards | ||||
Number of hedge relationship instruments effected with LIBOR | item | 1 | |||
Borrowings | $ 19,747 | $ 18,227 | ||
Going concern | ||||
Financial resources | 10,200 | |||
Cash and cash equivalents | 5,673 | $ 5,369 | $ 5,428 | |
Liquid fixed income securities | 400 | |||
Undrawn committed bank facilities | 4,100 | |||
Years 2 and 3 | ||||
Going concern | ||||
Undrawn committed bank facilities | 3,400 | |||
Years 1 and 2 | ||||
Going concern | ||||
Undrawn committed bank facilities | 500 | |||
Due later than six months but no later than one year | ||||
Going concern | ||||
Undrawn committed bank facilities | 200 | |||
Due within one year | ||||
Going concern | ||||
Short-term borrowings | $ 4,100 | |||
0.875% Non-callable bond | ||||
Application of new accounting standards | ||||
Borrowings | € | € 750 | |||
Interest rate on borrowings | 0.875% | 0.875% | ||
Instruments in a fair value hedge relationship | 0.875% Non-callable bond | ||||
Application of new accounting standards | ||||
Borrowings covered by hedges | € | € 300 | |||
Interest rate swaps | Instruments in a fair value hedge relationship | Group's EUR denominated net assets | ||||
Application of new accounting standards | ||||
Nominal amounts in local currency | € | 300 |
Basis of Preparation and Acco_3
Basis of Preparation and Accounting Policies - COVID-19 (Details) - 6 months ended Jun. 30, 2020 £ in Millions, $ in Millions | GBP (£) | USD ($) |
Impact of COVID-19 | ||
Represents the increase in the defined benefit pension deficit. | $ | $ 40 | |
UK defined benefit pension | UK defined benefit plans | ||
Impact of COVID-19 | ||
Deficit recovery contribution | £ | £ 79 |
Intangible assets (Details)
Intangible assets (Details) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2020USD ($) | Mar. 31, 2020USD ($) | Jun. 30, 2020USD ($) | Dec. 31, 2019USD ($) | Jun. 30, 2019USD ($) | |
Impairment of intangible assets | |||||
Impairment | $ 119,000,000 | ||||
Carrying value | $ 19,728,000,000 | $ 19,728,000,000 | $ 20,833,000,000 | $ 22,257,000,000 | |
Duaklir and Eklira/Tudorza | Projected revenue fall by 20% | |||||
Impairment of intangible assets | |||||
Group's valuation model | 20 | 20 | |||
Duaklir | |||||
Impairment of intangible assets | |||||
Impairment | $ 65,000,000 | ||||
Carrying value | 274,000,000 | $ 274,000,000 | |||
Duaklir | Projected revenue fall by 20% | |||||
Impairment of intangible assets | |||||
Increase in impairment charge due to changes in assumptions of valuation model | 60,000,000 | ||||
Eklira/Tudorza | |||||
Impairment of intangible assets | |||||
Impairment | 31,000,000 | ||||
Carrying value | 130,000,000 | 130,000,000 | |||
Eklira/Tudorza | Projected revenue fall by 20% | |||||
Impairment of intangible assets | |||||
Increase in impairment charge due to changes in assumptions of valuation model | 30,000,000 | ||||
FluMist | |||||
Impairment of intangible assets | |||||
Carrying value | 258,000,000 | $ 258,000,000 | |||
Reversal of impairment | $ 95,000,000 | ||||
Launched products | Bydureon | |||||
Impairment of intangible assets | |||||
Impairment | $ 102,000,000 | ||||
Carrying value | $ 612,000,000 | ||||
Group's valuation model | 10 | 10 | |||
Launched products | Bydureon | Projected revenue fall by 10% | |||||
Impairment of intangible assets | |||||
Group's valuation model | 10 | 10 | |||
Increase in impairment charge due to changes in assumptions of valuation model | $ 100,000,000 |
Net Debt (Details)
Net Debt (Details) - USD ($) $ in Millions | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | |
Interest bearing loans and borrowings | |||
Non-current installments of loans | $ (15,730) | ||
Non-current installments of loans - Non-cash & Other | 550 | ||
Non-current installments of loans - Exchange Movements | 30 | ||
Non-current installments of loans | (15,150) | $ (17,355) | |
Non-current installments of leases | (487) | ||
Non-current installments of leases - Non-cash & Other | 11 | ||
Non-current installments of leases - Exchange Movements | 11 | ||
Non-current installments of leases | (465) | (514) | |
Total long-term debt | (16,217) | ||
Total long-term debt - Non-cash & Other | 561 | ||
Total long-term debt - Exchange Movements | 41 | ||
Total long-term debt | (15,615) | ||
Current instalments of loans | (1,597) | ||
Current instalments of loans - Non-cash & Other | (556) | ||
Current instalments of loans - Exchange Movements | (6) | ||
Current instalments of loans | (2,159) | ||
Current instalments of leases | (188) | ||
Current instalments of leases - Cash Flow | 117 | ||
Current instalments of leases - Non-cash & Other | (107) | ||
Current instalments of leases - Exchange Movements | 4 | ||
Current instalments of leases | (174) | (206) | |
Interest-bearing loans and borrowings | (1,822) | ||
Interest-bearing loans and borrowings | (3,958) | (1,629) | |
Total current debt | (2,010) | ||
Total current debt - Cash Flow | (1,466) | ||
Total current debt - Non-cash & Other | (663) | ||
Total current debt - Exchange Movements | 7 | ||
Total current debt | (4,132) | ||
Gross borrowings | (18,227) | ||
Gross borrowings - Cash Flow | (1,466) | ||
Gross borrowings - Non-cash & Other | (102) | ||
Gross borrowings - Exchange Movements | 48 | ||
Gross borrowings | (19,747) | ||
Net derivative financial instruments | 43 | ||
Net derivative financial instruments - Cash Flow | 93 | ||
Net derivative financial instruments - Non-cash & Other | (154) | ||
Net derivative financial instruments | (18) | ||
Net borrowings | (18,184) | ||
Net borrowings - Cash Flow | (1,373) | ||
Net borrowings - Non-cash & Other | (256) | ||
Net borrowings - Exchange Movements | 48 | ||
Net borrowings | (19,765) | ||
Cash and cash equivalents at the beginning of the period | 5,369 | ||
Cash and cash equivalents - Cash Flow | 330 | ||
Cash and cash equivalents - Exchange Movements | (26) | ||
Cash and cash equivalents at the end of the period | 5,673 | 5,428 | |
Other investments - current | 849 | ||
Other investments, current - Cash Flow | (463) | ||
Other investments, current - Non-cash & Other | 62 | ||
Other investments, current - Exchange Movements | (6) | ||
Other investments - current | 442 | 819 | |
Other investments - non-current | 62 | ||
Other investments, non-current - Non-cash & Other | (62) | ||
Cash and investments | 6,280 | ||
Cash and investments - Cash Flow | (133) | ||
Cash and investments - Exchange Movements | (32) | ||
Cash and investments | 6,115 | ||
Net Debt | (11,904) | ||
Net Debt - Cash Flow | (1,506) | ||
Net Debt - Non-cash & Other | (256) | ||
Net Debt - Exchange Movements | 16 | ||
Net Debt | (13,650) | ||
Other investments - non-current | 1,577 | 1,362 | $ 1,401 |
Increase in net debt | 1,746 | ||
Net cash inflow from operating activities | 1,179 | 491 | |
Dividends paid | $ 2,398 | $ 2,432 | |
Percentage of 2019 full year dividends paid | 67.00% | ||
Put option | |||
Interest bearing loans and borrowings | |||
Potential payable | $ 2,219 | $ 2,146 | |
Commercial paper | |||
Interest bearing loans and borrowings | |||
Current borrowings and current portion of non-current borrowing - Cash Flow | (1,262) | ||
Interest-bearing loans and borrowings | (1,262) | ||
Bank collateral | |||
Interest bearing loans and borrowings | |||
Interest-bearing loans and borrowings | (71) | ||
Current borrowings and current portion of non-current borrowing - Cash Flow | (34) | ||
Interest-bearing loans and borrowings | (105) | ||
Other Short-term borrowings excluding overdrafts | |||
Interest bearing loans and borrowings | |||
Interest-bearing loans and borrowings | (8) | ||
Current borrowings and current portion of non-current borrowing - Cash Flow | (57) | ||
Current borrowings and current portion of non-current borrowing - Exchange Movements | 1 | ||
Interest-bearing loans and borrowings | (64) | ||
Overdrafts | |||
Interest bearing loans and borrowings | |||
Interest-bearing loans and borrowings | (146) | ||
Current borrowings and current portion of non-current borrowing - Cash Flow | (230) | ||
Current borrowings and current portion of non-current borrowing - Exchange Movements | 8 | ||
Interest-bearing loans and borrowings | $ (368) |
Financial Instruments (Details)
Financial Instruments (Details) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2020USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2019USD ($) | Dec. 31, 2019USD ($) | |
Financial instruments fair value gains | |||||
Fair value movements on equity investments | $ 898,000,000 | $ (174,000,000) | $ 1,069,000,000 | $ (54,000,000) | |
Reconciliation of changes in contingent liabilities in business combination | |||||
Contingent liabilities recognised in business combination at beginning of period | 4,139,000,000 | 5,106,000,000 | |||
Settlements | (353,000,000) | (368,000,000) | |||
Revaluations | (44,000,000) | ||||
Discount unwind | 141,000,000 | 179,000,000 | |||
Contingent liabilities recognised in business combination at end of period | 3,883,000,000 | $ 4,917,000,000 | 3,883,000,000 | $ 4,917,000,000 | |
Launched products | Bydureon | |||||
Reconciliation of changes in contingent liabilities in business combination | |||||
Increase/decrease in contingent consideration balance with change in current estimates | $ (22,000,000) | (22,000,000) | |||
Changes in fair value of contingent consideration | $ (22,000,000) | ||||
Group's valuation model | 10 | 10 | |||
Diabetes alliance | |||||
Reconciliation of changes in contingent liabilities in business combination | |||||
Contingent liabilities recognised in business combination at beginning of period | $ 3,300,000,000 | ||||
Settlements | (257,000,000) | ||||
Revaluations | (22,000,000) | ||||
Discount unwind | 115,000,000 | ||||
Contingent liabilities recognised in business combination at end of period | $ 3,136,000,000 | 3,136,000,000 | |||
Increase/decrease in contingent consideration balance with change in current estimates | 314,000,000 | $ 314,000,000 | |||
The increase/decrease in sales estimates | 10.00% | ||||
Other | |||||
Reconciliation of changes in contingent liabilities in business combination | |||||
Contingent liabilities recognised in business combination at beginning of period | $ 839,000,000 | ||||
Settlements | (96,000,000) | ||||
Revaluations | (22,000,000) | ||||
Discount unwind | 26,000,000 | ||||
Contingent liabilities recognised in business combination at end of period | 747,000,000 | 747,000,000 | |||
Interest-Bearing Loans and Borrowings | |||||
Financial instruments fair value gains | |||||
Total carrying value | 19,747,000,000 | 19,747,000,000 | |||
Fair value | 22,992,000,000 | 22,992,000,000 | |||
Other Investments | |||||
Financial instruments fair value gains | |||||
Fair value | 2,019,000,000 | 2,019,000,000 | |||
Money market funds | |||||
Financial instruments fair value gains | |||||
Fair value | 4,743,000,000 | 4,743,000,000 | |||
Loans | Instruments in a fair value hedge relationship | |||||
Financial instruments fair value gains | |||||
Fair value | 339,000,000 | 339,000,000 | |||
Loans | Instruments designated at fair value through profit and loss | |||||
Financial instruments fair value gains | |||||
Fair value | 339,000,000 | 339,000,000 | |||
Derivatives | |||||
Financial instruments fair value gains | |||||
Fair value | (18,000,000) | (18,000,000) | |||
Level 1 | Equity securities | |||||
Financial instruments fair value gains | |||||
Fair value | $ 188,000,000 | 188,000,000 | |||
Level 3 | |||||
Financial instruments fair value gains | |||||
Fair value movements on equity investments | $ 65,000,000 | ||||
Level 3 | Equity securities | |||||
Financial instruments fair value gains | |||||
Fair value | $ 103,000,000 |
Legal Proceedings and Conting_2
Legal Proceedings and Contingent Liabilities (Details) - USD ($) $ in Millions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2020 | Dec. 31, 2019 | |
Legal Proceedings and Contingent Liabilities | ||
Tax contingency related to transfer pricing audits included in tax accrual | $ 139 | $ 140 |
Estimated additional tax contingency and transfer pricing liabilities | $ 226 | $ 76 |
Subsequent Events (Details)
Subsequent Events (Details) - Global development and commercialisation agreement $ in Billions | 1 Months Ended |
Jul. 30, 2020USD ($) | |
Subsequent events | |
Upfront payment due | $ 1 |
Maximum amount of additional conditional payments for the successful achievement of regulatory approvals | 1 |
Maximum amount of potential sales-related milestones | $ 4 |
Product Sales year on year an_3
Product Sales year on year analysis - H1 2020 (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||||
Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Jun. 30, 2020 | |
Product sales | |||||||
Product Sales | $ 6,048 | $ 6,311 | $ 6,250 | $ 6,132 | $ 5,718 | $ 5,465 | |
World | |||||||
Product sales | |||||||
Product Sales | $ 6,048 | $ 12,359 | |||||
Actual %, year-on-year | 6.00% | 11.00% | |||||
CER %, year-on-year | 9.00% | 13.00% | |||||
Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 2,048 | $ 4,319 | |||||
Actual %, year-on-year | 5.00% | 9.00% | |||||
CER %, year-on-year | 12.00% | 14.00% | |||||
US | |||||||
Product sales | |||||||
Product Sales | $ 2,013 | $ 4,074 | |||||
Actual %, year-on-year | 7.00% | 11.00% | |||||
Europe | |||||||
Product sales | |||||||
Product Sales | $ 1,102 | $ 2,300 | |||||
Actual %, year-on-year | 5.00% | 13.00% | |||||
CER %, year-on-year | 9.00% | 17.00% | |||||
Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 885 | $ 1,666 | |||||
Actual %, year-on-year | 4.00% | 8.00% | |||||
CER %, year-on-year | 5.00% | 9.00% | |||||
Oncology | |||||||
Product sales | |||||||
Product Sales | $ 2,609 | 2,502 | 2,274 | 2,334 | 2,167 | 1,892 | |
Oncology | World | |||||||
Product sales | |||||||
Product Sales | $ 2,609 | $ 5,111 | |||||
Actual %, year-on-year | 20.00% | 26.00% | |||||
CER %, year-on-year | 24.00% | 28.00% | |||||
Oncology | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 750 | $ 1,461 | |||||
Actual %, year-on-year | 34.00% | 39.00% | |||||
CER %, year-on-year | 43.00% | 46.00% | |||||
Oncology | US | |||||||
Product sales | |||||||
Product Sales | $ 981 | $ 1,951 | |||||
Actual %, year-on-year | 15.00% | 20.00% | |||||
Oncology | Europe | |||||||
Product sales | |||||||
Product Sales | $ 442 | $ 888 | |||||
Actual %, year-on-year | 32.00% | 37.00% | |||||
CER %, year-on-year | 37.00% | 41.00% | |||||
Oncology | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 436 | $ 811 | |||||
Actual %, year-on-year | 3.00% | 10.00% | |||||
CER %, year-on-year | 4.00% | 9.00% | |||||
Tagrisso | |||||||
Product sales | |||||||
Product Sales | $ 1,034 | 982 | 884 | 891 | 784 | 630 | |
Tagrisso | World | |||||||
Product sales | |||||||
Product Sales | $ 1,034 | $ 2,016 | |||||
Actual %, year-on-year | 32.00% | 43.00% | |||||
CER %, year-on-year | 35.00% | 45.00% | |||||
Tagrisso | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 315 | $ 595 | |||||
Actual %, year-on-year | 65.00% | 81.00% | |||||
CER %, year-on-year | 74.00% | 89.00% | |||||
Tagrisso | US | |||||||
Product sales | |||||||
Product Sales | $ 354 | $ 725 | |||||
Actual %, year-on-year | 18.00% | 30.00% | |||||
Tagrisso | Europe | |||||||
Product sales | |||||||
Product Sales | $ 163 | $ 325 | |||||
Actual %, year-on-year | 46.00% | 53.00% | |||||
CER %, year-on-year | 51.00% | 58.00% | |||||
Tagrisso | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 202 | $ 371 | |||||
Actual %, year-on-year | 12.00% | 18.00% | |||||
CER %, year-on-year | 12.00% | 18.00% | |||||
Imfinzi | |||||||
Product sales | |||||||
Product Sales | $ 492 | 462 | 424 | 412 | 338 | 295 | |
Imfinzi | World | |||||||
Product sales | |||||||
Product Sales | $ 492 | $ 954 | |||||
Actual %, year-on-year | 46.00% | 51.00% | |||||
CER %, year-on-year | 48.00% | 52.00% | |||||
Imfinzi | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 30 | $ 63 | |||||
Imfinzi | US | |||||||
Product sales | |||||||
Product Sales | $ 287 | $ 574 | |||||
Actual %, year-on-year | 19.00% | 21.00% | |||||
Imfinzi | Europe | |||||||
Product sales | |||||||
Product Sales | $ 93 | $ 167 | |||||
Imfinzi | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 82 | $ 150 | |||||
Actual %, year-on-year | 55.00% | 70.00% | |||||
CER %, year-on-year | 56.00% | 71.00% | |||||
Lynparza | |||||||
Product sales | |||||||
Product Sales | $ 419 | 397 | 351 | 327 | 283 | 237 | |
Lynparza | World | |||||||
Product sales | |||||||
Product Sales | $ 419 | $ 816 | |||||
Actual %, year-on-year | 48.00% | 57.00% | |||||
CER %, year-on-year | 52.00% | 60.00% | |||||
Lynparza | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 64 | $ 120 | |||||
Actual %, year-on-year | 95.00% | ||||||
Lynparza | US | |||||||
Product sales | |||||||
Product Sales | $ 209 | $ 406 | |||||
Actual %, year-on-year | 47.00% | 55.00% | |||||
Lynparza | Europe | |||||||
Product sales | |||||||
Product Sales | $ 96 | $ 198 | |||||
Actual %, year-on-year | 45.00% | 51.00% | |||||
CER %, year-on-year | 50.00% | 56.00% | |||||
Lynparza | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 50 | $ 92 | |||||
Actual %, year-on-year | 20.00% | 35.00% | |||||
CER %, year-on-year | 21.00% | 34.00% | |||||
Calquence | |||||||
Product sales | |||||||
Product Sales | $ 107 | 88 | 56 | 44 | 35 | 29 | |
Calquence | World | |||||||
Product sales | |||||||
Product Sales | 107 | $ 195 | |||||
Calquence | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | 1 | 2 | |||||
Calquence | US | |||||||
Product sales | |||||||
Product Sales | 107 | 193 | |||||
Calquence | Established ROW | |||||||
Product sales | |||||||
Product Sales | (1) | ||||||
Koselugo | |||||||
Product sales | |||||||
Product Sales | 7 | ||||||
Koselugo | World | |||||||
Product sales | |||||||
Product Sales | 7 | 7 | |||||
Koselugo | US | |||||||
Product sales | |||||||
Product Sales | 7 | 7 | |||||
Zoladex | |||||||
Product sales | |||||||
Product Sales | 217 | 225 | 196 | 226 | 197 | 194 | |
Zoladex | World | |||||||
Product sales | |||||||
Product Sales | $ 217 | $ 442 | |||||
Actual %, year-on-year | 10.00% | 13.00% | |||||
CER %, year-on-year | 17.00% | 18.00% | |||||
Zoladex | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 139 | $ 288 | |||||
Actual %, year-on-year | 15.00% | 22.00% | |||||
CER %, year-on-year | 24.00% | 29.00% | |||||
Zoladex | US | |||||||
Product sales | |||||||
Product Sales | $ 3 | $ 5 | |||||
Actual %, year-on-year | 55.00% | 40.00% | |||||
Zoladex | Europe | |||||||
Product sales | |||||||
Product Sales | $ 33 | $ 68 | |||||
Actual %, year-on-year | 8.00% | 5.00% | |||||
CER %, year-on-year | 14.00% | 8.00% | |||||
Zoladex | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 42 | $ 81 | |||||
Actual %, year-on-year | (4.00%) | (7.00%) | |||||
CER %, year-on-year | (2.00%) | (6.00%) | |||||
Faslodex | |||||||
Product sales | |||||||
Product Sales | $ 146 | 166 | 166 | 205 | 267 | 254 | |
Faslodex | World | |||||||
Product sales | |||||||
Product Sales | $ 146 | $ 312 | |||||
Actual %, year-on-year | (45.00%) | (40.00%) | |||||
CER %, year-on-year | (43.00%) | (38.00%) | |||||
Faslodex | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 52 | $ 100 | |||||
Actual %, year-on-year | 2.00% | 4.00% | |||||
CER %, year-on-year | 10.00% | 10.00% | |||||
Faslodex | US | |||||||
Product sales | |||||||
Product Sales | $ 11 | $ 34 | |||||
Actual %, year-on-year | (91.00%) | (87.00%) | |||||
Faslodex | Europe | |||||||
Product sales | |||||||
Product Sales | $ 52 | $ 116 | |||||
Actual %, year-on-year | (7.00%) | 6.00% | |||||
CER %, year-on-year | (3.00%) | 9.00% | |||||
Faslodex | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 31 | $ 62 | |||||
Actual %, year-on-year | (13.00%) | (4.00%) | |||||
CER %, year-on-year | (13.00%) | (4.00%) | |||||
Iressa | |||||||
Product sales | |||||||
Product Sales | $ 70 | 77 | 80 | 91 | 118 | 134 | |
Iressa | World | |||||||
Product sales | |||||||
Product Sales | $ 70 | $ 147 | |||||
Actual %, year-on-year | (41.00%) | (42.00%) | |||||
CER %, year-on-year | (38.00%) | (40.00%) | |||||
Iressa | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 58 | $ 120 | |||||
Actual %, year-on-year | (26.00%) | (27.00%) | |||||
CER %, year-on-year | (23.00%) | (24.00%) | |||||
Iressa | US | |||||||
Product sales | |||||||
Product Sales | $ 4 | $ 7 | |||||
Actual %, year-on-year | (5.00%) | (3.00%) | |||||
Iressa | Europe | |||||||
Product sales | |||||||
Product Sales | $ 3 | $ 9 | |||||
Actual %, year-on-year | (85.00%) | (81.00%) | |||||
CER %, year-on-year | (85.00%) | (81.00%) | |||||
Iressa | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 5 | $ 11 | |||||
Actual %, year-on-year | (65.00%) | (67.00%) | |||||
CER %, year-on-year | (62.00%) | (66.00%) | |||||
Arimidex | |||||||
Product sales | |||||||
Product Sales | $ 58 | 50 | 51 | 63 | 60 | 51 | |
Arimidex | World | |||||||
Product sales | |||||||
Product Sales | $ 58 | $ 107 | |||||
Actual %, year-on-year | (4.00%) | (3.00%) | |||||
Arimidex | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 48 | $ 90 | |||||
Actual %, year-on-year | 35.00% | 26.00% | |||||
CER %, year-on-year | 41.00% | 30.00% | |||||
Arimidex | Europe | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 1 | |||||
Actual %, year-on-year | (93.00%) | (90.00%) | |||||
CER %, year-on-year | (93.00%) | (90.00%) | |||||
Arimidex | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 9 | $ 16 | |||||
Actual %, year-on-year | (42.00%) | (32.00%) | |||||
CER %, year-on-year | (43.00%) | (32.00%) | |||||
Casodex | |||||||
Product sales | |||||||
Product Sales | $ 47 | 42 | 43 | 52 | 57 | 48 | |
Casodex | World | |||||||
Product sales | |||||||
Product Sales | $ 47 | $ 89 | |||||
Actual %, year-on-year | (17.00%) | (15.00%) | |||||
CER %, year-on-year | (15.00%) | (13.00%) | |||||
Casodex | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 37 | $ 69 | |||||
Actual %, year-on-year | 8.00% | 8.00% | |||||
CER %, year-on-year | 11.00% | 11.00% | |||||
Casodex | Europe | |||||||
Product sales | |||||||
Product Sales | $ 1 | ||||||
Actual %, year-on-year | (84.00%) | ||||||
CER %, year-on-year | (84.00%) | ||||||
Casodex | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 10 | $ 19 | |||||
Actual %, year-on-year | (47.00%) | (43.00%) | |||||
CER %, year-on-year | (46.00%) | (42.00%) | |||||
Oncology, Others | |||||||
Product sales | |||||||
Product Sales | $ 12 | 13 | 26 | 20 | 28 | 20 | |
Oncology, Others | World | |||||||
Product sales | |||||||
Product Sales | $ 12 | $ 26 | |||||
Actual %, year-on-year | (59.00%) | (50.00%) | |||||
CER %, year-on-year | (55.00%) | (47.00%) | |||||
Oncology, Others | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 6 | $ 14 | |||||
Actual %, year-on-year | (35.00%) | (23.00%) | |||||
CER %, year-on-year | (18.00%) | (14.00%) | |||||
Oncology, Others | US | |||||||
Product sales | |||||||
Product Sales | $ (1) | ||||||
Oncology, Others | Europe | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 3 | |||||
Actual %, year-on-year | (32.00%) | (15.00%) | |||||
CER %, year-on-year | (35.00%) | (16.00%) | |||||
Oncology, Others | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 6 | $ 9 | |||||
Actual %, year-on-year | (67.00%) | (64.00%) | |||||
CER %, year-on-year | (74.00%) | (69.00%) | |||||
BioPharmaceuticals: CVRM | |||||||
Product sales | |||||||
Product Sales | $ 1,759 | 1,701 | 1,785 | 1,749 | 1,658 | 1,714 | |
BioPharmaceuticals: CVRM | World | |||||||
Product sales | |||||||
Product Sales | $ 1,759 | $ 3,460 | |||||
Actual %, year-on-year | 6.00% | 3.00% | |||||
CER %, year-on-year | 10.00% | 6.00% | |||||
BioPharmaceuticals: CVRM | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 839 | $ 1,612 | |||||
Actual %, year-on-year | 20.00% | 11.00% | |||||
CER %, year-on-year | 28.00% | 17.00% | |||||
BioPharmaceuticals: CVRM | US | |||||||
Product sales | |||||||
Product Sales | $ 496 | $ 988 | |||||
Actual %, year-on-year | (6.00%) | (9.00%) | |||||
BioPharmaceuticals: CVRM | Europe | |||||||
Product sales | |||||||
Product Sales | $ 277 | $ 586 | |||||
Actual %, year-on-year | (3.00%) | 3.00% | |||||
CER %, year-on-year | 1.00% | 6.00% | |||||
BioPharmaceuticals: CVRM | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 147 | $ 274 | |||||
Actual %, year-on-year | (1.00%) | ||||||
CER %, year-on-year | 1.00% | 2.00% | |||||
Farxiga | |||||||
Product sales | |||||||
Product Sales | $ 443 | 405 | 419 | 398 | 377 | 349 | |
Farxiga | World | |||||||
Product sales | |||||||
Product Sales | $ 443 | $ 848 | |||||
Actual %, year-on-year | 17.00% | 17.00% | |||||
CER %, year-on-year | 23.00% | 21.00% | |||||
Farxiga | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 165 | $ 306 | |||||
Actual %, year-on-year | 49.00% | 49.00% | |||||
CER %, year-on-year | 62.00% | 59.00% | |||||
Farxiga | US | |||||||
Product sales | |||||||
Product Sales | $ 124 | $ 237 | |||||
Actual %, year-on-year | (11.00%) | (12.00%) | |||||
Farxiga | Europe | |||||||
Product sales | |||||||
Product Sales | $ 107 | $ 223 | |||||
Actual %, year-on-year | 20.00% | 25.00% | |||||
CER %, year-on-year | 25.00% | 29.00% | |||||
Farxiga | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 47 | $ 82 | |||||
Actual %, year-on-year | 24.00% | 14.00% | |||||
CER %, year-on-year | 26.00% | 15.00% | |||||
Brilinta | |||||||
Product sales | |||||||
Product Sales | $ 437 | 408 | 428 | 416 | 389 | 348 | |
Brilinta | World | |||||||
Product sales | |||||||
Product Sales | $ 437 | $ 845 | |||||
Actual %, year-on-year | 12.00% | 15.00% | |||||
CER %, year-on-year | 16.00% | 17.00% | |||||
Brilinta | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 156 | $ 291 | |||||
Actual %, year-on-year | 30.00% | 34.00% | |||||
CER %, year-on-year | 39.00% | 40.00% | |||||
Brilinta | US | |||||||
Product sales | |||||||
Product Sales | $ 187 | $ 351 | |||||
Actual %, year-on-year | 11.00% | 9.00% | |||||
Brilinta | Europe | |||||||
Product sales | |||||||
Product Sales | $ 80 | $ 173 | |||||
Actual %, year-on-year | (9.00%) | 2.00% | |||||
CER %, year-on-year | (5.00%) | 5.00% | |||||
Brilinta | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 14 | $ 30 | |||||
Actual %, year-on-year | 6.00% | 7.00% | |||||
CER %, year-on-year | 10.00% | 10.00% | |||||
Onglyza | |||||||
Product sales | |||||||
Product Sales | $ 115 | 141 | 131 | 127 | 116 | 153 | |
Onglyza | World | |||||||
Product sales | |||||||
Product Sales | $ 115 | $ 256 | |||||
Actual %, year-on-year | (1.00%) | (5.00%) | |||||
CER %, year-on-year | 3.00% | (3.00%) | |||||
Onglyza | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 52 | $ 100 | |||||
Actual %, year-on-year | 19.00% | 15.00% | |||||
CER %, year-on-year | 27.00% | 21.00% | |||||
Onglyza | US | |||||||
Product sales | |||||||
Product Sales | $ 38 | $ 105 | |||||
Actual %, year-on-year | (9.00%) | (12.00%) | |||||
Onglyza | Europe | |||||||
Product sales | |||||||
Product Sales | $ 14 | $ 29 | |||||
Actual %, year-on-year | (22.00%) | (21.00%) | |||||
CER %, year-on-year | (19.00%) | (18.00%) | |||||
Onglyza | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 11 | $ 22 | |||||
Actual %, year-on-year | (20.00%) | (15.00%) | |||||
CER %, year-on-year | (17.00%) | (13.00%) | |||||
Bydureon | |||||||
Product sales | |||||||
Product Sales | $ 116 | 100 | 139 | 127 | 141 | 142 | |
Bydureon | World | |||||||
Product sales | |||||||
Product Sales | $ 116 | $ 216 | |||||
Actual %, year-on-year | (18.00%) | (24.00%) | |||||
CER %, year-on-year | (17.00%) | (23.00%) | |||||
Bydureon | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 2 | |||||
Actual %, year-on-year | (87.00%) | (74.00%) | |||||
CER %, year-on-year | (86.00%) | (72.00%) | |||||
Bydureon | US | |||||||
Product sales | |||||||
Product Sales | $ 101 | $ 185 | |||||
Actual %, year-on-year | (14.00%) | (21.00%) | |||||
Bydureon | Europe | |||||||
Product sales | |||||||
Product Sales | $ 12 | $ 24 | |||||
Actual %, year-on-year | (22.00%) | (29.00%) | |||||
CER %, year-on-year | (19.00%) | (26.00%) | |||||
Bydureon | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 5 | |||||
Actual %, year-on-year | (23.00%) | (37.00%) | |||||
CER %, year-on-year | (18.00%) | (34.00%) | |||||
Byetta | |||||||
Product sales | |||||||
Product Sales | $ 15 | 20 | 27 | 28 | 25 | 30 | |
Byetta | World | |||||||
Product sales | |||||||
Product Sales | $ 15 | $ 35 | |||||
Actual %, year-on-year | (42.00%) | (36.00%) | |||||
CER %, year-on-year | (41.00%) | (35.00%) | |||||
Byetta | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 5 | |||||
Actual %, year-on-year | (37.00%) | 13.00% | |||||
CER %, year-on-year | (30.00%) | 21.00% | |||||
Byetta | US | |||||||
Product sales | |||||||
Product Sales | $ 7 | $ 19 | |||||
Actual %, year-on-year | (53.00%) | (47.00%) | |||||
Byetta | Europe | |||||||
Product sales | |||||||
Product Sales | $ 4 | $ 7 | |||||
Actual %, year-on-year | (16.00%) | (29.00%) | |||||
CER %, year-on-year | (13.00%) | (26.00%) | |||||
Byetta | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 4 | |||||
Actual %, year-on-year | (26.00%) | (21.00%) | |||||
CER %, year-on-year | (26.00%) | (20.00%) | |||||
Other diabetes | |||||||
Product sales | |||||||
Product Sales | $ 10 | 13 | 16 | 14 | 11 | 11 | |
Other diabetes | World | |||||||
Product sales | |||||||
Product Sales | $ 10 | $ 23 | |||||
Actual %, year-on-year | (9.00%) | 3.00% | |||||
CER %, year-on-year | (5.00%) | 6.00% | |||||
Other diabetes | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 3 | |||||
Other diabetes | US | |||||||
Product sales | |||||||
Product Sales | $ 6 | $ 13 | |||||
Actual %, year-on-year | (31.00%) | (21.00%) | |||||
Other diabetes | Europe | |||||||
Product sales | |||||||
Product Sales | $ 3 | $ 6 | |||||
Actual %, year-on-year | 37.00% | 44.00% | |||||
CER %, year-on-year | 44.00% | 50.00% | |||||
Other diabetes | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 1 | ||||||
Actual %, year-on-year | (60.00%) | ||||||
CER %, year-on-year | (25.00%) | ||||||
Lokelma | |||||||
Product sales | |||||||
Product Sales | $ 17 | 11 | 8 | 4 | 2 | ||
Lokelma | World | |||||||
Product sales | |||||||
Product Sales | 17 | $ 28 | |||||
Lokelma | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | 1 | 1 | |||||
Lokelma | US | |||||||
Product sales | |||||||
Product Sales | 12 | 22 | |||||
Lokelma | Europe | |||||||
Product sales | |||||||
Product Sales | 1 | 2 | |||||
Lokelma | Established ROW | |||||||
Product sales | |||||||
Product Sales | 3 | 3 | |||||
Crestor | |||||||
Product sales | |||||||
Product Sales | 281 | 301 | 296 | 337 | 310 | 335 | |
Crestor | World | |||||||
Product sales | |||||||
Product Sales | $ 281 | $ 582 | |||||
Actual %, year-on-year | (10.00%) | (10.00%) | |||||
CER %, year-on-year | (6.00%) | (8.00%) | |||||
Crestor | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 177 | $ 369 | |||||
Actual %, year-on-year | (3.00%) | (9.00%) | |||||
CER %, year-on-year | 2.00% | (6.00%) | |||||
Crestor | US | |||||||
Product sales | |||||||
Product Sales | $ 17 | $ 45 | |||||
Actual %, year-on-year | (40.00%) | (17.00%) | |||||
Crestor | Europe | |||||||
Product sales | |||||||
Product Sales | $ 30 | $ 64 | |||||
Actual %, year-on-year | (18.00%) | (15.00%) | |||||
CER %, year-on-year | (16.00%) | (13.00%) | |||||
Crestor | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 57 | $ 104 | |||||
Actual %, year-on-year | (11.00%) | (5.00%) | |||||
CER %, year-on-year | (10.00%) | (5.00%) | |||||
Seloken/Toprol-XL | |||||||
Product sales | |||||||
Product Sales | $ 218 | 177 | 190 | 177 | 168 | 225 | |
Seloken/Toprol-XL | World | |||||||
Product sales | |||||||
Product Sales | $ 218 | $ 395 | |||||
Actual %, year-on-year | 29.00% | ||||||
CER %, year-on-year | 38.00% | 6.00% | |||||
Seloken/Toprol-XL | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 210 | $ 376 | |||||
Actual %, year-on-year | 35.00% | 8.00% | |||||
CER %, year-on-year | 45.00% | 14.00% | |||||
Seloken/Toprol-XL | US | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 6 | |||||
Actual %, year-on-year | (53.00%) | (78.00%) | |||||
Seloken/Toprol-XL | Europe | |||||||
Product sales | |||||||
Product Sales | $ 4 | $ 8 | |||||
Actual %, year-on-year | (48.00%) | (39.00%) | |||||
CER %, year-on-year | (48.00%) | (39.00%) | |||||
Seloken/Toprol-XL | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 5 | |||||
Actual %, year-on-year | 2.00% | ||||||
CER %, year-on-year | 9.00% | 5.00% | |||||
Atacand | |||||||
Product sales | |||||||
Product Sales | $ 59 | 66 | 60 | 55 | 56 | 50 | |
Atacand | World | |||||||
Product sales | |||||||
Product Sales | $ 59 | $ 126 | |||||
Actual %, year-on-year | 6.00% | 19.00% | |||||
CER %, year-on-year | 14.00% | 25.00% | |||||
Atacand | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 45 | $ 94 | |||||
Actual %, year-on-year | 21.00% | 23.00% | |||||
CER %, year-on-year | 33.00% | 31.00% | |||||
Atacand | US | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 5 | |||||
Actual %, year-on-year | (39.00%) | (15.00%) | |||||
Atacand | Europe | |||||||
Product sales | |||||||
Product Sales | $ 6 | $ 15 | |||||
Actual %, year-on-year | (43.00%) | (2.00%) | |||||
CER %, year-on-year | (43.00%) | (2.00%) | |||||
Atacand | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 6 | $ 12 | |||||
Actual %, year-on-year | 43.00% | 37.00% | |||||
CER %, year-on-year | 52.00% | 43.00% | |||||
CVRM, Others | |||||||
Product sales | |||||||
Product Sales | $ 48 | 59 | 72 | 65 | 63 | 71 | |
CVRM, Others | World | |||||||
Product sales | |||||||
Product Sales | $ 48 | $ 106 | |||||
Actual %, year-on-year | (23.00%) | (20.00%) | |||||
CER %, year-on-year | (20.00%) | (18.00%) | |||||
CVRM, Others | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 29 | $ 65 | |||||
Actual %, year-on-year | (31.00%) | (30.00%) | |||||
CER %, year-on-year | (28.00%) | (28.00%) | |||||
CVRM, Others | Europe | |||||||
Product sales | |||||||
Product Sales | $ 16 | $ 35 | |||||
Actual %, year-on-year | 25.00% | 15.00% | |||||
CER %, year-on-year | 29.00% | 18.00% | |||||
CVRM, Others | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 3 | $ 6 | |||||
Actual %, year-on-year | (65.00%) | (36.00%) | |||||
CER %, year-on-year | (69.00%) | (39.00%) | |||||
BioPharmaceuticals: Respiratory & Immunology | |||||||
Product sales | |||||||
Product Sales | $ 1,117 | 1,551 | 1,537 | 1,319 | 1,252 | 1,283 | |
BioPharmaceuticals: Respiratory & Immunology | World | |||||||
Product sales | |||||||
Product Sales | $ 1,117 | $ 2,668 | |||||
Actual %, year-on-year | (11.00%) | 5.00% | |||||
CER %, year-on-year | (8.00%) | 7.00% | |||||
BioPharmaceuticals: Respiratory & Immunology | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 221 | $ 759 | |||||
Actual %, year-on-year | (50.00%) | (21.00%) | |||||
CER %, year-on-year | (46.00%) | (18.00%) | |||||
BioPharmaceuticals: Respiratory & Immunology | US | |||||||
Product sales | |||||||
Product Sales | $ 472 | $ 984 | |||||
Actual %, year-on-year | 15.00% | 30.00% | |||||
BioPharmaceuticals: Respiratory & Immunology | Europe | |||||||
Product sales | |||||||
Product Sales | $ 267 | $ 587 | |||||
Actual %, year-on-year | (3.00%) | 5.00% | |||||
CER %, year-on-year | 1.00% | 8.00% | |||||
BioPharmaceuticals: Respiratory & Immunology | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 157 | $ 338 | |||||
Actual %, year-on-year | 23.00% | 29.00% | |||||
CER %, year-on-year | 26.00% | 31.00% | |||||
Symbicort | |||||||
Product sales | |||||||
Product Sales | $ 653 | 790 | 712 | 613 | 585 | 585 | |
Symbicort | World | |||||||
Product sales | |||||||
Product Sales | $ 653 | $ 1,442 | |||||
Actual %, year-on-year | 12.00% | 23.00% | |||||
CER %, year-on-year | 15.00% | 26.00% | |||||
Symbicort | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 135 | $ 290 | |||||
Actual %, year-on-year | 3.00% | 10.00% | |||||
CER %, year-on-year | 12.00% | 16.00% | |||||
Symbicort | US | |||||||
Product sales | |||||||
Product Sales | $ 248 | $ 558 | |||||
Actual %, year-on-year | 20.00% | 46.00% | |||||
Symbicort | Europe | |||||||
Product sales | |||||||
Product Sales | $ 161 | $ 356 | |||||
Actual %, year-on-year | (6.00%) | 1.00% | |||||
CER %, year-on-year | (3.00%) | 4.00% | |||||
Symbicort | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 109 | $ 238 | |||||
Actual %, year-on-year | 42.00% | 39.00% | |||||
CER %, year-on-year | 47.00% | 42.00% | |||||
Pulmicort | |||||||
Product sales | |||||||
Product Sales | $ 97 | 380 | 413 | 337 | 333 | 383 | |
Pulmicort | World | |||||||
Product sales | |||||||
Product Sales | $ 97 | $ 477 | |||||
Actual %, year-on-year | (71.00%) | (33.00%) | |||||
CER %, year-on-year | (69.00%) | (32.00%) | |||||
Pulmicort | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 58 | $ 371 | |||||
Actual %, year-on-year | (78.00%) | (36.00%) | |||||
CER %, year-on-year | (76.00%) | (34.00%) | |||||
Pulmicort | US | |||||||
Product sales | |||||||
Product Sales | $ 13 | $ 36 | |||||
Actual %, year-on-year | (60.00%) | (36.00%) | |||||
Pulmicort | Europe | |||||||
Product sales | |||||||
Product Sales | $ 15 | $ 40 | |||||
Actual %, year-on-year | (21.00%) | (8.00%) | |||||
CER %, year-on-year | (18.00%) | (4.00%) | |||||
Pulmicort | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 11 | $ 30 | |||||
Actual %, year-on-year | (43.00%) | (26.00%) | |||||
CER %, year-on-year | (42.00%) | (25.00%) | |||||
Fasenra | |||||||
Product sales | |||||||
Product Sales | $ 227 | 199 | 206 | 202 | 167 | 129 | |
Fasenra | World | |||||||
Product sales | |||||||
Product Sales | $ 227 | $ 426 | |||||
Actual %, year-on-year | 36.00% | 44.00% | |||||
CER %, year-on-year | 37.00% | 45.00% | |||||
Fasenra | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 7 | |||||
Actual %, year-on-year | (30.00%) | ||||||
CER %, year-on-year | (5.00%) | ||||||
Fasenra | US | |||||||
Product sales | |||||||
Product Sales | $ 152 | $ 272 | |||||
Actual %, year-on-year | 33.00% | 31.00% | |||||
Fasenra | Europe | |||||||
Product sales | |||||||
Product Sales | $ 42 | $ 88 | |||||
Actual %, year-on-year | 57.00% | 96.00% | |||||
CER %, year-on-year | 63.00% | ||||||
Fasenra | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 32 | $ 59 | |||||
Actual %, year-on-year | 32.00% | 41.00% | |||||
CER %, year-on-year | 33.00% | 41.00% | |||||
Daliresp/Daxas | |||||||
Product sales | |||||||
Product Sales | $ 53 | 53 | 58 | 53 | 56 | 48 | |
Daliresp/Daxas | World | |||||||
Product sales | |||||||
Product Sales | $ 53 | $ 106 | |||||
Actual %, year-on-year | (7.00%) | 1.00% | |||||
CER %, year-on-year | (7.00%) | 2.00% | |||||
Daliresp/Daxas | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 2 | |||||
Actual %, year-on-year | (17.00%) | (13.00%) | |||||
CER %, year-on-year | (9.00%) | (7.00%) | |||||
Daliresp/Daxas | US | |||||||
Product sales | |||||||
Product Sales | $ 45 | $ 90 | |||||
Actual %, year-on-year | (7.00%) | 1.00% | |||||
Daliresp/Daxas | Europe | |||||||
Product sales | |||||||
Product Sales | $ 6 | $ 13 | |||||
Actual %, year-on-year | (3.00%) | 7.00% | |||||
CER %, year-on-year | 1.00% | 11.00% | |||||
Daliresp/Daxas | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 1 | |||||
Actual %, year-on-year | (37.00%) | (3.00%) | |||||
CER %, year-on-year | (70.00%) | (36.00%) | |||||
Bevespi | |||||||
Product sales | |||||||
Product Sales | $ 10 | 12 | 12 | 10 | 10 | 10 | |
Bevespi | World | |||||||
Product sales | |||||||
Product Sales | $ 10 | $ 22 | |||||
Actual %, year-on-year | (1.00%) | 10.00% | |||||
CER %, year-on-year | (3.00%) | 10.00% | |||||
Bevespi | US | |||||||
Product sales | |||||||
Product Sales | $ 9 | $ 21 | |||||
Actual %, year-on-year | (6.00%) | 5.00% | |||||
Bevespi | Europe | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 1 | |||||
Breztri | |||||||
Product sales | |||||||
Product Sales | 7 | 4 | 1 | 1 | |||
Breztri | World | |||||||
Product sales | |||||||
Product Sales | 7 | 11 | |||||
Breztri | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | 5 | 9 | |||||
Breztri | Established ROW | |||||||
Product sales | |||||||
Product Sales | 2 | 2 | |||||
Respiratory, Others | |||||||
Product sales | |||||||
Product Sales | 70 | 113 | 135 | 102 | 101 | 128 | |
Respiratory, Others | World | |||||||
Product sales | |||||||
Product Sales | $ 70 | $ 184 | |||||
Actual %, year-on-year | (30.00%) | (20.00%) | |||||
CER %, year-on-year | (28.00%) | (18.00%) | |||||
Respiratory, Others | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 21 | $ 80 | |||||
Actual %, year-on-year | (52.00%) | (29.00%) | |||||
CER %, year-on-year | (52.00%) | (27.00%) | |||||
Respiratory, Others | US | |||||||
Product sales | |||||||
Product Sales | $ 5 | $ 7 | |||||
Respiratory, Others | Europe | |||||||
Product sales | |||||||
Product Sales | $ 42 | $ 89 | |||||
Actual %, year-on-year | (18.00%) | (16.00%) | |||||
CER %, year-on-year | (15.00%) | (14.00%) | |||||
Respiratory, Others | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 8 | |||||
Actual %, year-on-year | (60.00%) | (14.00%) | |||||
CER %, year-on-year | (36.00%) | 4.00% | |||||
Other medicines | |||||||
Product sales | |||||||
Product Sales | $ 563 | 557 | 653 | 731 | 641 | 576 | |
Other medicines | World | |||||||
Product sales | |||||||
Product Sales | $ 563 | $ 1,120 | |||||
Actual %, year-on-year | (12.00%) | (8.00%) | |||||
CER %, year-on-year | (10.00%) | (6.00%) | |||||
Other medicines | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 238 | $ 487 | |||||
Actual %, year-on-year | (5.00%) | (2.00%) | |||||
CER %, year-on-year | 1.00% | ||||||
Other medicines | US | |||||||
Product sales | |||||||
Product Sales | $ 64 | $ 151 | |||||
Actual %, year-on-year | (29.00%) | (26.00%) | |||||
Other medicines | Europe | |||||||
Product sales | |||||||
Product Sales | $ 116 | $ 239 | |||||
Actual %, year-on-year | (23.00%) | (4.00%) | |||||
CER %, year-on-year | (23.00%) | (4.00%) | |||||
Other medicines | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 145 | $ 243 | |||||
Actual %, year-on-year | (3.00%) | (9.00%) | |||||
CER %, year-on-year | (3.00%) | (9.00%) | |||||
Nexium | |||||||
Product sales | |||||||
Product Sales | $ 377 | 338 | 353 | 374 | 393 | 363 | |
Nexium | World | |||||||
Product sales | |||||||
Product Sales | $ 377 | $ 714 | |||||
Actual %, year-on-year | (4.00%) | (5.00%) | |||||
CER %, year-on-year | (1.00%) | (3.00%) | |||||
Nexium | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 184 | $ 371 | |||||
Actual %, year-on-year | 3.00% | ||||||
CER %, year-on-year | 9.00% | 5.00% | |||||
Nexium | US | |||||||
Product sales | |||||||
Product Sales | $ 40 | $ 80 | |||||
Actual %, year-on-year | (24.00%) | (32.00%) | |||||
Nexium | Europe | |||||||
Product sales | |||||||
Product Sales | $ 15 | $ 36 | |||||
Actual %, year-on-year | (7.00%) | 14.00% | |||||
CER %, year-on-year | (4.00%) | 18.00% | |||||
Nexium | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 138 | $ 227 | |||||
Actual %, year-on-year | (5.00%) | (4.00%) | |||||
CER %, year-on-year | (5.00%) | (4.00%) | |||||
Synagis | |||||||
Product sales | |||||||
Product Sales | $ 90 | 85 | 63 | 146 | 96 | 53 | |
Synagis | World | |||||||
Product sales | |||||||
Product Sales | $ 90 | $ 176 | |||||
Actual %, year-on-year | (5.00%) | 18.00% | |||||
CER %, year-on-year | (5.00%) | 18.00% | |||||
Synagis | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 5 | ||||||
Synagis | US | |||||||
Product sales | |||||||
Product Sales | $ 14 | $ 21 | |||||
Actual %, year-on-year | 41.00% | (40.00%) | |||||
Synagis | Europe | |||||||
Product sales | |||||||
Product Sales | $ 76 | $ 150 | |||||
Actual %, year-on-year | (11.00%) | 32.00% | |||||
CER %, year-on-year | (11.00%) | 32.00% | |||||
Losec/Prilosec | |||||||
Product sales | |||||||
Product Sales | $ 45 | 54 | 46 | 73 | 68 | 76 | |
Losec/Prilosec | World | |||||||
Product sales | |||||||
Product Sales | $ 45 | $ 99 | |||||
Actual %, year-on-year | (34.00%) | (32.00%) | |||||
CER %, year-on-year | (31.00%) | (30.00%) | |||||
Losec/Prilosec | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 37 | $ 81 | |||||
Actual %, year-on-year | (16.00%) | (15.00%) | |||||
CER %, year-on-year | (12.00%) | (12.00%) | |||||
Losec/Prilosec | US | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 3 | |||||
Actual %, year-on-year | (90.00%) | (44.00%) | |||||
Losec/Prilosec | Europe | |||||||
Product sales | |||||||
Product Sales | $ 5 | $ 10 | |||||
Actual %, year-on-year | (60.00%) | (68.00%) | |||||
CER %, year-on-year | (60.00%) | (68.00%) | |||||
Losec/Prilosec | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 5 | |||||
Actual %, year-on-year | (75.00%) | (62.00%) | |||||
CER %, year-on-year | (74.00%) | (62.00%) | |||||
Seroquel XR/IR | |||||||
Product sales | |||||||
Product Sales | $ 27 | 36 | 40 | 82 | 32 | 37 | |
Seroquel XR/IR | World | |||||||
Product sales | |||||||
Product Sales | $ 27 | $ 63 | |||||
Actual %, year-on-year | (16.00%) | (9.00%) | |||||
CER %, year-on-year | (14.00%) | (8.00%) | |||||
Seroquel XR/IR | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 15 | $ 27 | |||||
Actual %, year-on-year | 49.00% | 11.00% | |||||
CER %, year-on-year | 57.00% | 15.00% | |||||
Seroquel XR/IR | US | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 14 | |||||
Seroquel XR/IR | Europe | |||||||
Product sales | |||||||
Product Sales | $ 7 | $ 15 | |||||
Actual %, year-on-year | (71.00%) | (69.00%) | |||||
CER %, year-on-year | (71.00%) | (69.00%) | |||||
Seroquel XR/IR | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 4 | $ 7 | |||||
Actual %, year-on-year | (23.00%) | (36.00%) | |||||
CER %, year-on-year | (25.00%) | (37.00%) | |||||
Other, Others | |||||||
Product sales | |||||||
Product Sales | $ 24 | $ 44 | $ 151 | $ 56 | $ 52 | $ 47 | |
Other, Others | World | |||||||
Product sales | |||||||
Product Sales | $ 24 | $ 68 | |||||
Actual %, year-on-year | (53.00%) | (32.00%) | |||||
CER %, year-on-year | (52.00%) | (31.00%) | |||||
Other, Others | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 3 | |||||
Actual %, year-on-year | (88.00%) | (64.00%) | |||||
CER %, year-on-year | (93.00%) | (73.00%) | |||||
Other, Others | US | |||||||
Product sales | |||||||
Product Sales | $ 8 | $ 33 | |||||
Actual %, year-on-year | (74.00%) | (44.00%) | |||||
Other, Others | Europe | |||||||
Product sales | |||||||
Product Sales | $ 13 | $ 28 | |||||
Actual %, year-on-year | 3.00% | 5.00% | |||||
CER %, year-on-year | 1.00% | 5.00% | |||||
Other, Others | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 4 | |||||
Actual %, year-on-year | (34.00%) | ||||||
CER %, year-on-year | (22.00%) |
Product Sales year-on-year an_3
Product Sales year-on-year analysis - Q2 2020 (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||||
Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Jun. 30, 2020 | |
Product sales | |||||||
Product Sales | $ 6,048 | $ 6,311 | $ 6,250 | $ 6,132 | $ 5,718 | $ 5,465 | |
World | |||||||
Product sales | |||||||
Product Sales | $ 6,048 | $ 12,359 | |||||
Actual %, year-on-year | 6.00% | 11.00% | |||||
CER %, year-on-year | 9.00% | 13.00% | |||||
Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 2,048 | $ 4,319 | |||||
Actual %, year-on-year | 5.00% | 9.00% | |||||
CER %, year-on-year | 12.00% | 14.00% | |||||
US | |||||||
Product sales | |||||||
Product Sales | $ 2,013 | $ 4,074 | |||||
Actual %, year-on-year | 7.00% | 11.00% | |||||
Europe | |||||||
Product sales | |||||||
Product Sales | $ 1,102 | $ 2,300 | |||||
Actual %, year-on-year | 5.00% | 13.00% | |||||
CER %, year-on-year | 9.00% | 17.00% | |||||
Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 885 | $ 1,666 | |||||
Actual %, year-on-year | 4.00% | 8.00% | |||||
CER %, year-on-year | 5.00% | 9.00% | |||||
Oncology | |||||||
Product sales | |||||||
Product Sales | $ 2,609 | 2,502 | 2,274 | 2,334 | 2,167 | 1,892 | |
Oncology | World | |||||||
Product sales | |||||||
Product Sales | $ 2,609 | $ 5,111 | |||||
Actual %, year-on-year | 20.00% | 26.00% | |||||
CER %, year-on-year | 24.00% | 28.00% | |||||
Oncology | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 750 | $ 1,461 | |||||
Actual %, year-on-year | 34.00% | 39.00% | |||||
CER %, year-on-year | 43.00% | 46.00% | |||||
Oncology | US | |||||||
Product sales | |||||||
Product Sales | $ 981 | $ 1,951 | |||||
Actual %, year-on-year | 15.00% | 20.00% | |||||
Oncology | Europe | |||||||
Product sales | |||||||
Product Sales | $ 442 | $ 888 | |||||
Actual %, year-on-year | 32.00% | 37.00% | |||||
CER %, year-on-year | 37.00% | 41.00% | |||||
Oncology | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 436 | $ 811 | |||||
Actual %, year-on-year | 3.00% | 10.00% | |||||
CER %, year-on-year | 4.00% | 9.00% | |||||
Tagrisso | |||||||
Product sales | |||||||
Product Sales | $ 1,034 | 982 | 884 | 891 | 784 | 630 | |
Tagrisso | World | |||||||
Product sales | |||||||
Product Sales | $ 1,034 | $ 2,016 | |||||
Actual %, year-on-year | 32.00% | 43.00% | |||||
CER %, year-on-year | 35.00% | 45.00% | |||||
Tagrisso | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 315 | $ 595 | |||||
Actual %, year-on-year | 65.00% | 81.00% | |||||
CER %, year-on-year | 74.00% | 89.00% | |||||
Tagrisso | US | |||||||
Product sales | |||||||
Product Sales | $ 354 | $ 725 | |||||
Actual %, year-on-year | 18.00% | 30.00% | |||||
Tagrisso | Europe | |||||||
Product sales | |||||||
Product Sales | $ 163 | $ 325 | |||||
Actual %, year-on-year | 46.00% | 53.00% | |||||
CER %, year-on-year | 51.00% | 58.00% | |||||
Tagrisso | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 202 | $ 371 | |||||
Actual %, year-on-year | 12.00% | 18.00% | |||||
CER %, year-on-year | 12.00% | 18.00% | |||||
Imfinzi | |||||||
Product sales | |||||||
Product Sales | $ 492 | 462 | 424 | 412 | 338 | 295 | |
Imfinzi | World | |||||||
Product sales | |||||||
Product Sales | $ 492 | $ 954 | |||||
Actual %, year-on-year | 46.00% | 51.00% | |||||
CER %, year-on-year | 48.00% | 52.00% | |||||
Imfinzi | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 30 | $ 63 | |||||
Imfinzi | US | |||||||
Product sales | |||||||
Product Sales | $ 287 | $ 574 | |||||
Actual %, year-on-year | 19.00% | 21.00% | |||||
Imfinzi | Europe | |||||||
Product sales | |||||||
Product Sales | $ 93 | $ 167 | |||||
Imfinzi | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 82 | $ 150 | |||||
Actual %, year-on-year | 55.00% | 70.00% | |||||
CER %, year-on-year | 56.00% | 71.00% | |||||
Lynparza | |||||||
Product sales | |||||||
Product Sales | $ 419 | 397 | 351 | 327 | 283 | 237 | |
Lynparza | World | |||||||
Product sales | |||||||
Product Sales | $ 419 | $ 816 | |||||
Actual %, year-on-year | 48.00% | 57.00% | |||||
CER %, year-on-year | 52.00% | 60.00% | |||||
Lynparza | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 64 | $ 120 | |||||
Actual %, year-on-year | 95.00% | ||||||
Lynparza | US | |||||||
Product sales | |||||||
Product Sales | $ 209 | $ 406 | |||||
Actual %, year-on-year | 47.00% | 55.00% | |||||
Lynparza | Europe | |||||||
Product sales | |||||||
Product Sales | $ 96 | $ 198 | |||||
Actual %, year-on-year | 45.00% | 51.00% | |||||
CER %, year-on-year | 50.00% | 56.00% | |||||
Lynparza | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 50 | $ 92 | |||||
Actual %, year-on-year | 20.00% | 35.00% | |||||
CER %, year-on-year | 21.00% | 34.00% | |||||
Calquence | |||||||
Product sales | |||||||
Product Sales | $ 107 | 88 | 56 | 44 | 35 | 29 | |
Calquence | World | |||||||
Product sales | |||||||
Product Sales | 107 | $ 195 | |||||
Calquence | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | 1 | 2 | |||||
Calquence | US | |||||||
Product sales | |||||||
Product Sales | 107 | 193 | |||||
Calquence | Established ROW | |||||||
Product sales | |||||||
Product Sales | (1) | ||||||
Koselugo | |||||||
Product sales | |||||||
Product Sales | 7 | ||||||
Koselugo | World | |||||||
Product sales | |||||||
Product Sales | 7 | 7 | |||||
Koselugo | US | |||||||
Product sales | |||||||
Product Sales | 7 | 7 | |||||
Faslodex | |||||||
Product sales | |||||||
Product Sales | 146 | 166 | 166 | 205 | 267 | 254 | |
Faslodex | World | |||||||
Product sales | |||||||
Product Sales | $ 146 | $ 312 | |||||
Actual %, year-on-year | (45.00%) | (40.00%) | |||||
CER %, year-on-year | (43.00%) | (38.00%) | |||||
Faslodex | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 52 | $ 100 | |||||
Actual %, year-on-year | 2.00% | 4.00% | |||||
CER %, year-on-year | 10.00% | 10.00% | |||||
Faslodex | US | |||||||
Product sales | |||||||
Product Sales | $ 11 | $ 34 | |||||
Actual %, year-on-year | (91.00%) | (87.00%) | |||||
Faslodex | Europe | |||||||
Product sales | |||||||
Product Sales | $ 52 | $ 116 | |||||
Actual %, year-on-year | (7.00%) | 6.00% | |||||
CER %, year-on-year | (3.00%) | 9.00% | |||||
Faslodex | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 31 | $ 62 | |||||
Actual %, year-on-year | (13.00%) | (4.00%) | |||||
CER %, year-on-year | (13.00%) | (4.00%) | |||||
Zoladex | |||||||
Product sales | |||||||
Product Sales | $ 217 | 225 | 196 | 226 | 197 | 194 | |
Zoladex | World | |||||||
Product sales | |||||||
Product Sales | $ 217 | $ 442 | |||||
Actual %, year-on-year | 10.00% | 13.00% | |||||
CER %, year-on-year | 17.00% | 18.00% | |||||
Zoladex | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 139 | $ 288 | |||||
Actual %, year-on-year | 15.00% | 22.00% | |||||
CER %, year-on-year | 24.00% | 29.00% | |||||
Zoladex | US | |||||||
Product sales | |||||||
Product Sales | $ 3 | $ 5 | |||||
Actual %, year-on-year | 55.00% | 40.00% | |||||
Zoladex | Europe | |||||||
Product sales | |||||||
Product Sales | $ 33 | $ 68 | |||||
Actual %, year-on-year | 8.00% | 5.00% | |||||
CER %, year-on-year | 14.00% | 8.00% | |||||
Zoladex | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 42 | $ 81 | |||||
Actual %, year-on-year | (4.00%) | (7.00%) | |||||
CER %, year-on-year | (2.00%) | (6.00%) | |||||
Iressa | |||||||
Product sales | |||||||
Product Sales | $ 70 | 77 | 80 | 91 | 118 | 134 | |
Iressa | World | |||||||
Product sales | |||||||
Product Sales | $ 70 | $ 147 | |||||
Actual %, year-on-year | (41.00%) | (42.00%) | |||||
CER %, year-on-year | (38.00%) | (40.00%) | |||||
Iressa | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 58 | $ 120 | |||||
Actual %, year-on-year | (26.00%) | (27.00%) | |||||
CER %, year-on-year | (23.00%) | (24.00%) | |||||
Iressa | US | |||||||
Product sales | |||||||
Product Sales | $ 4 | $ 7 | |||||
Actual %, year-on-year | (5.00%) | (3.00%) | |||||
Iressa | Europe | |||||||
Product sales | |||||||
Product Sales | $ 3 | $ 9 | |||||
Actual %, year-on-year | (85.00%) | (81.00%) | |||||
CER %, year-on-year | (85.00%) | (81.00%) | |||||
Iressa | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 5 | $ 11 | |||||
Actual %, year-on-year | (65.00%) | (67.00%) | |||||
CER %, year-on-year | (62.00%) | (66.00%) | |||||
Arimidex | |||||||
Product sales | |||||||
Product Sales | $ 58 | 50 | 51 | 63 | 60 | 51 | |
Arimidex | World | |||||||
Product sales | |||||||
Product Sales | $ 58 | $ 107 | |||||
Actual %, year-on-year | (4.00%) | (3.00%) | |||||
Arimidex | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 48 | $ 90 | |||||
Actual %, year-on-year | 35.00% | 26.00% | |||||
CER %, year-on-year | 41.00% | 30.00% | |||||
Arimidex | Europe | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 1 | |||||
Actual %, year-on-year | (93.00%) | (90.00%) | |||||
CER %, year-on-year | (93.00%) | (90.00%) | |||||
Arimidex | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 9 | $ 16 | |||||
Actual %, year-on-year | (42.00%) | (32.00%) | |||||
CER %, year-on-year | (43.00%) | (32.00%) | |||||
Casodex | |||||||
Product sales | |||||||
Product Sales | $ 47 | 42 | 43 | 52 | 57 | 48 | |
Casodex | World | |||||||
Product sales | |||||||
Product Sales | $ 47 | $ 89 | |||||
Actual %, year-on-year | (17.00%) | (15.00%) | |||||
CER %, year-on-year | (15.00%) | (13.00%) | |||||
Casodex | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 37 | $ 69 | |||||
Actual %, year-on-year | 8.00% | 8.00% | |||||
CER %, year-on-year | 11.00% | 11.00% | |||||
Casodex | Europe | |||||||
Product sales | |||||||
Product Sales | $ 1 | ||||||
Actual %, year-on-year | (84.00%) | ||||||
CER %, year-on-year | (84.00%) | ||||||
Casodex | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 10 | $ 19 | |||||
Actual %, year-on-year | (47.00%) | (43.00%) | |||||
CER %, year-on-year | (46.00%) | (42.00%) | |||||
Oncology, Others | |||||||
Product sales | |||||||
Product Sales | $ 12 | 13 | 26 | 20 | 28 | 20 | |
Oncology, Others | World | |||||||
Product sales | |||||||
Product Sales | $ 12 | $ 26 | |||||
Actual %, year-on-year | (59.00%) | (50.00%) | |||||
CER %, year-on-year | (55.00%) | (47.00%) | |||||
Oncology, Others | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 6 | $ 14 | |||||
Actual %, year-on-year | (35.00%) | (23.00%) | |||||
CER %, year-on-year | (18.00%) | (14.00%) | |||||
Oncology, Others | US | |||||||
Product sales | |||||||
Product Sales | $ (1) | ||||||
Oncology, Others | Europe | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 3 | |||||
Actual %, year-on-year | (32.00%) | (15.00%) | |||||
CER %, year-on-year | (35.00%) | (16.00%) | |||||
Oncology, Others | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 6 | $ 9 | |||||
Actual %, year-on-year | (67.00%) | (64.00%) | |||||
CER %, year-on-year | (74.00%) | (69.00%) | |||||
BioPharmaceuticals: CVRM | |||||||
Product sales | |||||||
Product Sales | $ 1,759 | 1,701 | 1,785 | 1,749 | 1,658 | 1,714 | |
BioPharmaceuticals: CVRM | World | |||||||
Product sales | |||||||
Product Sales | $ 1,759 | $ 3,460 | |||||
Actual %, year-on-year | 6.00% | 3.00% | |||||
CER %, year-on-year | 10.00% | 6.00% | |||||
BioPharmaceuticals: CVRM | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 839 | $ 1,612 | |||||
Actual %, year-on-year | 20.00% | 11.00% | |||||
CER %, year-on-year | 28.00% | 17.00% | |||||
BioPharmaceuticals: CVRM | US | |||||||
Product sales | |||||||
Product Sales | $ 496 | $ 988 | |||||
Actual %, year-on-year | (6.00%) | (9.00%) | |||||
BioPharmaceuticals: CVRM | Europe | |||||||
Product sales | |||||||
Product Sales | $ 277 | $ 586 | |||||
Actual %, year-on-year | (3.00%) | 3.00% | |||||
CER %, year-on-year | 1.00% | 6.00% | |||||
BioPharmaceuticals: CVRM | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 147 | $ 274 | |||||
Actual %, year-on-year | (1.00%) | ||||||
CER %, year-on-year | 1.00% | 2.00% | |||||
Farxiga | |||||||
Product sales | |||||||
Product Sales | $ 443 | 405 | 419 | 398 | 377 | 349 | |
Farxiga | World | |||||||
Product sales | |||||||
Product Sales | $ 443 | $ 848 | |||||
Actual %, year-on-year | 17.00% | 17.00% | |||||
CER %, year-on-year | 23.00% | 21.00% | |||||
Farxiga | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 165 | $ 306 | |||||
Actual %, year-on-year | 49.00% | 49.00% | |||||
CER %, year-on-year | 62.00% | 59.00% | |||||
Farxiga | US | |||||||
Product sales | |||||||
Product Sales | $ 124 | $ 237 | |||||
Actual %, year-on-year | (11.00%) | (12.00%) | |||||
Farxiga | Europe | |||||||
Product sales | |||||||
Product Sales | $ 107 | $ 223 | |||||
Actual %, year-on-year | 20.00% | 25.00% | |||||
CER %, year-on-year | 25.00% | 29.00% | |||||
Farxiga | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 47 | $ 82 | |||||
Actual %, year-on-year | 24.00% | 14.00% | |||||
CER %, year-on-year | 26.00% | 15.00% | |||||
Brilinta | |||||||
Product sales | |||||||
Product Sales | $ 437 | 408 | 428 | 416 | 389 | 348 | |
Brilinta | World | |||||||
Product sales | |||||||
Product Sales | $ 437 | $ 845 | |||||
Actual %, year-on-year | 12.00% | 15.00% | |||||
CER %, year-on-year | 16.00% | 17.00% | |||||
Brilinta | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 156 | $ 291 | |||||
Actual %, year-on-year | 30.00% | 34.00% | |||||
CER %, year-on-year | 39.00% | 40.00% | |||||
Brilinta | US | |||||||
Product sales | |||||||
Product Sales | $ 187 | $ 351 | |||||
Actual %, year-on-year | 11.00% | 9.00% | |||||
Brilinta | Europe | |||||||
Product sales | |||||||
Product Sales | $ 80 | $ 173 | |||||
Actual %, year-on-year | (9.00%) | 2.00% | |||||
CER %, year-on-year | (5.00%) | 5.00% | |||||
Brilinta | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 14 | $ 30 | |||||
Actual %, year-on-year | 6.00% | 7.00% | |||||
CER %, year-on-year | 10.00% | 10.00% | |||||
Bydureon | |||||||
Product sales | |||||||
Product Sales | $ 116 | 100 | 139 | 127 | 141 | 142 | |
Bydureon | World | |||||||
Product sales | |||||||
Product Sales | $ 116 | $ 216 | |||||
Actual %, year-on-year | (18.00%) | (24.00%) | |||||
CER %, year-on-year | (17.00%) | (23.00%) | |||||
Bydureon | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 2 | |||||
Actual %, year-on-year | (87.00%) | (74.00%) | |||||
CER %, year-on-year | (86.00%) | (72.00%) | |||||
Bydureon | US | |||||||
Product sales | |||||||
Product Sales | $ 101 | $ 185 | |||||
Actual %, year-on-year | (14.00%) | (21.00%) | |||||
Bydureon | Europe | |||||||
Product sales | |||||||
Product Sales | $ 12 | $ 24 | |||||
Actual %, year-on-year | (22.00%) | (29.00%) | |||||
CER %, year-on-year | (19.00%) | (26.00%) | |||||
Bydureon | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 5 | |||||
Actual %, year-on-year | (23.00%) | (37.00%) | |||||
CER %, year-on-year | (18.00%) | (34.00%) | |||||
Onglyza | |||||||
Product sales | |||||||
Product Sales | $ 115 | 141 | 131 | 127 | 116 | 153 | |
Onglyza | World | |||||||
Product sales | |||||||
Product Sales | $ 115 | $ 256 | |||||
Actual %, year-on-year | (1.00%) | (5.00%) | |||||
CER %, year-on-year | 3.00% | (3.00%) | |||||
Onglyza | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 52 | $ 100 | |||||
Actual %, year-on-year | 19.00% | 15.00% | |||||
CER %, year-on-year | 27.00% | 21.00% | |||||
Onglyza | US | |||||||
Product sales | |||||||
Product Sales | $ 38 | $ 105 | |||||
Actual %, year-on-year | (9.00%) | (12.00%) | |||||
Onglyza | Europe | |||||||
Product sales | |||||||
Product Sales | $ 14 | $ 29 | |||||
Actual %, year-on-year | (22.00%) | (21.00%) | |||||
CER %, year-on-year | (19.00%) | (18.00%) | |||||
Onglyza | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 11 | $ 22 | |||||
Actual %, year-on-year | (20.00%) | (15.00%) | |||||
CER %, year-on-year | (17.00%) | (13.00%) | |||||
Byetta | |||||||
Product sales | |||||||
Product Sales | $ 15 | 20 | 27 | 28 | 25 | 30 | |
Byetta | World | |||||||
Product sales | |||||||
Product Sales | $ 15 | $ 35 | |||||
Actual %, year-on-year | (42.00%) | (36.00%) | |||||
CER %, year-on-year | (41.00%) | (35.00%) | |||||
Byetta | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 5 | |||||
Actual %, year-on-year | (37.00%) | 13.00% | |||||
CER %, year-on-year | (30.00%) | 21.00% | |||||
Byetta | US | |||||||
Product sales | |||||||
Product Sales | $ 7 | $ 19 | |||||
Actual %, year-on-year | (53.00%) | (47.00%) | |||||
Byetta | Europe | |||||||
Product sales | |||||||
Product Sales | $ 4 | $ 7 | |||||
Actual %, year-on-year | (16.00%) | (29.00%) | |||||
CER %, year-on-year | (13.00%) | (26.00%) | |||||
Byetta | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 4 | |||||
Actual %, year-on-year | (26.00%) | (21.00%) | |||||
CER %, year-on-year | (26.00%) | (20.00%) | |||||
Other diabetes | |||||||
Product sales | |||||||
Product Sales | $ 10 | 13 | 16 | 14 | 11 | 11 | |
Other diabetes | World | |||||||
Product sales | |||||||
Product Sales | $ 10 | $ 23 | |||||
Actual %, year-on-year | (9.00%) | 3.00% | |||||
CER %, year-on-year | (5.00%) | 6.00% | |||||
Other diabetes | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 3 | |||||
Other diabetes | US | |||||||
Product sales | |||||||
Product Sales | $ 6 | $ 13 | |||||
Actual %, year-on-year | (31.00%) | (21.00%) | |||||
Other diabetes | Europe | |||||||
Product sales | |||||||
Product Sales | $ 3 | $ 6 | |||||
Actual %, year-on-year | 37.00% | 44.00% | |||||
CER %, year-on-year | 44.00% | 50.00% | |||||
Other diabetes | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 1 | ||||||
Actual %, year-on-year | (60.00%) | ||||||
CER %, year-on-year | (25.00%) | ||||||
Lokelma | |||||||
Product sales | |||||||
Product Sales | $ 17 | 11 | 8 | 4 | 2 | ||
Lokelma | World | |||||||
Product sales | |||||||
Product Sales | 17 | $ 28 | |||||
Lokelma | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | 1 | 1 | |||||
Lokelma | US | |||||||
Product sales | |||||||
Product Sales | 12 | 22 | |||||
Lokelma | Europe | |||||||
Product sales | |||||||
Product Sales | 1 | 2 | |||||
Lokelma | Established ROW | |||||||
Product sales | |||||||
Product Sales | 3 | 3 | |||||
Crestor | |||||||
Product sales | |||||||
Product Sales | 281 | 301 | 296 | 337 | 310 | 335 | |
Crestor | World | |||||||
Product sales | |||||||
Product Sales | $ 281 | $ 582 | |||||
Actual %, year-on-year | (10.00%) | (10.00%) | |||||
CER %, year-on-year | (6.00%) | (8.00%) | |||||
Crestor | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 177 | $ 369 | |||||
Actual %, year-on-year | (3.00%) | (9.00%) | |||||
CER %, year-on-year | 2.00% | (6.00%) | |||||
Crestor | US | |||||||
Product sales | |||||||
Product Sales | $ 17 | $ 45 | |||||
Actual %, year-on-year | (40.00%) | (17.00%) | |||||
Crestor | Europe | |||||||
Product sales | |||||||
Product Sales | $ 30 | $ 64 | |||||
Actual %, year-on-year | (18.00%) | (15.00%) | |||||
CER %, year-on-year | (16.00%) | (13.00%) | |||||
Crestor | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 57 | $ 104 | |||||
Actual %, year-on-year | (11.00%) | (5.00%) | |||||
CER %, year-on-year | (10.00%) | (5.00%) | |||||
Seloken/Toprol-XL | |||||||
Product sales | |||||||
Product Sales | $ 218 | 177 | 190 | 177 | 168 | 225 | |
Seloken/Toprol-XL | World | |||||||
Product sales | |||||||
Product Sales | $ 218 | $ 395 | |||||
Actual %, year-on-year | 29.00% | ||||||
CER %, year-on-year | 38.00% | 6.00% | |||||
Seloken/Toprol-XL | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 210 | $ 376 | |||||
Actual %, year-on-year | 35.00% | 8.00% | |||||
CER %, year-on-year | 45.00% | 14.00% | |||||
Seloken/Toprol-XL | US | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 6 | |||||
Actual %, year-on-year | (53.00%) | (78.00%) | |||||
Seloken/Toprol-XL | Europe | |||||||
Product sales | |||||||
Product Sales | $ 4 | $ 8 | |||||
Actual %, year-on-year | (48.00%) | (39.00%) | |||||
CER %, year-on-year | (48.00%) | (39.00%) | |||||
Seloken/Toprol-XL | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 5 | |||||
Actual %, year-on-year | 2.00% | ||||||
CER %, year-on-year | 9.00% | 5.00% | |||||
Atacand | |||||||
Product sales | |||||||
Product Sales | $ 59 | 66 | 60 | 55 | 56 | 50 | |
Atacand | World | |||||||
Product sales | |||||||
Product Sales | $ 59 | $ 126 | |||||
Actual %, year-on-year | 6.00% | 19.00% | |||||
CER %, year-on-year | 14.00% | 25.00% | |||||
Atacand | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 45 | $ 94 | |||||
Actual %, year-on-year | 21.00% | 23.00% | |||||
CER %, year-on-year | 33.00% | 31.00% | |||||
Atacand | US | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 5 | |||||
Actual %, year-on-year | (39.00%) | (15.00%) | |||||
Atacand | Europe | |||||||
Product sales | |||||||
Product Sales | $ 6 | $ 15 | |||||
Actual %, year-on-year | (43.00%) | (2.00%) | |||||
CER %, year-on-year | (43.00%) | (2.00%) | |||||
Atacand | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 6 | $ 12 | |||||
Actual %, year-on-year | 43.00% | 37.00% | |||||
CER %, year-on-year | 52.00% | 43.00% | |||||
CVRM, Others | |||||||
Product sales | |||||||
Product Sales | $ 48 | 59 | 72 | 65 | 63 | 71 | |
CVRM, Others | World | |||||||
Product sales | |||||||
Product Sales | $ 48 | $ 106 | |||||
Actual %, year-on-year | (23.00%) | (20.00%) | |||||
CER %, year-on-year | (20.00%) | (18.00%) | |||||
CVRM, Others | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 29 | $ 65 | |||||
Actual %, year-on-year | (31.00%) | (30.00%) | |||||
CER %, year-on-year | (28.00%) | (28.00%) | |||||
CVRM, Others | Europe | |||||||
Product sales | |||||||
Product Sales | $ 16 | $ 35 | |||||
Actual %, year-on-year | 25.00% | 15.00% | |||||
CER %, year-on-year | 29.00% | 18.00% | |||||
CVRM, Others | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 3 | $ 6 | |||||
Actual %, year-on-year | (65.00%) | (36.00%) | |||||
CER %, year-on-year | (69.00%) | (39.00%) | |||||
BioPharmaceuticals: Respiratory & Immunology | |||||||
Product sales | |||||||
Product Sales | $ 1,117 | 1,551 | 1,537 | 1,319 | 1,252 | 1,283 | |
BioPharmaceuticals: Respiratory & Immunology | World | |||||||
Product sales | |||||||
Product Sales | $ 1,117 | $ 2,668 | |||||
Actual %, year-on-year | (11.00%) | 5.00% | |||||
CER %, year-on-year | (8.00%) | 7.00% | |||||
BioPharmaceuticals: Respiratory & Immunology | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 221 | $ 759 | |||||
Actual %, year-on-year | (50.00%) | (21.00%) | |||||
CER %, year-on-year | (46.00%) | (18.00%) | |||||
BioPharmaceuticals: Respiratory & Immunology | US | |||||||
Product sales | |||||||
Product Sales | $ 472 | $ 984 | |||||
Actual %, year-on-year | 15.00% | 30.00% | |||||
BioPharmaceuticals: Respiratory & Immunology | Europe | |||||||
Product sales | |||||||
Product Sales | $ 267 | $ 587 | |||||
Actual %, year-on-year | (3.00%) | 5.00% | |||||
CER %, year-on-year | 1.00% | 8.00% | |||||
BioPharmaceuticals: Respiratory & Immunology | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 157 | $ 338 | |||||
Actual %, year-on-year | 23.00% | 29.00% | |||||
CER %, year-on-year | 26.00% | 31.00% | |||||
Symbicort | |||||||
Product sales | |||||||
Product Sales | $ 653 | 790 | 712 | 613 | 585 | 585 | |
Symbicort | World | |||||||
Product sales | |||||||
Product Sales | $ 653 | $ 1,442 | |||||
Actual %, year-on-year | 12.00% | 23.00% | |||||
CER %, year-on-year | 15.00% | 26.00% | |||||
Symbicort | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 135 | $ 290 | |||||
Actual %, year-on-year | 3.00% | 10.00% | |||||
CER %, year-on-year | 12.00% | 16.00% | |||||
Symbicort | US | |||||||
Product sales | |||||||
Product Sales | $ 248 | $ 558 | |||||
Actual %, year-on-year | 20.00% | 46.00% | |||||
Symbicort | Europe | |||||||
Product sales | |||||||
Product Sales | $ 161 | $ 356 | |||||
Actual %, year-on-year | (6.00%) | 1.00% | |||||
CER %, year-on-year | (3.00%) | 4.00% | |||||
Symbicort | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 109 | $ 238 | |||||
Actual %, year-on-year | 42.00% | 39.00% | |||||
CER %, year-on-year | 47.00% | 42.00% | |||||
Pulmicort | |||||||
Product sales | |||||||
Product Sales | $ 97 | 380 | 413 | 337 | 333 | 383 | |
Pulmicort | World | |||||||
Product sales | |||||||
Product Sales | $ 97 | $ 477 | |||||
Actual %, year-on-year | (71.00%) | (33.00%) | |||||
CER %, year-on-year | (69.00%) | (32.00%) | |||||
Pulmicort | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 58 | $ 371 | |||||
Actual %, year-on-year | (78.00%) | (36.00%) | |||||
CER %, year-on-year | (76.00%) | (34.00%) | |||||
Pulmicort | US | |||||||
Product sales | |||||||
Product Sales | $ 13 | $ 36 | |||||
Actual %, year-on-year | (60.00%) | (36.00%) | |||||
Pulmicort | Europe | |||||||
Product sales | |||||||
Product Sales | $ 15 | $ 40 | |||||
Actual %, year-on-year | (21.00%) | (8.00%) | |||||
CER %, year-on-year | (18.00%) | (4.00%) | |||||
Pulmicort | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 11 | $ 30 | |||||
Actual %, year-on-year | (43.00%) | (26.00%) | |||||
CER %, year-on-year | (42.00%) | (25.00%) | |||||
Fasenra | |||||||
Product sales | |||||||
Product Sales | $ 227 | 199 | 206 | 202 | 167 | 129 | |
Fasenra | World | |||||||
Product sales | |||||||
Product Sales | $ 227 | $ 426 | |||||
Actual %, year-on-year | 36.00% | 44.00% | |||||
CER %, year-on-year | 37.00% | 45.00% | |||||
Fasenra | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 7 | |||||
Actual %, year-on-year | (30.00%) | ||||||
CER %, year-on-year | (5.00%) | ||||||
Fasenra | US | |||||||
Product sales | |||||||
Product Sales | $ 152 | $ 272 | |||||
Actual %, year-on-year | 33.00% | 31.00% | |||||
Fasenra | Europe | |||||||
Product sales | |||||||
Product Sales | $ 42 | $ 88 | |||||
Actual %, year-on-year | 57.00% | 96.00% | |||||
CER %, year-on-year | 63.00% | ||||||
Fasenra | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 32 | $ 59 | |||||
Actual %, year-on-year | 32.00% | 41.00% | |||||
CER %, year-on-year | 33.00% | 41.00% | |||||
Daliresp/Daxas | |||||||
Product sales | |||||||
Product Sales | $ 53 | 53 | 58 | 53 | 56 | 48 | |
Daliresp/Daxas | World | |||||||
Product sales | |||||||
Product Sales | $ 53 | $ 106 | |||||
Actual %, year-on-year | (7.00%) | 1.00% | |||||
CER %, year-on-year | (7.00%) | 2.00% | |||||
Daliresp/Daxas | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 2 | |||||
Actual %, year-on-year | (17.00%) | (13.00%) | |||||
CER %, year-on-year | (9.00%) | (7.00%) | |||||
Daliresp/Daxas | US | |||||||
Product sales | |||||||
Product Sales | $ 45 | $ 90 | |||||
Actual %, year-on-year | (7.00%) | 1.00% | |||||
Daliresp/Daxas | Europe | |||||||
Product sales | |||||||
Product Sales | $ 6 | $ 13 | |||||
Actual %, year-on-year | (3.00%) | 7.00% | |||||
CER %, year-on-year | 1.00% | 11.00% | |||||
Daliresp/Daxas | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 1 | |||||
Actual %, year-on-year | (37.00%) | (3.00%) | |||||
CER %, year-on-year | (70.00%) | (36.00%) | |||||
Bevespi | |||||||
Product sales | |||||||
Product Sales | $ 10 | 12 | 12 | 10 | 10 | 10 | |
Bevespi | World | |||||||
Product sales | |||||||
Product Sales | $ 10 | $ 22 | |||||
Actual %, year-on-year | (1.00%) | 10.00% | |||||
CER %, year-on-year | (3.00%) | 10.00% | |||||
Bevespi | US | |||||||
Product sales | |||||||
Product Sales | $ 9 | $ 21 | |||||
Actual %, year-on-year | (6.00%) | 5.00% | |||||
Bevespi | Europe | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 1 | |||||
Breztri | |||||||
Product sales | |||||||
Product Sales | 7 | 4 | 1 | 1 | |||
Breztri | World | |||||||
Product sales | |||||||
Product Sales | 7 | 11 | |||||
Breztri | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | 5 | 9 | |||||
Breztri | Established ROW | |||||||
Product sales | |||||||
Product Sales | 2 | 2 | |||||
Respiratory, Others | |||||||
Product sales | |||||||
Product Sales | 70 | 113 | 135 | 102 | 101 | 128 | |
Respiratory, Others | World | |||||||
Product sales | |||||||
Product Sales | $ 70 | $ 184 | |||||
Actual %, year-on-year | (30.00%) | (20.00%) | |||||
CER %, year-on-year | (28.00%) | (18.00%) | |||||
Respiratory, Others | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 21 | $ 80 | |||||
Actual %, year-on-year | (52.00%) | (29.00%) | |||||
CER %, year-on-year | (52.00%) | (27.00%) | |||||
Respiratory, Others | US | |||||||
Product sales | |||||||
Product Sales | $ 5 | $ 7 | |||||
Respiratory, Others | Europe | |||||||
Product sales | |||||||
Product Sales | $ 42 | $ 89 | |||||
Actual %, year-on-year | (18.00%) | (16.00%) | |||||
CER %, year-on-year | (15.00%) | (14.00%) | |||||
Respiratory, Others | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 8 | |||||
Actual %, year-on-year | (60.00%) | (14.00%) | |||||
CER %, year-on-year | (36.00%) | 4.00% | |||||
Other medicines | |||||||
Product sales | |||||||
Product Sales | $ 563 | 557 | 653 | 731 | 641 | 576 | |
Other medicines | World | |||||||
Product sales | |||||||
Product Sales | $ 563 | $ 1,120 | |||||
Actual %, year-on-year | (12.00%) | (8.00%) | |||||
CER %, year-on-year | (10.00%) | (6.00%) | |||||
Other medicines | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 238 | $ 487 | |||||
Actual %, year-on-year | (5.00%) | (2.00%) | |||||
CER %, year-on-year | 1.00% | ||||||
Other medicines | US | |||||||
Product sales | |||||||
Product Sales | $ 64 | $ 151 | |||||
Actual %, year-on-year | (29.00%) | (26.00%) | |||||
Other medicines | Europe | |||||||
Product sales | |||||||
Product Sales | $ 116 | $ 239 | |||||
Actual %, year-on-year | (23.00%) | (4.00%) | |||||
CER %, year-on-year | (23.00%) | (4.00%) | |||||
Other medicines | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 145 | $ 243 | |||||
Actual %, year-on-year | (3.00%) | (9.00%) | |||||
CER %, year-on-year | (3.00%) | (9.00%) | |||||
Nexium | |||||||
Product sales | |||||||
Product Sales | $ 377 | 338 | 353 | 374 | 393 | 363 | |
Nexium | World | |||||||
Product sales | |||||||
Product Sales | $ 377 | $ 714 | |||||
Actual %, year-on-year | (4.00%) | (5.00%) | |||||
CER %, year-on-year | (1.00%) | (3.00%) | |||||
Nexium | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 184 | $ 371 | |||||
Actual %, year-on-year | 3.00% | ||||||
CER %, year-on-year | 9.00% | 5.00% | |||||
Nexium | US | |||||||
Product sales | |||||||
Product Sales | $ 40 | $ 80 | |||||
Actual %, year-on-year | (24.00%) | (32.00%) | |||||
Nexium | Europe | |||||||
Product sales | |||||||
Product Sales | $ 15 | $ 36 | |||||
Actual %, year-on-year | (7.00%) | 14.00% | |||||
CER %, year-on-year | (4.00%) | 18.00% | |||||
Nexium | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 138 | $ 227 | |||||
Actual %, year-on-year | (5.00%) | (4.00%) | |||||
CER %, year-on-year | (5.00%) | (4.00%) | |||||
Synagis | |||||||
Product sales | |||||||
Product Sales | $ 90 | 85 | 63 | 146 | 96 | 53 | |
Synagis | World | |||||||
Product sales | |||||||
Product Sales | $ 90 | $ 176 | |||||
Actual %, year-on-year | (5.00%) | 18.00% | |||||
CER %, year-on-year | (5.00%) | 18.00% | |||||
Synagis | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 5 | ||||||
Synagis | US | |||||||
Product sales | |||||||
Product Sales | $ 14 | $ 21 | |||||
Actual %, year-on-year | 41.00% | (40.00%) | |||||
Synagis | Europe | |||||||
Product sales | |||||||
Product Sales | $ 76 | $ 150 | |||||
Actual %, year-on-year | (11.00%) | 32.00% | |||||
CER %, year-on-year | (11.00%) | 32.00% | |||||
Losec/Prilosec | |||||||
Product sales | |||||||
Product Sales | $ 45 | 54 | 46 | 73 | 68 | 76 | |
Losec/Prilosec | World | |||||||
Product sales | |||||||
Product Sales | $ 45 | $ 99 | |||||
Actual %, year-on-year | (34.00%) | (32.00%) | |||||
CER %, year-on-year | (31.00%) | (30.00%) | |||||
Losec/Prilosec | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 37 | $ 81 | |||||
Actual %, year-on-year | (16.00%) | (15.00%) | |||||
CER %, year-on-year | (12.00%) | (12.00%) | |||||
Losec/Prilosec | US | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 3 | |||||
Actual %, year-on-year | (90.00%) | (44.00%) | |||||
Losec/Prilosec | Europe | |||||||
Product sales | |||||||
Product Sales | $ 5 | $ 10 | |||||
Actual %, year-on-year | (60.00%) | (68.00%) | |||||
CER %, year-on-year | (60.00%) | (68.00%) | |||||
Losec/Prilosec | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 5 | |||||
Actual %, year-on-year | (75.00%) | (62.00%) | |||||
CER %, year-on-year | (74.00%) | (62.00%) | |||||
Seroquel XR/IR | |||||||
Product sales | |||||||
Product Sales | $ 27 | 36 | 40 | 82 | 32 | 37 | |
Seroquel XR/IR | World | |||||||
Product sales | |||||||
Product Sales | $ 27 | $ 63 | |||||
Actual %, year-on-year | (16.00%) | (9.00%) | |||||
CER %, year-on-year | (14.00%) | (8.00%) | |||||
Seroquel XR/IR | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 15 | $ 27 | |||||
Actual %, year-on-year | 49.00% | 11.00% | |||||
CER %, year-on-year | 57.00% | 15.00% | |||||
Seroquel XR/IR | US | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 14 | |||||
Seroquel XR/IR | Europe | |||||||
Product sales | |||||||
Product Sales | $ 7 | $ 15 | |||||
Actual %, year-on-year | (71.00%) | (69.00%) | |||||
CER %, year-on-year | (71.00%) | (69.00%) | |||||
Seroquel XR/IR | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 4 | $ 7 | |||||
Actual %, year-on-year | (23.00%) | (36.00%) | |||||
CER %, year-on-year | (25.00%) | (37.00%) | |||||
Other, Others | |||||||
Product sales | |||||||
Product Sales | $ 24 | $ 44 | $ 151 | $ 56 | $ 52 | $ 47 | |
Other, Others | World | |||||||
Product sales | |||||||
Product Sales | $ 24 | $ 68 | |||||
Actual %, year-on-year | (53.00%) | (32.00%) | |||||
CER %, year-on-year | (52.00%) | (31.00%) | |||||
Other, Others | Emerging Markets | |||||||
Product sales | |||||||
Product Sales | $ 2 | $ 3 | |||||
Actual %, year-on-year | (88.00%) | (64.00%) | |||||
CER %, year-on-year | (93.00%) | (73.00%) | |||||
Other, Others | US | |||||||
Product sales | |||||||
Product Sales | $ 8 | $ 33 | |||||
Actual %, year-on-year | (74.00%) | (44.00%) | |||||
Other, Others | Europe | |||||||
Product sales | |||||||
Product Sales | $ 13 | $ 28 | |||||
Actual %, year-on-year | 3.00% | 5.00% | |||||
CER %, year-on-year | 1.00% | 5.00% | |||||
Other, Others | Established ROW | |||||||
Product sales | |||||||
Product Sales | $ 1 | $ 4 | |||||
Actual %, year-on-year | (34.00%) | ||||||
CER %, year-on-year | (22.00%) |
Product Sales quarterly seque_3
Product Sales quarterly sequential quarterly - Q2 2020 (Details) - USD ($) $ in Millions | 3 Months Ended | |||||
Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | |
Product sales | ||||||
Product Sales | $ 6,048 | $ 6,311 | $ 6,250 | $ 6,132 | $ 5,718 | $ 5,465 |
Actual %, quarter-on-quarter | (4.00%) | 1.00% | 2.00% | 7.00% | 5.00% | (5.00%) |
CER %, quarter-on-quarter | (2.00%) | 1.00% | 3.00% | 8.00% | 5.00% | (6.00%) |
Oncology | ||||||
Product sales | ||||||
Product Sales | $ 2,609 | $ 2,502 | $ 2,274 | $ 2,334 | $ 2,167 | $ 1,892 |
Actual %, quarter-on-quarter | 4.00% | 10.00% | (3.00%) | 8.00% | 15.00% | 7.00% |
CER %, quarter-on-quarter | 6.00% | 10.00% | (2.00%) | 8.00% | 15.00% | 6.00% |
Tagrisso | ||||||
Product sales | ||||||
Product Sales | $ 1,034 | $ 982 | $ 884 | $ 891 | $ 784 | $ 630 |
Actual %, quarter-on-quarter | 5.00% | 11.00% | (1.00%) | 14.00% | 24.00% | 6.00% |
CER %, quarter-on-quarter | 7.00% | 11.00% | 13.00% | 25.00% | 6.00% | |
Imfinzi | ||||||
Product sales | ||||||
Product Sales | $ 492 | $ 462 | $ 424 | $ 412 | $ 338 | $ 295 |
Actual %, quarter-on-quarter | 6.00% | 9.00% | 3.00% | 22.00% | 15.00% | 13.00% |
CER %, quarter-on-quarter | 8.00% | 9.00% | 4.00% | 22.00% | 15.00% | 13.00% |
Lynparza | ||||||
Product sales | ||||||
Product Sales | $ 419 | $ 397 | $ 351 | $ 327 | $ 283 | $ 237 |
Actual %, quarter-on-quarter | 5.00% | 13.00% | 7.00% | 16.00% | 19.00% | 13.00% |
CER %, quarter-on-quarter | 7.00% | 13.00% | 8.00% | 15.00% | 20.00% | 13.00% |
Calquence | ||||||
Product sales | ||||||
Product Sales | $ 107 | $ 88 | $ 56 | $ 44 | $ 35 | $ 29 |
Actual %, quarter-on-quarter | 21.00% | 58.00% | 25.00% | 27.00% | 21.00% | 21.00% |
CER %, quarter-on-quarter | 23.00% | 58.00% | 25.00% | 27.00% | 19.00% | 23.00% |
Koselugo | ||||||
Product sales | ||||||
Product Sales | $ 7 | |||||
Zoladex | ||||||
Product sales | ||||||
Product Sales | $ 217 | $ 225 | $ 196 | $ 226 | $ 197 | $ 194 |
Actual %, quarter-on-quarter | (3.00%) | 15.00% | (14.00%) | 15.00% | 2.00% | 7.00% |
CER %, quarter-on-quarter | 15.00% | (12.00%) | 16.00% | 1.00% | 6.00% | |
Faslodex | ||||||
Product sales | ||||||
Product Sales | $ 146 | $ 166 | $ 166 | $ 205 | $ 267 | $ 254 |
Actual %, quarter-on-quarter | (12.00%) | (20.00%) | (23.00%) | 5.00% | (6.00%) | |
CER %, quarter-on-quarter | (9.00%) | (19.00%) | (23.00%) | 6.00% | (6.00%) | |
Iressa | ||||||
Product sales | ||||||
Product Sales | $ 70 | $ 77 | $ 80 | $ 91 | $ 118 | $ 134 |
Actual %, quarter-on-quarter | (9.00%) | (3.00%) | (13.00%) | (23.00%) | (12.00%) | 20.00% |
CER %, quarter-on-quarter | (7.00%) | (4.00%) | (12.00%) | (22.00%) | (11.00%) | 18.00% |
Arimidex | ||||||
Product sales | ||||||
Product Sales | $ 58 | $ 50 | $ 51 | $ 63 | $ 60 | $ 51 |
Actual %, quarter-on-quarter | 17.00% | (1.00%) | (20.00%) | 5.00% | 18.00% | 11.00% |
CER %, quarter-on-quarter | 16.00% | (2.00%) | (18.00%) | 5.00% | 17.00% | 10.00% |
Casodex | ||||||
Product sales | ||||||
Product Sales | $ 47 | $ 42 | $ 43 | $ 52 | $ 57 | $ 48 |
Actual %, quarter-on-quarter | 14.00% | (2.00%) | (18.00%) | (8.00%) | 19.00% | 4.00% |
CER %, quarter-on-quarter | 12.00% | (3.00%) | (17.00%) | (6.00%) | 18.00% | 3.00% |
Oncology, Others | ||||||
Product sales | ||||||
Product Sales | $ 12 | $ 13 | $ 26 | $ 20 | $ 28 | $ 20 |
Actual %, quarter-on-quarter | (11.00%) | (52.00%) | 30.00% | (27.00%) | 40.00% | (13.00%) |
CER %, quarter-on-quarter | (1.00%) | (52.00%) | 26.00% | (22.00%) | 29.00% | (14.00%) |
BioPharmaceuticals: CVRM | ||||||
Product sales | ||||||
Product Sales | $ 1,759 | $ 1,701 | $ 1,785 | $ 1,749 | $ 1,658 | $ 1,714 |
Actual %, quarter-on-quarter | 3.00% | (5.00%) | 2.00% | 5.00% | (3.00%) | (2.00%) |
CER %, quarter-on-quarter | 6.00% | (5.00%) | 3.00% | 6.00% | (3.00%) | (3.00%) |
Farxiga | ||||||
Product sales | ||||||
Product Sales | $ 443 | $ 405 | $ 419 | $ 398 | $ 377 | $ 349 |
Actual %, quarter-on-quarter | 9.00% | (3.00%) | 5.00% | 5.00% | 8.00% | (12.00%) |
CER %, quarter-on-quarter | 13.00% | (3.00%) | 6.00% | 5.00% | 9.00% | (12.00%) |
Brilinta | ||||||
Product sales | ||||||
Product Sales | $ 437 | $ 408 | $ 428 | $ 416 | $ 389 | $ 348 |
Actual %, quarter-on-quarter | 7.00% | (5.00%) | 3.00% | 7.00% | 12.00% | (7.00%) |
CER %, quarter-on-quarter | 9.00% | (5.00%) | 3.00% | 8.00% | 12.00% | (8.00%) |
Onglyza | ||||||
Product sales | ||||||
Product Sales | $ 115 | $ 141 | $ 131 | $ 127 | $ 116 | $ 153 |
Actual %, quarter-on-quarter | (19.00%) | 8.00% | 3.00% | 9.00% | (24.00%) | 3.00% |
CER %, quarter-on-quarter | (17.00%) | 8.00% | 4.00% | 11.00% | (24.00%) | 3.00% |
Bydureon | ||||||
Product sales | ||||||
Product Sales | $ 116 | $ 100 | $ 139 | $ 127 | $ 141 | $ 142 |
Actual %, quarter-on-quarter | 16.00% | (28.00%) | 9.00% | (10.00%) | (1.00%) | 3.00% |
CER %, quarter-on-quarter | 17.00% | (28.00%) | 10.00% | (10.00%) | 3.00% | |
Byetta | ||||||
Product sales | ||||||
Product Sales | $ 15 | $ 20 | $ 27 | $ 28 | $ 25 | $ 30 |
Actual %, quarter-on-quarter | (28.00%) | (24.00%) | (2.00%) | 10.00% | (17.00%) | (6.00%) |
CER %, quarter-on-quarter | (28.00%) | (24.00%) | (4.00%) | 13.00% | (16.00%) | (5.00%) |
Other diabetes | ||||||
Product sales | ||||||
Product Sales | $ 10 | $ 13 | $ 16 | $ 14 | $ 11 | $ 11 |
Actual %, quarter-on-quarter | (21.00%) | (22.00%) | 17.00% | 26.00% | (8.00%) | |
CER %, quarter-on-quarter | (19.00%) | (22.00%) | 17.00% | 22.00% | 8.00% | (17.00%) |
Lokelma | ||||||
Product sales | ||||||
Product Sales | $ 17 | $ 11 | $ 8 | $ 4 | $ 2 | |
Actual %, quarter-on-quarter | 56.00% | 42.00% | 87.00% | |||
CER %, quarter-on-quarter | 58.00% | 42.00% | 74.00% | |||
Crestor | ||||||
Product sales | ||||||
Product Sales | $ 281 | $ 301 | $ 296 | $ 337 | $ 310 | $ 335 |
Actual %, quarter-on-quarter | (7.00%) | 2.00% | (12.00%) | 9.00% | (7.00%) | (5.00%) |
CER %, quarter-on-quarter | (4.00%) | 1.00% | (11.00%) | 9.00% | (7.00%) | (6.00%) |
Seloken/Toprol-XL | ||||||
Product sales | ||||||
Product Sales | $ 218 | $ 177 | $ 190 | $ 177 | $ 168 | $ 225 |
Actual %, quarter-on-quarter | 23.00% | (6.00%) | 7.00% | 6.00% | (25.00%) | 41.00% |
CER %, quarter-on-quarter | 27.00% | (6.00%) | 8.00% | 8.00% | (25.00%) | 38.00% |
Atacand | ||||||
Product sales | ||||||
Product Sales | $ 59 | $ 66 | $ 60 | $ 55 | $ 56 | $ 50 |
Actual %, quarter-on-quarter | (11.00%) | 11.00% | 8.00% | (1.00%) | 12.00% | (14.00%) |
CER %, quarter-on-quarter | (5.00%) | 12.00% | 9.00% | (1.00%) | 14.00% | (15.00%) |
CVRM, Others | ||||||
Product sales | ||||||
Product Sales | $ 48 | $ 59 | $ 72 | $ 65 | $ 63 | $ 71 |
Actual %, quarter-on-quarter | (18.00%) | (21.00%) | 13.00% | 4.00% | (11.00%) | (3.00%) |
CER %, quarter-on-quarter | (16.00%) | (22.00%) | 16.00% | 2.00% | (8.00%) | (5.00%) |
BioPharmaceuticals: Respiratory & Immunology | ||||||
Product sales | ||||||
Product Sales | $ 1,117 | $ 1,551 | $ 1,537 | $ 1,319 | $ 1,252 | $ 1,283 |
Actual %, quarter-on-quarter | (28.00%) | 1.00% | 17.00% | 5.00% | (2.00%) | (6.00%) |
CER %, quarter-on-quarter | (26.00%) | 1.00% | 17.00% | 6.00% | (2.00%) | (6.00%) |
Symbicort | ||||||
Product sales | ||||||
Product Sales | $ 653 | $ 790 | $ 712 | $ 613 | $ 585 | $ 585 |
Actual %, quarter-on-quarter | (17.00%) | 11.00% | 16.00% | 5.00% | (8.00%) | |
CER %, quarter-on-quarter | (15.00%) | 11.00% | 17.00% | 4.00% | 1.00% | (8.00%) |
Pulmicort | ||||||
Product sales | ||||||
Product Sales | $ 97 | $ 380 | $ 413 | $ 337 | $ 333 | $ 383 |
Actual %, quarter-on-quarter | (74.00%) | (8.00%) | 22.00% | 1.00% | (13.00%) | (2.00%) |
CER %, quarter-on-quarter | (73.00%) | (9.00%) | 23.00% | 3.00% | (13.00%) | (2.00%) |
Daliresp/Daxas | ||||||
Product sales | ||||||
Product Sales | $ 53 | $ 53 | $ 58 | $ 53 | $ 56 | $ 48 |
Actual %, quarter-on-quarter | (1.00%) | (8.00%) | 10.00% | (6.00%) | 17.00% | (11.00%) |
CER %, quarter-on-quarter | (3.00%) | (8.00%) | 10.00% | (7.00%) | 18.00% | (12.00%) |
Fasenra | ||||||
Product sales | ||||||
Product Sales | $ 227 | $ 199 | $ 206 | $ 202 | $ 167 | $ 129 |
Actual %, quarter-on-quarter | 14.00% | (3.00%) | 2.00% | 21.00% | 29.00% | 3.00% |
CER %, quarter-on-quarter | 15.00% | (3.00%) | 2.00% | 21.00% | 30.00% | 4.00% |
Bevespi | ||||||
Product sales | ||||||
Product Sales | $ 10 | $ 12 | $ 12 | $ 10 | $ 10 | $ 10 |
Actual %, quarter-on-quarter | (19.00%) | 9.00% | 8.00% | 4.00% | ||
CER %, quarter-on-quarter | (21.00%) | 9.00% | 5.00% | 8.00% | 2.00% | (5.00%) |
Breztri | ||||||
Product sales | ||||||
Product Sales | $ 7 | $ 4 | $ 1 | $ 1 | ||
Actual %, quarter-on-quarter | 58.00% | (74.00%) | ||||
CER %, quarter-on-quarter | 64.00% | (73.00%) | ||||
Respiratory, Others | ||||||
Product sales | ||||||
Product Sales | $ 70 | $ 113 | $ 135 | $ 102 | $ 101 | $ 128 |
Actual %, quarter-on-quarter | (38.00%) | (16.00%) | 33.00% | 1.00% | (21.00%) | (14.00%) |
CER %, quarter-on-quarter | (36.00%) | (17.00%) | 38.00% | (1.00%) | (23.00%) | (12.00%) |
Other medicines | ||||||
Product sales | ||||||
Product Sales | $ 563 | $ 557 | $ 653 | $ 731 | $ 641 | $ 576 |
Actual %, quarter-on-quarter | 1.00% | (15.00%) | (11.00%) | 14.00% | 11.00% | (35.00%) |
CER %, quarter-on-quarter | 4.00% | (15.00%) | (10.00%) | 14.00% | 12.00% | (36.00%) |
Nexium | ||||||
Product sales | ||||||
Product Sales | $ 377 | $ 338 | $ 353 | $ 374 | $ 393 | $ 363 |
Actual %, quarter-on-quarter | 12.00% | (4.00%) | (6.00%) | (5.00%) | 8.00% | (7.00%) |
CER %, quarter-on-quarter | 14.00% | (4.00%) | (6.00%) | (4.00%) | 8.00% | (8.00%) |
Synagis | ||||||
Product sales | ||||||
Product Sales | $ 90 | $ 85 | $ 63 | $ 146 | $ 96 | $ 53 |
Actual %, quarter-on-quarter | 6.00% | 35.00% | (57.00%) | 52.00% | 81.00% | (79.00%) |
CER %, quarter-on-quarter | 7.00% | 35.00% | (57.00%) | 53.00% | 81.00% | (79.00%) |
Losec/Prilosec | ||||||
Product sales | ||||||
Product Sales | $ 45 | $ 54 | $ 46 | $ 73 | $ 68 | $ 76 |
Actual %, quarter-on-quarter | (15.00%) | 18.00% | (38.00%) | 8.00% | (11.00%) | 27.00% |
CER %, quarter-on-quarter | (15.00%) | 17.00% | (38.00%) | 9.00% | (10.00%) | 26.00% |
Seroquel XR/IR | ||||||
Product sales | ||||||
Product Sales | $ 27 | $ 36 | $ 40 | $ 82 | $ 32 | $ 37 |
Actual %, quarter-on-quarter | (26.00%) | (12.00%) | (50.00%) | (14.00%) | (34.00%) | |
CER %, quarter-on-quarter | (23.00%) | (12.00%) | (49.00%) | (10.00%) | (33.00%) | |
Other, Others | ||||||
Product sales | ||||||
Product Sales | $ 24 | $ 44 | $ 151 | $ 56 | $ 52 | $ 47 |
Actual %, quarter-on-quarter | (46.00%) | (71.00%) | 8.00% | 11.00% | (65.00%) | |
CER %, quarter-on-quarter | (42.00%) | (70.00%) | 11.00% | (64.00%) |
Sequential Quarterly Product _2
Sequential Quarterly Product Sales - FY 2019 (Details) - USD ($) $ in Millions | 3 Months Ended | |||||
Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | |
Product sales | ||||||
Product Sales | $ 6,048 | $ 6,311 | $ 6,250 | $ 6,132 | $ 5,718 | $ 5,465 |
Actual %, quarter-on-quarter | (4.00%) | 1.00% | 2.00% | 7.00% | 5.00% | (5.00%) |
CER %, quarter-on-quarter | (2.00%) | 1.00% | 3.00% | 8.00% | 5.00% | (6.00%) |
Oncology | ||||||
Product sales | ||||||
Product Sales | $ 2,609 | $ 2,502 | $ 2,274 | $ 2,334 | $ 2,167 | $ 1,892 |
Actual %, quarter-on-quarter | 4.00% | 10.00% | (3.00%) | 8.00% | 15.00% | 7.00% |
CER %, quarter-on-quarter | 6.00% | 10.00% | (2.00%) | 8.00% | 15.00% | 6.00% |
Tagrisso | ||||||
Product sales | ||||||
Product Sales | $ 1,034 | $ 982 | $ 884 | $ 891 | $ 784 | $ 630 |
Actual %, quarter-on-quarter | 5.00% | 11.00% | (1.00%) | 14.00% | 24.00% | 6.00% |
CER %, quarter-on-quarter | 7.00% | 11.00% | 13.00% | 25.00% | 6.00% | |
Imfinzi | ||||||
Product sales | ||||||
Product Sales | $ 492 | $ 462 | $ 424 | $ 412 | $ 338 | $ 295 |
Actual %, quarter-on-quarter | 6.00% | 9.00% | 3.00% | 22.00% | 15.00% | 13.00% |
CER %, quarter-on-quarter | 8.00% | 9.00% | 4.00% | 22.00% | 15.00% | 13.00% |
Lynparza | ||||||
Product sales | ||||||
Product Sales | $ 419 | $ 397 | $ 351 | $ 327 | $ 283 | $ 237 |
Actual %, quarter-on-quarter | 5.00% | 13.00% | 7.00% | 16.00% | 19.00% | 13.00% |
CER %, quarter-on-quarter | 7.00% | 13.00% | 8.00% | 15.00% | 20.00% | 13.00% |
Calquence | ||||||
Product sales | ||||||
Product Sales | $ 107 | $ 88 | $ 56 | $ 44 | $ 35 | $ 29 |
Actual %, quarter-on-quarter | 21.00% | 58.00% | 25.00% | 27.00% | 21.00% | 21.00% |
CER %, quarter-on-quarter | 23.00% | 58.00% | 25.00% | 27.00% | 19.00% | 23.00% |
Faslodex | ||||||
Product sales | ||||||
Product Sales | $ 146 | $ 166 | $ 166 | $ 205 | $ 267 | $ 254 |
Actual %, quarter-on-quarter | (12.00%) | (20.00%) | (23.00%) | 5.00% | (6.00%) | |
CER %, quarter-on-quarter | (9.00%) | (19.00%) | (23.00%) | 6.00% | (6.00%) | |
Zoladex | ||||||
Product sales | ||||||
Product Sales | $ 217 | $ 225 | $ 196 | $ 226 | $ 197 | $ 194 |
Actual %, quarter-on-quarter | (3.00%) | 15.00% | (14.00%) | 15.00% | 2.00% | 7.00% |
CER %, quarter-on-quarter | 15.00% | (12.00%) | 16.00% | 1.00% | 6.00% | |
Iressa | ||||||
Product sales | ||||||
Product Sales | $ 70 | $ 77 | $ 80 | $ 91 | $ 118 | $ 134 |
Actual %, quarter-on-quarter | (9.00%) | (3.00%) | (13.00%) | (23.00%) | (12.00%) | 20.00% |
CER %, quarter-on-quarter | (7.00%) | (4.00%) | (12.00%) | (22.00%) | (11.00%) | 18.00% |
Arimidex | ||||||
Product sales | ||||||
Product Sales | $ 58 | $ 50 | $ 51 | $ 63 | $ 60 | $ 51 |
Actual %, quarter-on-quarter | 17.00% | (1.00%) | (20.00%) | 5.00% | 18.00% | 11.00% |
CER %, quarter-on-quarter | 16.00% | (2.00%) | (18.00%) | 5.00% | 17.00% | 10.00% |
Casodex | ||||||
Product sales | ||||||
Product Sales | $ 47 | $ 42 | $ 43 | $ 52 | $ 57 | $ 48 |
Actual %, quarter-on-quarter | 14.00% | (2.00%) | (18.00%) | (8.00%) | 19.00% | 4.00% |
CER %, quarter-on-quarter | 12.00% | (3.00%) | (17.00%) | (6.00%) | 18.00% | 3.00% |
Oncology, Others | ||||||
Product sales | ||||||
Product Sales | $ 12 | $ 13 | $ 26 | $ 20 | $ 28 | $ 20 |
Actual %, quarter-on-quarter | (11.00%) | (52.00%) | 30.00% | (27.00%) | 40.00% | (13.00%) |
CER %, quarter-on-quarter | (1.00%) | (52.00%) | 26.00% | (22.00%) | 29.00% | (14.00%) |
BioPharmaceuticals: CVRM | ||||||
Product sales | ||||||
Product Sales | $ 1,759 | $ 1,701 | $ 1,785 | $ 1,749 | $ 1,658 | $ 1,714 |
Actual %, quarter-on-quarter | 3.00% | (5.00%) | 2.00% | 5.00% | (3.00%) | (2.00%) |
CER %, quarter-on-quarter | 6.00% | (5.00%) | 3.00% | 6.00% | (3.00%) | (3.00%) |
Farxiga | ||||||
Product sales | ||||||
Product Sales | $ 443 | $ 405 | $ 419 | $ 398 | $ 377 | $ 349 |
Actual %, quarter-on-quarter | 9.00% | (3.00%) | 5.00% | 5.00% | 8.00% | (12.00%) |
CER %, quarter-on-quarter | 13.00% | (3.00%) | 6.00% | 5.00% | 9.00% | (12.00%) |
Brilinta | ||||||
Product sales | ||||||
Product Sales | $ 437 | $ 408 | $ 428 | $ 416 | $ 389 | $ 348 |
Actual %, quarter-on-quarter | 7.00% | (5.00%) | 3.00% | 7.00% | 12.00% | (7.00%) |
CER %, quarter-on-quarter | 9.00% | (5.00%) | 3.00% | 8.00% | 12.00% | (8.00%) |
Onglyza | ||||||
Product sales | ||||||
Product Sales | $ 115 | $ 141 | $ 131 | $ 127 | $ 116 | $ 153 |
Actual %, quarter-on-quarter | (19.00%) | 8.00% | 3.00% | 9.00% | (24.00%) | 3.00% |
CER %, quarter-on-quarter | (17.00%) | 8.00% | 4.00% | 11.00% | (24.00%) | 3.00% |
Bydureon | ||||||
Product sales | ||||||
Product Sales | $ 116 | $ 100 | $ 139 | $ 127 | $ 141 | $ 142 |
Actual %, quarter-on-quarter | 16.00% | (28.00%) | 9.00% | (10.00%) | (1.00%) | 3.00% |
CER %, quarter-on-quarter | 17.00% | (28.00%) | 10.00% | (10.00%) | 3.00% | |
Byetta | ||||||
Product sales | ||||||
Product Sales | $ 15 | $ 20 | $ 27 | $ 28 | $ 25 | $ 30 |
Actual %, quarter-on-quarter | (28.00%) | (24.00%) | (2.00%) | 10.00% | (17.00%) | (6.00%) |
CER %, quarter-on-quarter | (28.00%) | (24.00%) | (4.00%) | 13.00% | (16.00%) | (5.00%) |
Other diabetes | ||||||
Product sales | ||||||
Product Sales | $ 10 | $ 13 | $ 16 | $ 14 | $ 11 | $ 11 |
Actual %, quarter-on-quarter | (21.00%) | (22.00%) | 17.00% | 26.00% | (8.00%) | |
CER %, quarter-on-quarter | (19.00%) | (22.00%) | 17.00% | 22.00% | 8.00% | (17.00%) |
Lokelma | ||||||
Product sales | ||||||
Product Sales | $ 17 | $ 11 | $ 8 | $ 4 | $ 2 | |
Actual %, quarter-on-quarter | 56.00% | 42.00% | 87.00% | |||
CER %, quarter-on-quarter | 58.00% | 42.00% | 74.00% | |||
Crestor | ||||||
Product sales | ||||||
Product Sales | $ 281 | $ 301 | $ 296 | $ 337 | $ 310 | $ 335 |
Actual %, quarter-on-quarter | (7.00%) | 2.00% | (12.00%) | 9.00% | (7.00%) | (5.00%) |
CER %, quarter-on-quarter | (4.00%) | 1.00% | (11.00%) | 9.00% | (7.00%) | (6.00%) |
Seloken/Toprol-XL | ||||||
Product sales | ||||||
Product Sales | $ 218 | $ 177 | $ 190 | $ 177 | $ 168 | $ 225 |
Actual %, quarter-on-quarter | 23.00% | (6.00%) | 7.00% | 6.00% | (25.00%) | 41.00% |
CER %, quarter-on-quarter | 27.00% | (6.00%) | 8.00% | 8.00% | (25.00%) | 38.00% |
Atacand | ||||||
Product sales | ||||||
Product Sales | $ 59 | $ 66 | $ 60 | $ 55 | $ 56 | $ 50 |
Actual %, quarter-on-quarter | (11.00%) | 11.00% | 8.00% | (1.00%) | 12.00% | (14.00%) |
CER %, quarter-on-quarter | (5.00%) | 12.00% | 9.00% | (1.00%) | 14.00% | (15.00%) |
CVRM, Others | ||||||
Product sales | ||||||
Product Sales | $ 48 | $ 59 | $ 72 | $ 65 | $ 63 | $ 71 |
Actual %, quarter-on-quarter | (18.00%) | (21.00%) | 13.00% | 4.00% | (11.00%) | (3.00%) |
CER %, quarter-on-quarter | (16.00%) | (22.00%) | 16.00% | 2.00% | (8.00%) | (5.00%) |
BioPharmaceuticals: Respiratory & Immunology | ||||||
Product sales | ||||||
Product Sales | $ 1,117 | $ 1,551 | $ 1,537 | $ 1,319 | $ 1,252 | $ 1,283 |
Actual %, quarter-on-quarter | (28.00%) | 1.00% | 17.00% | 5.00% | (2.00%) | (6.00%) |
CER %, quarter-on-quarter | (26.00%) | 1.00% | 17.00% | 6.00% | (2.00%) | (6.00%) |
Symbicort | ||||||
Product sales | ||||||
Product Sales | $ 653 | $ 790 | $ 712 | $ 613 | $ 585 | $ 585 |
Actual %, quarter-on-quarter | (17.00%) | 11.00% | 16.00% | 5.00% | (8.00%) | |
CER %, quarter-on-quarter | (15.00%) | 11.00% | 17.00% | 4.00% | 1.00% | (8.00%) |
Pulmicort | ||||||
Product sales | ||||||
Product Sales | $ 97 | $ 380 | $ 413 | $ 337 | $ 333 | $ 383 |
Actual %, quarter-on-quarter | (74.00%) | (8.00%) | 22.00% | 1.00% | (13.00%) | (2.00%) |
CER %, quarter-on-quarter | (73.00%) | (9.00%) | 23.00% | 3.00% | (13.00%) | (2.00%) |
Fasenra | ||||||
Product sales | ||||||
Product Sales | $ 227 | $ 199 | $ 206 | $ 202 | $ 167 | $ 129 |
Actual %, quarter-on-quarter | 14.00% | (3.00%) | 2.00% | 21.00% | 29.00% | 3.00% |
CER %, quarter-on-quarter | 15.00% | (3.00%) | 2.00% | 21.00% | 30.00% | 4.00% |
Daliresp/Daxas | ||||||
Product sales | ||||||
Product Sales | $ 53 | $ 53 | $ 58 | $ 53 | $ 56 | $ 48 |
Actual %, quarter-on-quarter | (1.00%) | (8.00%) | 10.00% | (6.00%) | 17.00% | (11.00%) |
CER %, quarter-on-quarter | (3.00%) | (8.00%) | 10.00% | (7.00%) | 18.00% | (12.00%) |
Bevespi | ||||||
Product sales | ||||||
Product Sales | $ 10 | $ 12 | $ 12 | $ 10 | $ 10 | $ 10 |
Actual %, quarter-on-quarter | (19.00%) | 9.00% | 8.00% | 4.00% | ||
CER %, quarter-on-quarter | (21.00%) | 9.00% | 5.00% | 8.00% | 2.00% | (5.00%) |
Breztri | ||||||
Product sales | ||||||
Product Sales | $ 7 | $ 4 | $ 1 | $ 1 | ||
Actual %, quarter-on-quarter | 58.00% | (74.00%) | ||||
CER %, quarter-on-quarter | 64.00% | (73.00%) | ||||
Respiratory, Others | ||||||
Product sales | ||||||
Product Sales | $ 70 | $ 113 | $ 135 | $ 102 | $ 101 | $ 128 |
Actual %, quarter-on-quarter | (38.00%) | (16.00%) | 33.00% | 1.00% | (21.00%) | (14.00%) |
CER %, quarter-on-quarter | (36.00%) | (17.00%) | 38.00% | (1.00%) | (23.00%) | (12.00%) |
Other medicines | ||||||
Product sales | ||||||
Product Sales | $ 563 | $ 557 | $ 653 | $ 731 | $ 641 | $ 576 |
Actual %, quarter-on-quarter | 1.00% | (15.00%) | (11.00%) | 14.00% | 11.00% | (35.00%) |
CER %, quarter-on-quarter | 4.00% | (15.00%) | (10.00%) | 14.00% | 12.00% | (36.00%) |
Nexium | ||||||
Product sales | ||||||
Product Sales | $ 377 | $ 338 | $ 353 | $ 374 | $ 393 | $ 363 |
Actual %, quarter-on-quarter | 12.00% | (4.00%) | (6.00%) | (5.00%) | 8.00% | (7.00%) |
CER %, quarter-on-quarter | 14.00% | (4.00%) | (6.00%) | (4.00%) | 8.00% | (8.00%) |
Synagis | ||||||
Product sales | ||||||
Product Sales | $ 90 | $ 85 | $ 63 | $ 146 | $ 96 | $ 53 |
Actual %, quarter-on-quarter | 6.00% | 35.00% | (57.00%) | 52.00% | 81.00% | (79.00%) |
CER %, quarter-on-quarter | 7.00% | 35.00% | (57.00%) | 53.00% | 81.00% | (79.00%) |
Losec/Prilosec | ||||||
Product sales | ||||||
Product Sales | $ 45 | $ 54 | $ 46 | $ 73 | $ 68 | $ 76 |
Actual %, quarter-on-quarter | (15.00%) | 18.00% | (38.00%) | 8.00% | (11.00%) | 27.00% |
CER %, quarter-on-quarter | (15.00%) | 17.00% | (38.00%) | 9.00% | (10.00%) | 26.00% |
Seroquel XR/IR | ||||||
Product sales | ||||||
Product Sales | $ 27 | $ 36 | $ 40 | $ 82 | $ 32 | $ 37 |
Actual %, quarter-on-quarter | (26.00%) | (12.00%) | (50.00%) | (14.00%) | (34.00%) | |
CER %, quarter-on-quarter | (23.00%) | (12.00%) | (49.00%) | (10.00%) | (33.00%) | |
Other, Others | ||||||
Product sales | ||||||
Product Sales | $ 24 | $ 44 | $ 151 | $ 56 | $ 52 | $ 47 |
Actual %, quarter-on-quarter | (46.00%) | (71.00%) | 8.00% | 11.00% | (65.00%) | |
CER %, quarter-on-quarter | (42.00%) | (70.00%) | 11.00% | (64.00%) |
Historic Collaboration Revenue
Historic Collaboration Revenue (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | |
Revenues | ||||||
Total collaboration revenue | $ 227 | $ 105 | $ 270 | $ 131 | $ 819 | $ 1,041 |
Crestor | Initial Collaboration Revenue | Spain | ||||||
Revenues | ||||||
Total collaboration revenue | 61 | |||||
Crestor | Ongoing Collaboration Revenue | Spain | ||||||
Revenues | ||||||
Total collaboration revenue | 39 | |||||
Lynparza | Ongoing Collaboration Revenue | Regulatory milestones | ||||||
Revenues | ||||||
Total collaboration revenue | 135 | 60 | 60 | 140 | ||
Lynparza | Ongoing Collaboration Revenue | Sales milestones | ||||||
Revenues | ||||||
Total collaboration revenue | 450 | 250 | ||||
Lynparza/Selumetinb | Ongoing Collaboration Revenue | Option payments | ||||||
Revenues | ||||||
Total collaboration revenue | 100 | 400 | ||||
Enhertu | Ongoing Collaboration Revenue | Profit share | ||||||
Revenues | ||||||
Total collaboration revenue | 36 | |||||
Roxadustat | Ongoing Collaboration Revenue | Profit share | ||||||
Revenues | ||||||
Total collaboration revenue | 11 | |||||
Royal income | Ongoing Collaboration Revenue | ||||||
Revenues | ||||||
Total collaboration revenue | 34 | 32 | 62 | 49 | ||
Other Collaboration Revenue | ||||||
Revenues | ||||||
Total collaboration revenue | $ 54 | $ 39 | $ 108 | $ 141 |
Other Operating Income and Ex_3
Other Operating Income and Expense (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | |
Operating profit, other operating income and expense | ||||||
Total other operating income and expense | $ 121 | $ 113 | $ 601 | $ 706 | $ 1,541 | $ 2,527 |
Seroquel | ||||||
Operating profit, other operating income and expense | ||||||
Total other operating income and expense | 527 | |||||
Legal settlement | ||||||
Operating profit, other operating income and expense | ||||||
Total other operating income and expense | 346 | |||||
Atacand | ||||||
Operating profit, other operating income and expense | ||||||
Total other operating income and expense | 210 | |||||
Anaesthetics | ||||||
Operating profit, other operating income and expense | ||||||
Total other operating income and expense | 172 | |||||
Alvesco, Omnaris and Zetonna | ||||||
Operating profit, other operating income and expense | ||||||
Total other operating income and expense | 139 | |||||
Other operating income and expense | ||||||
Operating profit, other operating income and expense | ||||||
Total other operating income and expense | 200 | 191 | 389 | 405 | ||
Ex-US, India and Japan | Hypertension medicines | ||||||
Operating profit, other operating income and expense | ||||||
Total other operating income and expense | 350 | |||||
Japan | Inderal, Tenormin, Seloken and Omepral | ||||||
Operating profit, other operating income and expense | ||||||
Total other operating income and expense | $ 51 | |||||
US | Synagis | ||||||
Operating profit, other operating income and expense | ||||||
Total other operating income and expense | $ 515 | 515 | ||||
Ex-China, Japan, US and Mexico | Losec | ||||||
Operating profit, other operating income and expense | ||||||
Total other operating income and expense | 243 | |||||
US, Canada, Europe and Russia | Seroquel and Seroquel XR | ||||||
Operating profit, other operating income and expense | ||||||
Total other operating income and expense | 213 | |||||
Various countries | Arimidex and Casodex | ||||||
Operating profit, other operating income and expense | ||||||
Total other operating income and expense | $ 181 | |||||
Europe and ex-US | Nexium and Vimovo | ||||||
Operating profit, other operating income and expense | ||||||
Total other operating income and expense | $ 728 |